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Zusammenfassung 
 
 
Während der vergangen Jahrzehnte hat die Anwendung von Teilchentherapie zur Behandlung 
von Krebspatienten rasant zugenommen. Durch die physikalischen Eigenschaften der 
Ionenstrahlen, hauptsächlich das invertierte Tiefendosisprofil und die steilen longitudinalen 
und lateralen Dosisgradienten, wird Teilchentherapie zu einer vielversprechenden Modalität 
zur Behandlung von tiefliegenden Tumoren nahe an Risikostrukturen. Heutzutage werden nur 
Protonen und Kohlenstoffionen klinisch angewandt, jedoch könnten auch neue Ionenarten im 
klinischen Bereich Vorteile bringen. Heliumionen werden dafür in Erwägung gezogen, da ihre 
physikalischen und biologischen Eigenschaften zwischen derer von Protonen und 
Kohlenstoffionen liegen. Am Heidelberger Ionenstrahl Therapiezentrum (HIT) sind neben 
den etablierten Protonen und Kohlenstoffionen auch Helium- und Sauerstoffionen für 
experimentelle Zwecke vorhanden, deren klinische Anwendung in der nahen Zukunft 
angestrebt wird. Allerdings müssen für den klinischen Einsatz neuer Teilchen die 
dosimetrischen und biologischen Eigenschaften der Teilchen genau bestimmt werden und 
weiterhin ausführliche Vergleiche zwischen Bestrahlungsplänen mit bekannten und neuen 
Teilchen durchgeführt werden.  
In dieser Arbeit wurden die Therapie von gut differenzierten, bösartigen Meningiomas mit 
Protonen und Heliumionen verglichen. Dafür wurden am HIT ausführliche Studien zu den 
dosimetrischen Eigenschaften aller verfügbaren Ionenarten im therapeutischen Energiebereich 
hinsichtlich der Tiefendosisverteilung und der lateralen Dosisprofile durchgeführt. 
Anschließend wurden für Heliumionen ausführliche Vergleiche und Validierungen der Monte 
Carlo (MC) Simulationen FLUKA mit Tiefendosismessungen durchgeführt, welche auf 
Experimenten zur Bestimmung der Strahlcharakteristika in Vakuum, die bisher kaum 
erforscht wurden, aufbauen. Als nächster Schritt wurde dazu der detaillierte Strahlverlauf in 
die Simulationen eingebaut („phase space approach“). Anschließend wurde das FLUKA-
basierte Monte Carlo „Monte Carlo Treatment Planning Tool“ (MCTP) für 
Bestrahlungsfelder mit unterschiedlichen Größen und Tiefen in Wasser für alle verfügbaren 
Ionenarten am HIT verifiziert. In Verbindung mit validierten biologischen Modellen wurde 
das MCTP für Vergleiche zwischen Protonen- und Heliumionenplänen für Bestrahlungen von 
Meningioma benutzt.  
Die experimentellen Ergebnisse der dosimetrischen Charakterisierung lassen darauf schließen, 
dass die Behandlung mit Heliumionen zu einer gleichmäßigeren Dosisverteilung als bei 
Behandlung mit Protonen führt, hauptsächlich wegen geringerer lateraler Streuung und 
geringerer Reichweitenunsicherheit. Dabei sind außerdem die distalen und lateralen 
Dosiskanten schärfer und der Dosisschwanz weniger ausgeprägt als bei Kohlenstoffionen. Es 
wurde eine gute Übereinstimmung zwischen der MC FLUKA Vorhersage und den 
experimentellen Messungen gefunden, was deren Anwendbarkeit als Strahlenmodell zur 
Vorbereitung des klinischen Einsatzes von Heliumionen bestätigt. Daraus folgend stellt das 
MCTP Tool validiert gegen Dosismessungen auch für anspruchsvolle Zielvolumina eine 
solide Forschungsbasis für Behandlungsplan-Vergleiche am HIT dar. Weiterhin wird die 
Anwendung verschiedener state-of-the-art-Modelle für die relative biologische Wirksamkeit 
damit unterstützt. Die Ergebnisse dieser Arbeit für die Vergleiche verschiedener 
xiv 
 
Behandlungspläne unter verschiedenen Bedingungen zeigen, dass Heliumionen eine 
Alternative zur Protonentherapie sein können, basierend auf ihren vorteilhaften 
physikalischen und biologischen Eigenschaften. Damit könnten sie insbesondere für gut 
differenzierte, bösartige Meningioma eine vielversprechende, neue Behandlungsmethode sein. 
Um die klinische Anwendung voranzutreiben sind weitere Planungs-Studien und biologische 
Untersuchungen geplant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Abstract 
 
 
Particle therapy for cancer patient treatments has gained in popularity over the last decades. 
The physical characteristics of ion beams over conventional radiotherapy with photons, 
mainly the inverted depth dose profile, with sharp longitudinal and lateral dose gradient, make 
ion therapy an interesting modality for treatment of deep-seated tumors near critical 
structures. Nowadays, only protons and carbon ions are used in clinical routine. The 
introduction of other ions species in clinical practice is foreseen as potential asset for 
improving clinical outcomes. Helium ions, with physical and biological properties in between 
protons and carbon ions, have been pointed out as potential candidates. At the Heidelberg ion 
beam therapy center (HIT), helium and oxygen ions, which are currently only used for 
experiments, are foreseen to be employed clinically in the near future in addition to the 
established protons and carbon ions. The introduction of ion species in the clinical practice 
needs to be supported by a thorough assessment of their dosimetric and biological properties, 
and subsequently by treatment planning comparisons with clinically used proton and carbon 
ion beams.  
This thesis aimed at comparing the treatment of low-grade meningiomas with protons and 
helium ions. To achieve this goal, an extensive study of the basic dosimetric features of the 
different ions available at the HIT was performed in the entire therapeutic energy range, 
comparing depth dose distributions and lateral profiles in water. Subsequently, thorough 
comparisons and validations of the Monte Carlo (MC) code FLUKA for helium ion beams 
was conducted against in-depth dosimetric measurements, after an experimentally-driven 
tuning of the less known initial beam characteristics in vacuum. After integration of the 
detailed beamline model into a simulation framework with a new original phase space 
approach, a dosimetric verification of the FLUKA-based Monte Carlo Treatment Planning 
tool (MCTP) for spread-out Bragg peaks of different sizes and at different depths in water was 
performed for all ion species available at HIT. Using this engine coupled to a validated 
biological model, plan comparisons between protons and helium ions were investigated for 
meningioma patient treatments. 
The experimental results of the dosimetric characterization indicate that helium ions could 
afford a more conformal treatment, due to a smaller lateral scattering and longitudinal 
straggling than with protons, leading to better lateral and distal fall-off, as well as a lower 
fragmentation tail compared to carbon and oxygen ions. Overall, good agreements were found 
between MC FLUKA predictions and measurements of helium ions, confirming the suitability 
of the code for beam modeling in preparation of clinical establishment at HIT. Subsequently, 
the MCTP tool was validated against dosimetric measurements for challenging targets, to 
provide a solid research engine for treatment planning comparisons at HIT, supporting the 
usage of multiple state-of-the-art models of relative biological effectiveness. The final results 
of the thesis for treatment plan comparisons under different treatment conditions indicate than 
helium ions could be an alternative to proton therapy due to their favorable physical and 
biological characteristics, and thus could provide promising treatment for low-grade 
meningioma in the head. Future treatment planning studies and biological investigations with 
helium ions are foreseen to proceed toward clinical implementation. 
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 Introduction Chapter 1.
 
 
 
 
Cancer is one of the leading causes of death worldwide with the second largest morbidity in 
the European Union. According to the world health organization 2012 report, there are 14 
million new cases and 8.2 million cancer-related deaths worldwide annually. By 2030, the 
prevalence of cancer is expected to rise by nearly 70% due to the ageing population and 
endogenous factors, as well as external risks such as tobacco-use, pollution, chemical agents, 
and other environmental factors. Cancer is a broad term to characterize cell degeneration and 
abnormal cell proliferation. The first tumor cells to localize are called the primary cancer and 
can, at later stages, invade other parts of the body (metastatic). The main approach to treating 
cancer is with either surgery, radiotherapy, chemotherapy or a combination of these 
treatments. Other systematic therapy like chemotherapy can also be proposed such as 
hormonotherapy. While surgery and radiotherapy focus on treating the primary cancer alone, 
chemotherapy aims at curing metastatic disease as well. Roughly 50% of patients with 
malignant tumors are undergoing radiotherapy in combination with surgery and/or 
chemotherapy (Durante and Löffler 2010).  
Radiotherapy seeks to deliver enough energy to the primary tumor to damage 
deoxyribonucleic acid helix (DNA) within the tumorous cells by the process of ionization. 
Thus, the goal is to eradicate the malignant cells while sparing the surrounding tissues and 
critical organ at risks. A trade-off then has to be considered to satisfy this balance between an 
effective treatment and avoiding/decreasing complications probability and risk of secondary 
cancer in the normal tissue. In order to achieve this goal, conventional radiotherapy 
techniques using high energy photons evolved to provide a more conformal dose delivery to 
the tumor. However, limitations from physical interaction properties of photons can be 
overcome when instead using ions, due to their more favorable physical properties. So far 
over 150,000 patients have been treated with ions, mainly with protons, since the first clinical 
applications of ion therapy at the Lawrence Berkeley Laboratory (LBL) in the 1950’s 
(Lawrence et al 1964, Lyman and Howard 1977, Phillips et al 1977, Jermann 2015). Ions can 
provide a superior treatment to photons for different cancer localization such as inoperable 
tumors in the head and neck region, chordomas or chondrosarcomas (Schulz-Ertner et al 
2007, Tsujii et al 2007, Durante and Löffler 2010, Löffler and Durante 2013). Several clinical 
trials are necessary to obtain hard evidence of the advantage of ions over photons. 
Furthermore, ions could enhance clinical outcome for pediatric cases and tumors near highly 
functional structures by reducing the normal tissue complication probability (NTCP) and in 
turn decrease the risk of radiation-induced secondary cancer and damage to organs at risk 
(D’Avila Nunes 2015). One example is skull base meningioma (Gudjonsson et al 1999, 
Vernimmen et al 2001), where ion therapy could better spare critical organs (e.g. chiasma, 
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brainstem, optical nerves …) in comparison to conventional radiotherapy and was 
experimented with promising results in several proton therapy centers (Weber et al 2011, 
Austin-Seymour et al 1990, Noel et al 2005).  
In addition to the clinically used protons and carbon ions, helium ions could be beneficial for 
patient treatments as well. After their introduction at the Lawrence Berkeley National 
Laboratory in 1975 and clinical use until 1992 for skull base tumor (Kaplan et al 1994) and 
uveal melanoma (Castro et al 1994, Char et al 1998), a renewed interest in helium ions grew 
over the last decade with the rising number of related publications (Kempe et al 2007, Knäusl 
et al 2016, Grün et al 2015, Burigo et al 2015), and their recent availability at the Heidelberg 
ion beam therapy center (HIT, Haberer et al 2004, Combs et al 2010a) with a state-to-the-art 
delivery system (Tessonnier et al 2017a, Tessonnier et al 2017b), as it will be presented in the 
following chapters. From a theoretical standpoint, helium ions can in principle provide better 
conformity to the tumor than protons and carbon ions due to their physical properties, i.e. 
reduced straggling (both lateral and distal) compared to protons and lower dose fragmentation 
tail than carbon ions. Regarding biological outcome, the relative biological effectiveness 
(RBE) of helium is higher than that of protons. Compared to carbon ions the RBE is lower but 
presents less variability, thus decreasing the uncertainty in the dose delivered to the patient. 
For these reasons, helium ions may be of particular use in pediatrics and cases with tumors 
close to critical structures such as low-grade meningiomas. Additionally, it could be of 
interest in high-risk meningiomas for dose escalation in complement to radiotherapy with 
photons as investigated at HIT for carbon ions (Combs et al 2010b). 
 
The aim of this thesis is to introduce the necessary elements for the treatment of low-grade 
meningiomas with helium ions compared to protons. This work is organized as follows: 
 
- Chapter 2 describes the rationale of the use of ions through a general description of 
their physical and biological properties. An overview of current clinical 
implementation and treatment planning in ion therapy will be presented. 
 
- Chapter 3 presents detailed measurements and comparisons of the four ions available 
at HIT: protons, helium, carbon and oxygen ions. It details the different characteristics 
of the available ions as well as their physical advantages and drawbacks using the 
latest state-of-the-art active beam delivery system.  
 
- Chapter 4 deals with modelling of helium ion beams with the Monte Carlo code 
FLUKA (Ferrari et al 2005, Böhlen et al 2013, Battistoni et al 2016) and a thorough 
comparison to measurements, allowing for validation of Monte Carlo predictions for 
further evaluation of both Monte Carlo-based and analytical treatment planning 
systems, the latter using Monte Carlo generated database. 
 
- Chapter 5 presents an improved framework for patient-specific simulations at HIT 
based on the latest version of FLUKA, with new features such as the optional use of 
input phase space files and the rotation of voxelized patient geometries. It covers a 
comprehensive validation of the phase space approach for protons and carbon ions 
against simulations using the detailed HIT beamline, as well as experimental 
measurements. 
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- Chapter 6 introduces a prototype Monte Carlo treatment planning system (MCTP, 
Böhlen et al 2014, Mairani et al 2013) used to optimize spread-out Bragg peaks at 
several depths in water, with two different sizes and the four HIT ions. The validation 
of several dosimetric parameters against measurements ensures the reliability of this 
tool for absorbed dose calculations to be used in further planning comparisons with 
patient data. The possibility to link the MC tool to sound biological models is also 
presented. 
 
- Chapter 7 compares meningioma treatment plans biologically optimized for protons 
and helium ions. Additionally, the effect of various planning parameters such as 
fraction dose size or the use of the ripple filter (RiFi, Weber and Kraft 1999), as well 
as the impact of a different tumor tissue type, were investigated using the same patient 
cases.  
 
- Chapter 8 concludes this work and provides a future perspective of the clinical 
implementation of helium ions at HIT. It also presents work in progress related to both 
radiobiology and Monte Carlo modelling. 
 
- Appendices A-D present supplementary material not included in the main chapters as 
well as side works related to the thesis. 
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 Ion Beam Therapy Chapter 2.
 
 
 
 
In this Chapter, a general introduction to particle therapy concepts will be summarized, 
followed by a description of the Heidelberg ion-beam therapy center and Monte Carlo code 
used in this thesis. 
 
 Radiotherapy 2.1.
The main goal of radiotherapy is the treatment of patient tumors through a lethal deposition of 
energy to the cancerous cells while minimizing damage to the surrounding healthy tissues and 
organs at risk (OAR). The amount of energy deposited by ionizing radiation to matter in a 
finite volume is defined as the absorbed dose (ICRU 1993): 
 
𝐷 =
d?̅?
d𝑚
 ,                         (2.1)   
 
with D, the absorbed dose (J/kg), for a mean energy 𝜀 ̅deposited inside a finite volume V of 
mass m. The absorbed dose unit name is the Gray (Gy).  
Following equation 2.1, the dose D, deposited in a thin slice of absorber material with density 
ρ (g.cm-3) by a monoenergetic beam of charged particles (e.g., ion beam or secondary 
electrons from photons interactions under the assumption of charged particle equilibrium) can 
be calculated as follows (Podgorsak 2005): 
 
𝐷 =  Ф ×  
𝑆
𝜌
  ,                      (2.2)       
with S, the stopping power of the charged particle in the considered material, and Ф, the 
particle fluence (cm
-2
). Subsequently, the dose D can be obtained as reported in Schardt et al 
(2010): 
 
𝐷 =  1.6 ∙ 10−9 × Ф ×
d𝐸
d𝑥
 ×  
1
𝜌
  ,                      (2.3)      
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with 
d𝐸
d𝑥
 , in units of keV.µm-1, the stopping power linked to the energy loss of the charged 
particles per unit path length. This quantity is related to the linear energy transfer (LET), the 
energy deposited locally per unit path length, by a particle in a stopping material. 
In the biological setting, radiation induces both direct and indirect damages to the cell’s vital 
constituents: the DNA molecules (figure 2.1). Charged particles (from primary or secondary 
radiations) cause ionization of molecules undergoing rapid chemical changes with the 
possibility of breaking intra-molecular bonds (physical and chemical phase, Boag 1975). Such 
effects include single strand DNA helix breaks (SSB), double strand DNA helix breaks (DSB) 
or a more complex clustered strand breaks. If not repaired properly or in time, the damage 
may lead to the cell death (Goodhead 1994, Goodhead 2006). Irradiation, through the 
tumorous cell death, will provoke shrinkage or total sterilization of the patient cancer (early 
reactions on biological phase). However, such treatment methods can adversely affect normal, 
healthy tissues of a patient. Unwanted energy deposition in the normal cells causing their 
death or mutation could lead to radiation induced secondary cancer years after treatment (late 
reactions on biological phase). Thus, a highly conformal dose delivery to the tumor is 
desirable. 
Several irradiation techniques are possible depending on the tumor localization, with two 
main categories of radiotherapy procedures: brachytherapy and external beam radiotherapy 
(Podgorsak 2005). While the radiation source (
192
Ir, 
125
I) in brachytherapy is placed directly in 
the proximity of the target (intracavitary, interstitial, surface or intraoperative brachytherapy), 
in external beam therapy the source is positioned at a specified distance away from the 
patient. External beam therapy is achieved mainly with photon (from a linear accelerator of 
electron beams or a 
60
Co teletherapy unit) and electron beams, as well as, with less 
availability, protons, ions or neutrons. 
 
 
 
 
Figure 2.1: Simplified charts of the different pathways for radiation-induced DNA damage. 
On the left, interaction through direct and indirect damage due to an ionization event or the 
creation of free radicals, respectively. The right panel depicts the two types of damage on 
DNA, SSB and DSB (adapted from Hall 2012). 
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Since the first applications of radiotherapy at the end of the 19
th
 century after the discovery of 
X-rays by Wilhelm Roentgen in 1895, major technological and computational advancements 
were made from conventional radiotherapy with simple beam ballistics to complex and 
conformal treatment delivery. Modern-day photon radiation delivery is performed via 
intensity modulated radiation therapy (Webb 2003) or volumetric intensity modulated arc 
therapy (Rao et al 2010) techniques, to achieve better coverage of the tumor target while 
sparing the surrounding healthy tissues. Wilson (1946) was the first to propose the use of fast 
ions for radiation therapy as an alternative to photon radiation. The main advantage of ions 
over photons, illustrated in figure 2.2, is their inverted depth dose distribution. Photons have a 
maximum dose deposition at a shallow depth, which then decreases with the attenuation of 
photons in matters at greater depths. On the other hand, ions lose their energy (and thus 
velocity) as they traverse a medium, leading to an enhanced dose deposition at the end of the 
path, in the so-called Bragg peak (Bragg (1905)), while having low dose in the entrance in 
comparison to photons, and no dose due to the primary particles after the peak. 
The superimposition of multiple pristine Bragg peaks affords target coverage in a spread-out 
Bragg peak (SOBP), as illustrated in figure 2.2. In the case of ions heavier than protons, low 
dose after the peak can be observed due to fragmentation processes of the primary beam. 
Furthermore, these heavy-ions exhibit optimal dosimetric characteristics such as a reduced 
lateral spread and a sharper Bragg peak, potentially leading to a reduction in dose delivery to 
the surrounding healthy tissues. In addition to the physical advantages, ions possess enhanced 
biological effectiveness, due to the higher ionization density compared to photon beams, 
particularly in the Bragg peak region and in the case of heavy ions (Kraft 2000). These 
various aspects will be addressed in the following sections.  
 
 
 
 
Figure 2.2: Left: Depth dose profiles for 
60
Co, 25MV photons, and 
12
C ions (200 and 270 
MeV/u) in water (Schardt et al 2010); Right: Depth dose distributions of 10 MV photons and 
superimposition of several pristine Bragg peaks creating a SOBP (adapted from Levin et al 
2005). 
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Lawrence Berkeley Laboratory was the pioneering institution to lead the world’s first clinical 
application of ion beams, beginning with protons in 1954 (Tobias et al 1958), then helium 
ions in 1957 (Lawrence et al 1964), followed by heavier ion treatments in 1975 (Castro et al 
1980). Since then, the interest in particle therapy has grown with the new technological 
developments above sixty particle therapy facilities in operation and around forty under 
constructions, according to the November 2016 update of the Particle Therapy Co-Operative 
Group (PTCOG). The total number of patients treated with charged particles at the end of 
2015 was 154203 (131240 with protons, 19376 with carbon ions, 2054 with helium ions and 
1533 with other particles). 
 
 Ion beams physical properties 2.2.
The physical advantages of ions are resulting from the interaction properties of ions in matter, 
especially the energy loss of ions as they lose velocity and the associated range straggling, the 
lateral spread of the beam and the nuclear reaction. 
 
 Energy loss, range and range straggling  2.2.1.
The total energy loss of ions in matter 
d𝐸
d𝑥
|
𝑡𝑜𝑡
 can be decomposed in three components: 
 
d𝐸
d𝑥
|
𝑡𝑜𝑡
=  
d𝐸
d𝑥
|
𝑒𝑙
 + 
d𝐸
d𝑥
|
𝑛𝑢𝑐
+ 
d𝐸
d𝑥
|
𝑟𝑎𝑑
 .                              (2.4) 
 
The first component 
d𝐸
d𝑥
|
𝑒𝑙
is the energy loss related to the inelastic interactions with atomic 
electrons (electronic stopping power), 
d𝐸
d𝑥
|
𝑛𝑢𝑐
corresponds to the energy loss due to elastic 
interaction with the target nuclei (nuclear stopping power) and 
d𝐸
d𝑥
|
𝑟𝑎𝑑
is the energy loss 
involving radiative processes. For the energy range used in ion beam therapy up to ~450 
MeV/u (Bragg peak at ~34cm for carbon ions), corresponding to a velocity about 70% of the 
speed of light, the energy loss is dominated by the electronic stopping power. Thus, it can be 
described by the Bethe-Bloch (Bethe 1930, Bethe 1933, Fano 1963) formula: 
 
−
d𝐸
d𝑥
= 2𝜋𝑟𝑒
2𝑚𝑒𝑐
2𝑁𝑒
𝑍𝑝
2
𝛽2
[𝑙𝑛 (
2𝑚𝑒𝑐
2𝛽2(1 √1−𝛽2⁄ )2𝑇𝑚𝑎𝑥
〈𝐼〉2
) − 2𝛽2 − 2
𝐶
𝑍𝑡
− 𝛿 ].      (2.5) 
 
The term C and 𝛿 describe the energy shell and density correction terms introduced in Fano 
(1963), while c corresponds to the speed of light and Zt as well as Zp represent the nuclear 
charge Z of the target and particle, respectively. β is the projectile velocity (scaled in term of 
c), 𝑁𝑒 is the target electron density and 〈𝐼〉 its mean ionization potential. re and me are the 
radius and rest mass of an electron, respectively. Tmax is the maximum energy transferred in a 
single collision with a free electron. The formula indicates that as the particle will be slowed 
down, the energy loss will increase due to the dependency in 
1
𝛽2
. This formula 2.5 is valid for 
describing stopping power for energy above ~ 1MeV/u. For lower energies, recombination 
processes lead to a decrease of the projectile effective charge and thus of the energy loss after 
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having reached a maximum (e.g. at about 350 keV/u in water for 
12
C as seen in Figure 2.3), at 
the Bragg peak position. This decrease is taken into account by substituting the Zeff term in 
equation 2.5 instead of Zp, approximated as described by Barkas (1963): 
 
𝑍𝑒𝑓𝑓 = 𝑍𝑝 × [1 − 𝑒
−𝛼𝛽𝑍𝑝
−2 3⁄
],            (2.5) 
 
with α ~ 125. 
 
An absorber material of particular interest in ion beam therapy is water. The mean ionization 
potential 〈𝐼〉 was defined for protons at 75 eV (ICRU 1994), however new values from the 
literature suggest higher values for protons and heavier ions in a range from 75 to 80 eV, with 
an ICRU value at 78 eV (ICRU 2009, Bichsel et al 2000, Krämer et al 2000, Kumazaki et al 
2007, Andreo et al 2013) and as investigated in Chapter 4. The evolution of the stopping 
power in water for protons and 
12
C ion beams is illustrated in figure 2.3. As described in 
figure 2.3, the contribution of the nuclear stopping power is relevant only at extremely low 
residual range of the particles, in the last µm, and can be neglected for particle therapy 
application (Elsässer et al 2009). Radiative stopping power is mainly present in high 
relativistic regime and can be therefore neglected as well, since therapy is working mostly in 
the medium-relativistic regime. 
 
 
 
 
 
Figure 2.3: Specific energy loss 
d𝐸
d𝑥
 in water for carbon ion and proton beams. (Schardt et al 
2010) 
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The mean range of a particle, corresponding to the thickness of absorber medium traversed, is 
close, for ions, to the finite path length from the “continuous slowing down approximation”, 
since heavy charged particles undergo little lateral scattering. Thus, the range of a particle 
with an initial energy E can be calculated as follows: 
 
𝑅(𝐸) = ∫ (
d𝐸´
d𝑥
)−1𝑑𝐸´
0
𝐸
 ,                      (2.6) 
 
From equation 2.4 and 2.6, due to the dependency on 𝑍𝑝
2 and 
1
𝛽2
, it can be found that the range 
of different ions with a same velocity β can be scaled approximately with 
𝐴
𝑍𝑝
2. The mean range 
of different ions in water is displayed in figure 2.4 
However, equation 2.4 describes the mean stopping power for a single particle. Due to 
statistical fluctuation on the number of collisions for each particle, leading to energy loss 
straggling (Bohr 1913, Ahlen 1980) and thus a broader energy spectrum of the incident 
particles, the range will differ slightly for each particle, resulting into a broadened Bragg 
peak. This phenomenon is called range straggling. The straggling width can be approximated, 
as reported in Schardt et al (2010), for a particle with a mean range R, as:  
 
𝜎𝑅
𝑅
=  
1
√𝑀
 × 𝑓 (
𝐸
𝑀𝑐2
) ,           (2.7) 
 
with f a function with slow variation. Thus, heavier ions will undergo less range straggling, 
and thus have a sharper Bragg peak, as illustrated in figure 2.5. However, it can be beneficial 
for a treatment to have a broader Bragg peak. This can be achieved by artificially widening 
the initial energy spread of the accelerator with a passive energy degrader such as the ripple 
filter, leading to broadened initial energy spectra before the target. 
 
 
Figure 2.4: Mean range of different ions in water. (Schardt et al 2010) 
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Figure 2.5: Bragg peak of protons and carbon ions, with the same mean range, measured in 
water. (Schardt et al 2010) 
 
 
 
 
Figure 2.6: Lateral deflection of protons, helium, carbon and oxygen ion beams in water.     
(Parodi 2004) 
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 Lateral scattering 2.2.2.
The different interactions with the absorber will lead to small deflection of the incident beam, 
mainly dominated by multiple elastic Coulomb scattering. The Molière solution (1948) 
describes the angular distribution at a certain penetration depth, and was found in good 
agreement with measurements (Gottschalk et al 1993). An approximation for small angles 
was given by Highland (1975, 1979), described at a penetration depth by a Gaussian with a 
width 𝜎𝜃: 
 
𝜎𝜃[𝑟𝑎𝑑] =
14.1𝑀𝑒𝑉
𝛽𝜌𝑐
× 𝑍𝑝 × √
𝑑
𝐿𝑟𝑎𝑑
× [1 +
1
9
𝑙𝑜𝑔10 (
𝑑
𝐿𝑟𝑎𝑑
)],           (2.8) 
 
where d is the thickness of the traversed medium, Lrad the radiation length (with values 
available in Tsai (1974)) and p the particle momentum. Other quantities are already described 
in equation 2.5. Lateral straggling of different ions will be experimentally investigated in the 
Chapter 3. For similar penetration depth, the energy of lighter ions is lower than that of the 
heavier ions, manifested in the 
1
𝛽𝜌𝑐
 dependency to a larger lateral spread as seen in figure 2.6.  
 
 Nuclear interactions and fragmentation 2.2.3.
Ions can undergo interactions with the medium via the strong nuclear force. Nuclear 
interactions will lead to a decrease of the initial primary beam fluence Ф0, along the depth z, 
following: 
 
Ф(z) = Ф0 × 𝑒
−𝑁𝜎𝑟𝑧 ,           (2.9) 
 
with N the density of nuclei in the medium and σr the total reaction cross-section. 
 
 
 
Figure 2.7: Left: Proton beam (175MeV) Monte Carlo predicted dose distribution in PMMA, 
with and without nuclear interactions (Parodi 2004). Right: Monte Carlo predicted dose 
deposition of carbon ion beams (400 MeV/u), separating the contribution of the primary beam 
and fragmentation products in water. (Mairani 2008)  
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In ion beam therapy, nuclear interactions will impact the dose distribution even if their cross-
section is substantially smaller than that of Coulomb interactions. The effects of nuclear 
interactions have two main drawbacks as seen in figure 2.7, (1) the reduced entrance-to-peak 
ratio, due to the reduction of the primary beam fluence and (2), the rise of a dose 
fragmentation tail, due to the produced fragments with a lower Z, which will consequently 
undergo additional multiple Coulomb scattering events with greater lateral spreading than the 
initial beam. However, some fragments from the target or the projectile, such as 
11
C or 
15
O 
can be of interest for in-vivo range monitoring (review in Kraan 2015) with positron emission 
imaging (e.g. positron emission tomography, see section 2.8). The prompt gammas emitted as 
a result of nuclear interaction can also be used for range monitoring with prompt gamma 
imaging techniques (Min et al 2006, Hueso-Gonzalez et al 2016). 
Protons are undergoing nucleon-nucleus reactions, leading as a final state to the production of 
target light fragments (e.g. from evaporation process), nucleons and de-excitation gamma-
rays.  For heavier ions, nucleus-nucleus interactions result in fragments from the particle 
and/or the medium. In the energy range of ion therapy, peripheral collisions are mostly 
dominant, mainly due to geometrical reasons. When these nuclear reactions occur, the beam 
particle and target can lose nucleons, described by the abrasion-ablation model (Serber 1947) 
as illustrated in figure 2.8. In the first step, nucleons are abraded from the overlapping zone 
(“fireball”), while outer nucleons are only slightly affected. In a second step, the target 
fragments and remaining projectile undergo de-excitation by evaporation of nucleons or 
clusters (ablation). The remaining projectile fragment keeps nearly the same velocity and 
direction as the initial projectile. Nuclear interactions and fragmentation processes have been 
investigated extensively as for example in Goldhaber and Heckman (1978), Hüfner (1985) or 
and Lynch (1987). 
 
 
 
 
 
Figure 2.8: Illustrations of the abrasion-ablation model of peripheral collisions. (Schardt et al 
2010)  
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 Ion beam biological properties 2.3.
In addition to physical advantages of ions over photons, enhancement of biological 
effectiveness and its dependency on dose, tissue type and LET are of interest. The two main 
phenomena are the relative biological effectiveness (RBE) and the oxygen enhancement ratio 
(OER). The RBE is defined as: 
 
𝑅𝐵𝐸 =  
𝐷𝑝ℎ𝑜𝑡𝑜𝑛
𝐷𝑖𝑜𝑛
|
𝑖𝑠𝑜𝑒𝑓𝑓𝑒𝑐𝑡
.                  (2.10) 
 
It represents the ratio between the photon dose (𝐷𝑝ℎ𝑜𝑡𝑜𝑛) and the ion dose (𝐷𝑖𝑜𝑛) needed to 
achieve a same biological effect or endpoint. It can be illustrated as in figure 2.9 (left panel), 
with RBE for two different endpoints, either a cell survival of 10% (RBE10) or 1% (RBE1). It 
can be understood that due to the shape of the curves, the RBE will depend on the reference 
dose. Furthermore, the shape of the survival curves for photons will depend on the tissue type 
and can be described by the linear quadratic model (LQ, Fowler 1989): 
 
𝑆(𝐷) =   𝑒−(𝛼𝐷+ 𝛽𝐷
2) ,                            (2.11) 
 
with α and β, describing the linear and quadratic part of the curve respectively, with the ratio 
α/β being characteristic of the tissue type and the type of radiation. For photon radiation, a 
large α/β (>5) is characteristic of a cell type with small repair functions, and thus a large 
sensitivity to radiation (a common characteristic of tumorous tissues), while a relatively small 
α/β (<5) is attributed to normal tissues. In addition to its dependencies on the dose and the 
tissue type, RBE is also LET dependent, as seen in figure 2.9 (right panel) from Hall (2012). 
With higher LET, RBE decreases due to an “overkill” effect (Hall 2012), where energy is 
“wasted” due to the excess of ionizing events. RBE is assumed to be 1.1 for protons (ICRU 
2007), however some studies are showing and modeling a variable RBE, as supported by in-
vitro data (Polster et al 2015, Giovannini et al 2016, Mairani et al 2017a). Furthermore, a 
recent study shows a clinical evidence of variable RBE for pediatric cases (Peeler et al 2016). 
For heavier ions, different RBE models are proposed as for example the Local Effect Model 
(LEM, Elsässer et al 2010) or the Microdosimetric Kinetic Model (MKM, Inaniwa et al 2010) 
used clinically in Europe and Japan, respectively. In particle therapy, the effective dose 
(biological dose or equivalent dose), represents the absorbed dose multiplied by the RBE to 
achieve an isoeffect with photons, and is expressed in GyRBE (ICRU 2007). 
The OER is defined as: 
 
𝑂𝐸𝑅 =  
𝐷ℎ𝑦𝑝𝑜𝑥𝑖𝑎
𝐷𝑎𝑖𝑟
|
𝑖𝑠𝑜𝑒𝑓𝑓𝑒𝑐𝑡
.                           (2.12) 
  
The OER is the ratio of doses without (Dhypoxia) and with oxygen (Dair) to produce the same 
biologic effect. As seen in figure 2.9 (right panel), OER decreases with the increasing LET. In 
other words, for a hypoxic tumor, with a low oxygenation level, lower LET particles will be 
less efficient than higher LET particles. And thus heavier particles could be more 
advantageous than protons in tumor control rate (Scifoni et al 2013). 
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Fractionation of the treatment plan (in typically 20-30 fractions), allows the exploitation of 
the differential effect on the survival between low and high α/β tissue types. The rationale 
behind fractionation can be explained by the concept of the classic 4R’s: Repair (repair of 
damages by normal tissue cells), Redistribution (change in cells cycle between fractions), 
Reoxygenation (oxygenation of the tumor and thus higher efficiency) and Repopulation 
(increase in cell division). Radiosensitivity is now also considered as an important factor and 
the 5
th
 R due to the intrinsic radiosensitivity/radioresistance of different cell types. 
Fractionation can also impact RBE by affecting the shoulder of the cell survival between 
photons and ions, progressively increasing RBE after the first few fractions, as seen in Hall 
(2012). 
 
 
 
 
 
 
 
 
 
Figure 2.9: Left: Cell survivals for photons and heavy ions from Schardt et al (2010), and 
RBE at two different end points. Right: RBE and OER as function of LET from Hall (2012). 
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 Accelerator and beam delivery 2.4.
 Accelerator types 2.4.1.
Methods in ion acceleration and delivery have evolved over the last few decades (Owen et al 
2016). Most particle therapy centers currently in operation are equipped with proton 
cyclotrons, with recent developments affording a compact design, with high intensity and 
stable delivery, such as the supra-conducting synchro-cyclotron. However, energy variation is 
made available by adding degraders, which deteriorate the beam quality and intensity. Some 
synchro-cyclotron models are foreseen to be used in conjunction with other ions, such as the 
planned C-400 (IBA), but a prototype has yet to be made available (Jongen et al 2010, Owen 
et al 2016). On the other hand, synchrotrons allow for active energy variation and are the only 
clinically viable method to deliver heavy ion beams at the moment. 
Cyclotrons and particularly synchrotrons are expensive in comparison to conventional 
radiotherapy; however, technological developments as well as the increase in the number of 
centers will lead to more affordable market price with greater possibilities, such as one room 
solutions. 
The development of novel beam production and delivery techniques is also underway, such as 
laser-based accelerator systems (Schwoerer et al 2006) and dielectric-wall accelerators (Poole 
et al 2007). 
Regardless of the acceleration mechanism, the energetic ions are brought to the treatment 
room through a horizontal/vertical fixed beamline or gantry system, the latter providing 
greater geometric freedom for dose delivery. Compact gantry systems are available for 
protons and are becoming the gold-standard. The first worldwide heavy ion gantry was 
located at the Heidelberg Ion Beam Therapy center (see section 2.5) while underdevelopment 
at HIMAC facility (Iwata et al 2013, Noda 2016, Owen et al 2016). 
 
 Delivery techniques 2.4.2.
After transport through the beamline, different beam delivery techniques are possible. 
Historically, the first techniques were “passive”, using passive elements with scattering 
system, energy degraders (modulating wheels / range shifters) and beam shapers (collimator, 
compensator), as seen in figure 2.10. The passive method provides a laterally broader beam 
from the initial pencil-like irradiation and then spreads the Bragg-peak longitudinally to adapt 
the distal edge of the dose distribution to the target position and size, while shaping the beam 
laterally accordingly. However, this technique can lead to unwanted dose in regions of normal 
tissue upstream from the tumor. 
Another delivery techniques, so-called “active” beam shaping, such as raster scanning 
developed at GSI (Haberer et al 1993), affords target volume scanning with magnetic 
deflection of the beam (figure 2.11) for a fully active beam delivery. Scanning techniques 
were also introduced at the Paul Scherrer Institut (PSI) with spot scanning (Pedroni et al 
1995), achieving longitudinal variation from the cyclotron beam with a passive range shifter. 
Scanning is performed for each energy slice, meaning that a certain depth has to be selected 
either by an active system (synchrotron for fully active beam delivery) or with degraders from 
an initial energy (cyclotron), providing conformal treatments with respect to tumor shape. 
Inverse treatment planning is implemented to design irradiations composed of several 
thousands of pencil beam scanning positions (called raster points in this work), as briefly 
described in section 2.6. 
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Figure 2.10: Schematic of a passive beam delivery from Schardt et al (2010), describing the 
evolution of the initial beam through the different passive elements to shape the beam to the 
tumour. 
 
 
 
 
 
 
Figure 2.11: Workflow of an active beam scanning irradiation delivery from Schardt et al 
(2010), with an energy selection to reach a certain depth and a magnetic lateral scan to shape 
the delivery to the target volume. 
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  The Heidelberg ion beam therapy center 2.5.
The HIT center is a synchrotron based clinical facility with an active beam scanning delivery 
system similar to the prototype at GSI. In addition to two horizontal beam clinical treatment 
rooms, a third room is equipped with an isocentric gantry (figure 2.12). A third horizontal 
beam room is available for experiments. In addition to the clinically used protons (
1
H) and 
carbon ions (
12
C), two other ion species are available, 
4
He and 
16
O.  
For each ion species, the synchrotron can accelerate 255 discrete energies (205 for oxygen) up 
to ~220MeV/u for protons and helium ions, and up to ~430 MeV/u for carbon and oxygen 
ions, each with ~32 cm range, except for 
16
O with a range about 23 cm. A detailed description 
of the beams characteristics are presented in Chapter 3. The beam spot size (i.e., lateral size in 
air at isocenter) and intensity is adjustable for each energy from a library of 6 foci and 12 
beam intensities. In clinical practice, 4 foci and 10 intensities are most commonly used 
(Parodi et al 2012). The so-called “Beam applications and monitoring system” (BAMS), 
situated at the end of the beamline, consists of three ionization chambers (IC) to monitor the 
fluence delivered per raster point and two multiple wires proportional chambers (MWPC) to 
verify and give feedback loop controls on the position of the beam and the its size during 
irradiation. 
Treatment rooms are equipped with a 6 degrees of freedom robotic treatment table, granting 
sub-millimetric patient positioning before irradiation and verification with 2D-kV x-ray 
imaging systems.  
 
 
 
 
 
 
Figure 2.12: Layout of the HIT facility adapted from https://www.klinikum.uniheidelberg.de/, 
with (1) ion sources, (2) linear accelerator, (3) synchrotron, (4) high energy beam transfer 
line, (5) horizontal treatment rooms, (6) x-ray positioning control system, (7) gantry, (8) 
gantry treatment room, (9) PET-CT room and, (10) experimental room. 
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 Treatment planning system and uncertainties 2.6.
The treatment planning system (TPS) is used in modern conventional radiotherapy to create 
optimized radiation treatment plans from a complex patient geometry via an inverse planning 
algorithm. Such an approach is also needed for particle therapy, in the case of active beam 
delivery, to calculate particle fluence for thousands of raster points to reach specified dose 
levels. At HIT, the commercial TPS used (SyngoPT, Siemens), is based on TRiP98, the TPS 
developed at GSI for active beam scanning (Krämer 2009, Krämer et al 2000). It allows 
calculation of physical and biological dose distributions, the latest using the LEM model for 
RBE predictions. The TPS uses a physical database describing the laterally integrated depth 
dose distributions and lateral dose profiles (modelled with a double Gaussian 
parameterization), as obtained from experimentally validated Monte Carlo (MC) simulations 
(see section 2.7). Thus, the absorbed dose for a pencil beam can be calculated according to: 
 
𝐷𝑃𝐵(𝑥, 𝑦, 𝑧) = 𝑑𝑑𝑑(𝑧) × 𝐿𝑎𝑡(𝑟, 𝑧)  ×  𝑁𝑃𝐵,                        (2.13) 
 
with 𝐷𝑃𝐵(𝑥, 𝑦, 𝑧) beingthe dose due to a pencil beam, 𝑑𝑑𝑑(𝑧) the laterally integrated depth 
dose distribution for the corresponding energy, representing the dose deposition along the 
depth per particles, 𝐿𝑎𝑡(𝑟, 𝑧) the description of the lateral distribution, represented by a 
normalized double Gaussian at HIT, and 𝑁𝑃𝐵 the number of particles related to this pencil 
beam. 
Subsequently the total dose for each voxel can be obtained by summing up the dose 
contribution of each pencil beam following: 
 
𝐷𝑡𝑜𝑡𝑎𝑙(𝑥, 𝑦, 𝑧) =  ∑ 𝐷𝑃𝐵(𝑥, 𝑦, 𝑧)𝑃𝐵 .                                (2.14) 
 
For biological calculation of heavy ions, spectra of the fragments along the depth is pre-
calculated with MC (Parodi et al 2012) and coupled to the LEM for RBE predictions. 
 
As in conventional radiotherapy, plans are based on computed tomography (CT) of the 
patient, which is typically used in combination with other modalities (e.g. magnetic resonance 
imaging (MRI), positron emission tomography (PET)) for delineation of the OAR and targets 
(planning target volume (PTV), clinical target volume (CTV), gross tumor volume (GTV)). 
For dosimetric calculations on the CT images, while in conventional radiotherapy a 
calibration is performed between Hounsfield unit (HU) and mass as well as electron density, 
in particle therapy the calibration is defined between HU and water equivalent path length or 
stopping power ratio. The ion beam range is then expressed in the patient geometry in terms 
of water equivalent thickness. The WEPL is linked to the ratio of the stopping power between 
the given material and water, which is correlated to the relative electron density of this 
material and thus to its HU on the CT. An example of HU-WEPL calibration curve is shown 
in figure 2.13. However, this conversion is one of the main sources of uncertainty in particle 
therapy estimated at about 1-3% (accounting for both HU values uncertainty and calibration 
curve uncertainty), thus meaning 1 to 3 mm range uncertainty for a 10 cm deep-seated tumor 
(Rietzel et al 2007). Several means to reduce these uncertainties involve the investigation of 
alternative calibration methods such as dual energy-CT (Yang et al 2010, Landry et al 2011, 
Hünemohr 2014) or ion-based radiography/tomography (Schneider et al 2005, Schulte et al 
2008, Rinaldi et al 2013, Meyer et al 2017), in order to determine more precisely the stopping 
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power ratio of the material, thus decreasing the safety margins applied in clinical practice. 
Furthermore, other sources of uncertainty appear along the course of fractionated treatment, 
such as patient misalignment, as well as inter-fractional changes (anatomical changes) and 
intra-fractional patient motion (e.g. respiration, heart beat). For these sources of uncertainties, 
other dedicated techniques can try to reduce the uncertainties (e.g. cone beam CT imaging and 
re-planning (Landry et al 2015)), while other methods focus on their quantification, such as 
in-vivo monitoring with PET (see section 2.8, Parodi 2008, Bauer et al 2013a) or range 
verification with prompt gamma imaging (Min et al 2006, Richter et al 2016).  
Newer versions of TPS incorporate more robust planning strategies (Fredriksson 2013) by 
including some of these uncertainties (e.g. HU-WEPL conversion, patient positioning) to 
more accurately predict the actual delivered dose to the target in the patient. 4D treatment 
planning is also employed (Richter et al 2013) to take into account motion, typically induced 
by respiration (e.g. on liver, lungs). 
 
 
 
 
 
 
 
 
 
Figure 2.13: HU-WEPL calibration curve from measurements of tissue equivalent materials 
(Krämer et al 2000) 
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Figure 2.14: Left: Depth dose distributions comparison between FLUKA MC predictions and 
measurements for protons and carbon ions. Right: Lateral profiles comparisons between 
simulations and measurements for carbon ions. (Battistoni et al 2016) 
 
 
 FLUKA Monte Carlo code 2.7.
MC codes are powerful tools in the field of particle physics and therapy. They provide the 
means to precisely describe the interactions of particles within matter, taking into account the 
particular geometry and medium composition traversed by the particles. Several codes are 
used in the field of ion beam therapy such as FLUKA (Ferrari et al 2005, Böhlen et al 2014), 
GEANT4 (Agostinelli et al 2003, Allison et al 2006), MCNPx (Hughes et al 1997), PHITS 
(Niita et al 2006) and SHIELD-HIT (Dementyev and Sobolevsky 1999, Gudowska et al 
2004). Their predictions are particularly useful in describing the particle interaction and dose 
deposition inside voxelized patient geometry as in Bauer et al (2014), to support quality 
assurance and treatment verification (Molinelli et al 2013) or as support in developing new 
techniques (e.g. imaging, detectors applications). At HIT, the FLUKA MC code was chosen 
to generate the analytical TPS physics database (depth dose distribution, double Gaussian 
functions, secondary particles depth spectra for biological dose calculations of heavy 
ions(Parodi et al 2012, Parodi et al 2013, Mairani et al 2010)), as well as to support treatment 
verification with PET range verification analysis (see section 2.8, Bauer et al 2013a, as well 
as physical dose calculation and biological dose calculation for radiobiological experiments 
(Bauer et al 2014, Mairani et al 2016a, Mairani et al 2017a). Before its implementation, 
validation of FLUKA’s dosimetric predictions was achieved for protons, carbon ions and 
oxygen ions (Parodi et al 2012, Parodi et al 2013, Kurz et al 2012) (figure 2.14). 
The FLUKA code is a general purpose MC code simulating the interaction and transport of 
particles, developed in collaboration between the European Organization for Nuclear 
Research (CERN) and the Italian institute for nuclear physics (INFN). General information 
and descriptions can be found in Battistoni et al 2016 and www.fluka.org. The description of 
energy loss and fluctuation is based on an alternative approach to Landau and Vasilov 
distributions (Ferrari et al 1997) by simulating secondary electron production and transport 
down to 1keV (Battistoni et al 2016). Multiple Coulomb scattering is handled with an 
extended model based on Molière Theory, with the possibility of single Coulomb scattering. 
Nuclear processes (figure 2.14) are handled by the PEANUT (Pre-Equilibrium Approach to 
Nuclear Thermalization, Ferrari and Sala 1997) models for hadron-nucleus interactions for an 
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energy range from the MeV order up to 5GeV, describing the interactions along the steps of a 
generalized intranuclear cascade (GINC), followed by a pre-equilibrium particle emission and 
equilibrium phase. Based on a statistical approach, produced nuclei from the interaction can 
undergo evaporation. Nucleus-nucleus interactions are described by two distinct models in the 
therapeutic energy range, RQMD (relativistic quantum molecular dynamics, Sorge et al 1989) 
from 100 MeV/u to 5GeV/u, and the BME (Boltzmann master equation, Cavinato et al 1998) 
below 100 MeV/u, and can be interfaced with PEANUT (e.g. for further processing of 
fragments).  
Biological modeling can be interfaced with the FLUKA code from an external database. At 
HIT, a re-implementation of the LEM was linked to FLUKA (Mairani et al 2010), predicting 
the RBE-weighted dose (DRBE) for a mixed radiation field such as in the case of carbon ions. 
The dose-weighted average ?̅? and ?̅? terms, from the LQ formalism, are computed online for 
each voxel j(x,y,z) in the following approach: 
 
𝛼?̅? =  
∑ 𝛥𝑑𝑖,𝑗∙𝛼𝑖,𝑗𝑖
∑ 𝛥𝑑𝑖,𝑗𝑖
      and      √𝛽?̅? =  
∑ 𝛥𝑑𝑖,𝑗∙ √𝛽𝑖,𝑗 𝑖
∑ 𝛥𝑑𝑖,𝑗𝑖
  ,                  (2.15) 
 
where 𝛥𝑑𝑖,𝑗 is the dose from a particle i of the mixed radiation field in voxel j, associated to 
its corresponding α and β terms, and then summed over the ith particles depositing dose inside 
the voxel j. The α and β terms are calculated on the run knowing the particles LET from the 
simulation and its corresponding α or β term from user external database (Battistoni et al 
2016). Other biological models, phenomenological (Wedenberg et al 1993, Mairani et al 
2016a) or biophysical (MKM), can also be interfaced by the user. 
 
 
 
 
 
Figure 2.15: Diagram of the FLUKA nuclear interaction models for both hadron-nucleus and 
nucleus-nucleus interaction (from www.fluka.org , 18
th
 FLUKA course). 
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 Positron emission tomography 2.8.
Nuclear processes described in section 2.2 can lead to the creation of β+ emitters from either 
the fragmentation of the projectile or the target, as illustrated in figure 2.16 for protons (only 
from target fragments) and carbon ions (from both target fragments and projectiles, the latter 
stopping close to the Bragg peak position). As stated in section 2.2, these residuals of the 
nuclear interactions can provide useful information for monitoring the delivery “in-vivo”, and 
indirectly inferring the ion beam range. However, PET information cannot provide absolute 
dose distributions and must be compared to a reference set of data, e.g. based on MC 
simulations or prior PET. 
Several approaches have been investigated for PET monitoring, as reviewed in Kraan (2015), 
in-beam PET (e.g. during irradiations), in-room PET (after the irradiation but in the same 
room) or offline PET (after irradiation, with a PET/CT system in another room). From the 
pioneering work in GSI (in-beam PET, Enghardt et al 2004) and Massachusetts General 
Hospital (offline PET/CT system, Parodi et al 2007), the advantages of in-vivo PET range 
verification in the clinic has been demonstrated, as well as its limitation. At HIT, an offline 
approach was considered and used in clinical routine for in-vivo monitoring. Details about its 
workflow can be found in Bauer et al (2013a). In summary, after completing a fraction of 
radiation treatment, the patient is transported to the PET/CT room, immobilized in the same 
position as in the treatment room, where a 30 minute PET scan is acquired in list-mode. 
Compared to in-beam PET acquisition, many uncertainties are introduced due to the re-
positioning of the patient, reduced radioactivity (due to the short lifetime positron emitters), 
the biological washout due to the patient physiology, and the loss of information if several 
beams are used, with imaging only of the integral beam delivery. Despite these drawbacks 
such methods can be readily integrated into the clinical workflow and show fairly good results 
(Shakirin et al 2011), compared to the more demanding implementation of in-beam PET or 
the suggested in-room PET, as evaluated in Shakirin et al (2011). 
At HIT, PET acquisitions are compared to MC-based PET predictions simulated on the 
planning CT. Positron emitter 3D distributions are recorded for 
11
C, 
13
N, 
15
O, 
30
P, 
38
K and 
post-processed to take into account physical decay from the irradiation to the acquisition time 
as well as tissue dependent biological washout (after HU-based segmentation, e.g. into fat, 
brain, soft bone, hard bone as in Parodi et al (2007)), and then convolved with a Gaussian 
kernel representing the response of the PET acquisition/reconstruction.  
The range analysis is performed with an in-house-built graphical interface based on 
MeVisLab (www.mevislab.de) (Chen et al 2017), giving range shift estimations in beam-eye-
view (BEV) using CT and PET information as seen in figure 2.17. In Handrack (2016), an 
assessment of the PET range verification performance with phantoms and patients was 
performed. Comparisons between PET simulation vs. PET simulation, PET measurement vs. 
PET measurement, PET simulation vs. PET measurement were achieved, reflecting different 
kinds of complexity and introduction of uncertainties. While phantom studies showed the 
potential of achieving range retrieval with errors below 1.5 mm, clinical studies indicated 
larger deviations due to the introduction of uncertainty in patient re-positioning and biological 
washout. Results suggest the use of a reference PET-CT acquisition for comparisons to 
further PET acquisitions to reduce the large uncertainty brought by the biological washout in 
MC simulations, as already suggested in Frey et al (2014). 
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Figure 2.16: PET activity induced from a quasi-monoenergetic beam irradiation for protons 
(left) and carbon ions (right) (Parodi 2004) 
 
 
 
 
Figure 2.17: PET predictions from MC FLUKA on measured CT (from acquired PET/CT) 
(top panel left) and PET/CT measurement (top panel right) for a patient case, and 
corresponding analysis of the PET range difference through a BEV map (bottom left) and 
associated histogram (bottom right) (Handrack 2016). 
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 Summary - towards “helium therapy” 2.9.
This Chapter as introduced the physical and biological rationale for particle therapy as well as 
the description of the HIT facility, where the experimental work presented in the next chapters 
has been achieved. As previously stated in section 2.1, other ions than the clinically used 
protons and carbon ions have already been explored clinically back in the 50’s to 90’s at the 
Berkeley institute (Lawrence et al 1964, Kaplan et al 1994, Char et al 1998). However such 
treatments were not relying on the latest evolution of radiotherapy and particle therapy, 
featuring: (1) the introduction of the patient 3D geometry for radiotherapy treatment planning 
(Dobbs et al 1983), (2) the development of inverse planning algorithms (Brahme 1988, 
Bortfeld et al 1990) (3) the implementation of new delivery techniques in particle therapy 
(e.g. fully active delivery). The general characteristics of ions are known regarding the 
physical and biological concepts presented in section 2.2 and 2.3, respectively. However, in 
order to introduce in modern clinical routine ions such as 
4
He, new experimental 
measurements with the latest delivery techniques are needed in order to:  
(1) compare the physical features of these “new” ions with respect to the standard protons and 
carbon ions, with similar, state-of-the-art delivery techniques; 
(2) thoroughly validate MC predictions used for planning/dose recalculation or for database 
creation as in Parodi et al (2012); 
(3) evaluate the biological properties needed for radiobiological modeling; 
(4) perform treatment planning comparisons between ions for different tumor entities. 
For helium ions, step (1) will be described in Chapter 3 and continued in Chapter 6. The 
validation of MC FLUKA predictions, step (3), will be shown in Chapter 4, and in Chapter 6 
for the deployment of a novel MC-based TPS. Biological validations of different 
radiobiological properties (step (3)) have been enabled by the work of this thesis and are still 
under investigations, but the resulting RBE model proposed for planning will be used for step 
(4) and presented in Chapter 7, using the improved simulation framework presented in 
Chapter 5. Chapter 8 will then conclude the thesis with an outlook to the next steps toward 
helium ion therapy including new biological experiments (cells, animals), the improvement of 
the computational tools (e.g. MC improvements, new analytical TPS) as well as the 
possibility of in-vivo range verification with PET.  
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 Experimental dosimetric Chapter 3.
comparison of 1H, 4He, 
12C and 16O scanned ion 
beams at HIT 
 
 
 
In this chapter, a thorough experimental comparison of the different ions available at HIT is 
performed, highlighting potential advantages of helium ions for therapy. The database 
obtained from all the reported measurements was a necessary step in order to perform the 
validation of the dose predictions from the Monte Carlo code FLUKA for helium ions, as 
presented in Chapter 4. The newly obtained dosimetric measurements were also used to refine 
the FLUKA simulations of the remaining different ions of HIT. The work presented in this 
chapter has been submitted for publication (Tessonnier et al 2017a). 
 
 
 
 Background 3.1.
Since the first clinical applications of ion beams (mainly protons and helium ions) to radiation 
therapy half a century ago at Lawrence Berkeley Laboratory (LBL), the interest for particle 
therapy has grown considerably. Currently, there are roughly sixty facilities in operation 
(www.ptcog.ch 2016) using either carbon ions (10 centers) or protons (52 centers). The 
rationale for implementing particle therapy over conventional photon radiotherapy stems from 
the favorable physical and biological properties. The increased ionization density, especially 
enhanced at the end of the beam range in the so-called Bragg peak (BP), theoretically allows 
for a better dose conformation to the tumor, while optimally sparing surrounding healthy 
tissue (Schardt et al 2010). Moreover, the higher linear energy transfer (LET) of ions in 
comparison to photons offers radiobiological benefits, especially in terms of a selectively 
enhanced relative biological effectiveness (RBE) within the Bragg peak for ions heavier than 
protons.  
At HIT, additionally to the clinically used protons and carbon ions beams, two others beam 
species are available for physical and biological research: 
4
He and 
16
O ions. Interest in using 
these particles for clinical purposes increased over the last decade, as reflected in the number 
of recent publications comparing physical and biological features. Most studies are based 
either on Monte Carlo simulations (Kempe et al 2007, Kantemiris et al 2011, Burigo et al 
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2015) or analytical models (Fuchs et al 2015, Krämer et al 2016), providing comparisons of 
the physical dosimetric characteristics or biological effects when coupled with biological 
models. Preclinical planning studies based on analytical dose calculation algorithms have also 
been recently published (Grün et al 2015, Knäusl et al 2016).  
Helium ions, used successfully during the Berkeley trial for patient treatment (Castro et al 
1997), possess properties in between proton and carbon ions. Compared to protons, they are 
expected to offer improved dose conformation to the target due to reduced lateral scattering 
and to exhibit a higher RBE. In comparison to carbon ions, helium ions afford increased 
sparing of the healthy tissue located behind the tumor, which can be mainly attributed to the 
reduced fragmentation tail. On the other hand, oxygen ions exhibit an even higher LET than 
carbon ions, thus enabling a lower oxygen enhancement ratio and a higher efficiency against 
hypoxic tumors (Scifoni et al 2013). Experimental dosimetric characteristics of proton beams 
for active and passive delivery can be found in the literature (Pedroni et al 2005, Parodi et al 
2012, Würl et al 2016, Grassberger et al 2015) for depth and lateral dose distributions as well 
as for carbon ions (Schwaab et al 2011, Inaniwa et al 2014, Tessonnier et al 2016). However, 
compared to the relatively well-established proton and carbon ion therapy, only few 
dosimetric studies are available for helium (Lyman and Howard 1977, Krämer et al 2016) and 
oxygen ions (Kurz et al 2012) to validate the different proposed calculation models. The 
acquisition of new dosimetric data is thus essential to provide validated inputs for treatment 
planning systems in preparation for radiobiological experiments which aim to assess 
radiobiological properties and validate available biological models (Krämer et al 2016, 
Mairani et al 2016a, Dokic et al 2016). The combination of these dosimetric data with 
radiobiological information will enable experimentally validated treatment planning studies 
for clinical evaluation of the treatment of choice in different anatomical locations.  
We present in this chapter quantitative comparisons of the dosimetric characteristics of 
protons, helium, carbon and oxygen ions from recently acquired data in a facility using an 
active beam delivery. The selected data, completing the description of all ion species available 
at HIT, feature depth dose distributions (ddds), lateral profiles and their single or double 
Gaussian parametrization, as well as dosimetric characteristics of spread-out Bragg peaks 
(SOBP). This study aims to provide a fundamental set of data for validation of dose 
calculation models. 
 
 Material and Methods 3.2.
 Pencil-Beam - Depth dose distributions 3.2.1.
 Reference measurements 3.2.1.1.
Pencil-beam ddds were acquired in a clinical room of HIT. Measurements were performed 
with the PeakFinder (PKF) water column (PTW, Freiburg) equipped with two large parallel 
plane ionization chambers (ICs, radius 4.08 cm) at a reference voltage of 400V, allowing for 
acquisition of laterally integrated ddd with sub-millimetric precision (Karger et al 2010, 
Sanchez-Parcerisa et al 2012, Kurz et al 2012). For all acquired ddds, the step size in the BP 
region was set to 0.05 mm. The PKF was set right after the nozzle, as described in the work of 
Sanchez-Parcerisa et al (2012), and the absolute position in water was retrieved as if the beam 
was impinging on water from vacuum, i.e., by correcting for the energy loss in the vacuum 
window, beam monitor system and air gap of the HIT beamline. According to Sanchez-
Parcerisa et al (2012), the achievable BP accuracy is estimated to be better than 0.05 mm, 
though estimated at 0.1 mm by manufacturer. Furthermore, the reproducibility was assessed 
by repeating a reference measurement for the highest carbon ion beam energy over the 
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measurement period of four non-consecutive days and in two clinical rooms. The 
reproducibility was found in the same range as the accuracy presented by Sanchez-Parcerisa 
et al 2012 with a value of about 0.05 mm. 
The energy library of the HIT synchrotron foresees 255 discrete energies for protons, helium 
(
4
He) and carbon ions (
12
C), and 205 for oxygen ions (
16
O), with energy range of [48.12-
221.05 MeV/u], [50.57-220.51 MeV/u], [88.83-430.10 MeV/u] and [103.77-430.32 MeV/u], 
respectively. A total of 10 discrete energies for protons, helium and carbon ions, and 8 for 
oxygen ions, due to the restricted energy range, were chosen for this study. The datasets 
common to all ions shared a similar energy index from the energy tables, thus corresponding 
to similar range in water, with less than 2 mm difference in BP position. Details about the 
chosen energies are presented in table 3.1. The irradiation consisted in the delivery of quasi-
monoenergetic beams along the central axis, with an initial energy corresponding to the 
selected index. Irradiations were performed with clinical-like lateral beam sizes (foci). For 
protons and helium ions, the smallest focus (focus index 1) was used, which exhibits a full-
width at half-maximum (FWHM) size in air at isocenter without ripple filter (RiFi) of [32.4-
8.1 mm] (Parodi et al 2012) and [18.6-4.9 mm], respectively, in the energy range above 
mentioned. For carbon and oxygen ions, focus index 3 was chosen, with FWHM values 
without RiFi of [12.1-7.8 mm] (Parodi et al 2012) and [13.1-10.1 mm], respectively, in the 
selected energy range. However, as evaluated in Kurz et al (2012), the focus size does not 
influence on the BP position. The beam intensity was set to 3.2 · 10
8
, 8.0 · 10
7
, 1.0 · 10
6
 and 
4.0 · 10
6
 particles per second, respectively, for protons, helium, carbon and oxygen ions, 
corresponding to the same intensity index (intensity 4) in the HIT accelerator libraries. This 
intensity allowed staying in the same charge measurement range of the PKF electrometer for 
all ions and energies, preventing from charges overflow and ensuring a good signal quality. 
Measurements were performed with and without RiFi, from an absolute depth in water of 16 
mm to at least 20 mm after the BP position.  
The position of the BP was found by fitting the region of the ddd above 85% of the maximum 
dose with a 4
th
 order polynomial. In a second step, as in Kempe et al (2007) and Bortfeld 
(1997), the distal range 80% (R80), corresponding to the distal position of the ddd reaching 
80% of the maximal dose was extracted from linear interpolation and evaluated as a function 
of the initial beam energy. The other parameters of interest for all ddds (with or without RiFi) 
were: 
- the Peak-width 80% (PW), corresponding to the distance in mm between the proximal 
and the distal positions in water of the dose level 80%, 
- the entrance-to-peak ratio (EPR), corresponding to the ratio of the peak dose relative 
to the entrance dose at 16 mm in water, 
- the distal fall-off, corresponding to the distance in mm between the positions of the 
distal 80% and 20% dose fall-offs in water, 
- the tail-to-peak ratio, corresponding to the ratio of the dose in water 10 mm after the 
BP position, relative to the peak dose. 
These ddd parameters were evaluated as a function of their corresponding R80 for each 
ion/energy combination without RiFi. Furthermore the range shift and PW changes introduced 
by the RiFi were analyzed by comparing the corresponding parameters with and without RiFi. 
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Energy Index Ion  Energy [MeV/u] RiFi Voltage [V] Study 
6 
p 54.19 
w / wo 400 ddds 
He 56.44 
C 100.07 
O 117.20 
30 
p 78.30 
w / wo 400 ddds 
He 79.78 
C 145.47 
O 171.03 
33 
p 80.90 
wo 
100, 200, 300, 400, 500, 600 
CCE 
He 82.33 
C 150.42 50,100,150, 200,250, 300,350, 400, 500, 600 
O 176.88 100, 200, 300, 400, 500, 600 
60 
p 101.90 
w / wo 400 ddds 
He 103.05 
C 190.75 
O 224.84 
90 
p 121.95 
w / wo 400 ddds 
He 122.93 
C 229.76 
O 271.59 
120 
p 139.84 
w / wo 400 ddds 
He 140.71 
C 264.95 
O 313.96 
150 
p 156.35 
w / wo 400 ddds 
He 157.03 
C 297.79 
O 353.56 
152 
C 299.94 
wo 
50,100,150, 200,250, 300,350, 400, 500, 600 
CCE 
O 356.20 100, 200, 300, 400, 500, 600 
180 
p 172.11 
w / wo 400 ddds 
He 172.28 
C 329.44 
O 391.82 
205 O 430.32 w / wo 400 ddds 
210 
p 191.18 
w / wo 400 ddds He 190.85 
C 368.21 
240 
p 211.42 
w / wo 400 ddds He 210.92 
C 409.97 
255 
p 221.05 
w / wo 400 ddds 
He 220.51 
wo 100, 200, 300, 400, 500, 600 CCE 
C 430.10 
w / wo 400 ddds 
wo 50,100, 200, 300, 400, 500, 600 CCE 
 
Table 3.1: Details of the depth dose distribution (ddd) measurements: irradiation parameters 
and PeakFinder settings. CCE stands for charge collection efficiency and w/wo for 
with/without. The energy represents the nominal energy from the HIT accelerator library. p 
stands for protons, He for helium ions, C for carbon ions and O for oxygen ions. 
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 Charge Collection Efficiency 3.2.1.2.
The charge collection efficiency (CCE) of the PKF was investigated as in Kurz et al (2012) 
for three energies within the therapeutic range of each ion. Two different power supplies were 
used: the dedicated power supply of the PKF (maximum 400V) and an external one (up to 
600V). The combinations of voltage/ions used to investigate the CCE are shown in table 3.1. 
The saturation charge Qsat used to estimate the CCE in the reference measurements (400V) is 
evaluated by fitting the inverse of the charge Q collected at a voltage V with either 1/V or 1/V² 
(Podgorsak 2005), and extrapolating this relationship to zero. The uncertainty on the 
measured charge at 400V is evaluated from two measurements at 400V with the reference 
power supply and a third measurement with the secondary one. The CCE is defined as the 
ratio between the charge Q at 400V and the evaluated Qsat. The analysis for each energy and 
ion was performed on different comparable subsets of the ddd: the plateau region, the peak 
region, or the entire ddd. 
 
 Pencil-Beam – Lateral dose profiles  3.2.2.
The evaluation of the lateral dose profiles was performed in a water phantom (Karger et al 
1999) for three energies in the therapeutic energy range: [80.90 - 157.43 - 221.06 MeV/u], 
[82.33 - 158.08 - 220.51 MeV/u], [150.42 - 299.94 - 430.10 MeV/u] and [176.88 - 356.20 - 
430.32 MeV/u] for protons, helium, carbon and oxygen ions, respectively. For each ion, these 
energies have a comparable range in water (except for the highest energy of oxygen ions). As 
described in Schwaab et al (2011) and as it will be described in detail in Chapter 5, lateral 
profiles were measured horizontally, perpendicular to a vertical scanned line irradiation. Each 
irradiation plan was composed of 101 pencil beams centered horizontally at the isocenter, and 
ranging from -50 to +50 mm vertically with a step size of 1 mm. The irradiation of these 
vertical lines was performed in the HIT experimental room, using the HIT raster scanning 
system (Haberer et al 1993). The smallest foci for every ions were used, corresponding to a 
FWHM in air at isocenter of [19.6 - 10.7 - 8.1 mm], [11.3 - 6.3 - 4.9 mm], [6.5 - 3.9 - 3.4 mm] 
and [5.4 - 3.1 - 2.7 mm] for protons, helium, carbon and oxygen ions respectively, at the 
above given initial beam energies. The water phantom was positioned with its entrance 
window at the isocenter. The 24 motorized pinpoint ICs (PTW, 0.030cm
3
) are arranged in a 
block of 6 rows in depth, separated by 10 mm one from each other. In each row, 4 ICs are 
aligned horizontally, with a distance of 12 mm between the ICs. From one row to another, the 
ICs are shifted horizontally by 6mm, to avoid shadowing. The first two rows are separated 
vertically by 7 mm from the next two rows, the latter being separated also by 7 mm from the 
last two rows. This geometric arrangement allows to record data for each irradiation at 4 
different lateral points for 6 different positions in depth. After each line scan, in order to 
complete the profile, the block was moved 2 mm horizontally. After 6 irradiations, profiles 
were completed for a lateral extension of 46 mm, either from -15 mm to 31 mm or -21 to 25 
mm, depending on the row. The block was then moved further in depth and the same 
procedure was repeated. For each energy and ion, profiles were acquired in depth from about 
16 mm in water to positions 30 mm after the BP. The number of particles was adapted for 
every plan in order to acquire one full measurement in one synchrotron extraction cycle, 
leading to doses in the high dose region of about 1-2 Gy. 
As described in Schwaab et al (2011) and Parodi et al (2013), a lateral distribution can be as 
approximated by a double Gaussian distribution (Pedroni et al 2005) with the narrow 
Gaussian representing the primary core and the broad Gaussian the secondary halo: 
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𝑑(𝑥, 𝑦) = 𝑛 × [
1−𝑤
2𝜋𝜎12
 ×  𝑒
− 
(𝑥−𝑠ℎ)2
2𝜎1
2 + 
𝑤
2𝜋𝜎22
 ×  𝑒
− 
(𝑥−𝑠ℎ)2
2𝜎2
2 ] ,                (3.1) 
 
assuming a y value at 0 for the line irradiation, with d being the relative dose, x the position of 
the lateral profile, σ1 and σ2 the widths of the narrow and broad Gaussians respectively. w 
stands for the relative weight of the two Gaussians, n is a normalization factor and sh is a 
potential shift to the central position due to position uncertainties of the IC block, the water 
tank or the beam position. This kind of double Gaussian parameterization of the ions lateral 
dose profiles is implemented in the clinical treatment planning system (TPS) of HIT, based on 
single spot Monte-Carlo simulations for protons and carbon ions (Parodi et al 2013), with the 
Monte-Carlo code validated beforehand against line profile measurements to remove 
positional uncertainties of single spot measurements.  
Every profile was processed with ROOT (root.cern.ch), using the MINUIT minimization 
package with a least square optimization. The fitting weights, as described in Schwaab et al 
(2011), were defined as 1 (√𝑑/100)2⁄ , with d the measured dose. A first optimization was 
performed to retrieve the shift for every profile. This procedure allows restricting the profile 
values to lateral positions within +/-25 mm, ensuring similar lateral range for every profile 
and subsequently less variation in the retrieval of the double Gaussian parameters. During the 
second optimization pass, dose profile points with less than 0.1% of the maximum dose of the 
Bragg curve (1-2 Gy) were discarded, avoiding low dose noisy data and ensuring a correct 
convergence of the optimizer. As starting values before the second optimization for the first 
depth, σ1 was initialized as the width at isocenter expected from the accelerator library, σ2 was 
set to 0 with a weight w equal to 0. For all the next depths the initialization values were taken 
from the values obtained in the previous depth. As described in Parodi et al (2013), for light 
ions, σ1 was kept constant after 35% of the distal dose fall-off, determined from the ddd 
measurements. In order to have a fair comparison between the evolution of the double 
Gaussian parameters along the depth in water for the different ions, the extracted σ values 
were corrected for the initial beam size which changes from ion to ion. To this purpose, the σ1 
value at 0 cm depth, σ1-0cm was estimated with a linear fit from the first measurement points, 
and then quadratically subtracted from the fitted σ1 and σ2 values. 
 
𝜎𝑐𝑜𝑟𝑟(𝑧) = √𝜎(𝑧)2 − 𝜎0𝑐𝑚
2
 ,                    (3.2)  
 
This approach yields σcorr, the Gaussian width (σ1 or σ2) corrected for the beam width at 
isocenter, and can be interpreted as the evolution along the depth z of an infinitely narrow 
beam impinging on the water tank. 
A simpler description may be obtained with a single Gaussian parametrization instead of the 
double Gaussian function. After normalization to their local maximum, only the profile data 
values exceeding 20% of the local maximum are kept, in order to properly describe the main 
Gaussian core: 
 
𝑑(𝑥, 𝑦) = 𝑛 × 
1
2𝜋𝜎0²
 ×  𝑒
− 
(𝑥−𝑠ℎ)2
2𝜎0
2
 ,        (3.3) 
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assuming a y value at 0 for the line irradiation, with d being the relative dose, x the position 
on the lateral profile σo the width of the Gaussian, n a normalization factor and sh the shift to 
the central position. As described previously, σ0-0cm is estimated and subtracted quadratically 
to σ0 to ensure a fair comparison between the ions. 
 
 Spread-Out-Bragg-Peak  3.2.3.
To evaluate the impact of the ion properties on a higher level of complexity compared to 
pencil-beam situations, SOBP plans were created. The analytical TPS TRiP98 (Krämer et al 
2000, Krämer and Scholz 2000) was used to create these plans. The clinical database for 
protons and carbon ions is relying on previous works (Parodi et al 2012, Parodi et al 2013), 
while for oxygen ions the pre-clinical database is based on the work described in Kurz et al 
(2012). For helium ions, a pre-clinical database was created in this work from MC simulations 
based on the code FLUKA, for single spot irradiation, after an extensive validation against 
ddds similar to the approach described in Kurz et al (2012), as it will be described in detail in 
Chapter 4. The SOBP in water was prescribed to have a size of 140 mm × 140 mm × 140 mm, 
centered at 80 mm depth, for a planned physical dose of 1 Gy. A RiFi was used for carbon 
and oxygen ions. The optimization was performed only in depth. To obtain the planned SOBP 
lateral size, from this one-dimensionally optimized plan, a simple lateral expansion was made. 
Thus, within the same energy slice, every created pencil beam is delivering the same number 
of particles. The lateral step size between two pencil beams within one energy slice was set to 
2 mm, inferior to 1/3 of the FWHM at isocenter in air for all ions/energies. The number of 
energy slices was 38 for protons (from 89.91 to 116.85 MeV/u), 39 for helium ions (from 
89.64 to 116.58 MeV/u), and 20 for carbon (from 173.63 to 223.56 MeV/u) and oxygen ions 
(from 204.44 to 264.16 MeV/u). The irradiation was performed in the experimental room of 
HIT with an active beam delivery system.  
The dosimetric characterization was performed in the water tank described above (cf section 
3.2.2), positioned with its entrance window at the isocenter. Measurements were carried out 
both in depth and laterally. In the distal fall-off region the step size in depth for each 
measurement was about 1 mm. For the lateral measurement, 11 lateral profiles were acquired 
with at a distance of 10 mm in depth. In the lateral fall-off region the lateral step size was 
about 1 mm. 
In the depth dose measurements several parameters were analyzed: the entrance-to-plateau 
ratio (with the entrance dose taken at 16.7mm depth), the SOBP size (between the position of 
the proximal and distal 90% dose), the distal fall-off (R20-R80) and the tail-to-peak ratio (with 
the tail defined at 10 mm after R90). Some other dosimetric properties were investigated to 
verify the quality of the irradiation with measurements done inside the SOBP, such as the 
homogeneity (ratio between the minimum and maximum dose in the SOBP), the mean dose 
and its standard deviation. The lateral fall-off, defined as the distance between the 20% and 
80% doses of the normalized lateral profile, was investigated as a function of the depth in 
water. In the SOBP, the lateral sizes of the treated- (receiving at least 90% of the prescribed 
dose) and irradiated- (receiving at least 50% of the prescribed dose) volume were compared. 
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 Results  3.3.
 Pencil-Beam - Depth dose distributions 3.3.1.
 Charge collection efficiency 3.3.1.1.
Prior to analyzing the results and comparing the ddd characteristics, the CCE of the PKF 
chambers for the different ions were evaluated. The dependencies on 1/V and 1/V² as a 
function of 1/Q were investigated thoroughly for carbon ions, as in Kurz et al (2012) for 
oxygen ions. Figure 3.1 presents the inverse of the collected charge Q, in the peak region, for 
low energy carbon ions (150.42 MeV/u) as a function of 1/V (left panel) or 1/V² (right panel) 
together with the linear fit for V values above 150V (in the near saturation region with 
CCE>0.97) or for the entire voltage range. In the lower panel the CCE is displayed as a 
function of V. The adjusted R² was evaluated for the data in the near-saturation or the entire 
voltage range. The adjusted R² is defined as: 
 
𝑅𝑎𝑑𝑗
2 = 1 − 
𝑆𝑆𝑟𝑒𝑠 (𝑛−𝑝−1)⁄
𝑆𝑆𝑡𝑜𝑡 (𝑛−1)⁄
,         (3.4) 
𝑆𝑆𝑡𝑜𝑡 = ∑ (𝑦𝑖 − ?̅?)
2
𝑖 ,           (3.5) 
𝑆𝑆𝑟𝑒𝑠 = ∑ (𝑦𝑖 − 𝑓𝑖)
2
𝑖 ,           (3.6) 
 
with R²adj, the adjusted R², n the number of collected data, p the number of variable of the fit. 
SStot is the total sum of squares (linked to the data variance) with yi the charge Q at either 1/V 
or 1/V² and ?̅? the mean of the charge on the n data. SStot is the residual sum of squares with fi 
the predicted charge by the model at either 1/V or 1/V². 
 Fitting on the entire V range [50V-600V] was giving low agreements with the data on the 
near saturation region, with an adjusted R² between [0.17-0.92] for the 1/V and 1/V² 
dependencies. While fitting only in the near saturation region, adjusted R² showed better 
results with values between [0.96-0.99]. The linear fit on 1/V² showed the best agreement 
(R²>0.98) and was kept for the complete analysis of the CCE. As mentioned by Kurz et al 
(2012), the dependencies on 1/V and 1/V² are not purely linear, with a probable contribution 
of initial and general recombination (Palmans et al 2006). The results of the analysis are 
presented in table 3.2. All CCE are above 0.99. The uncertainty on the CCE was evaluated to 
be at maximum 0.4%. This finding ensures fair comparisons of the dosimetric properties of 
the ions while using the PKF as detector, as reported in the following sections. In the peak 
regions, the CCE is found lower for heavier ions due to reduced lateral and longitudinal 
straggling and superior ionization density. For low energy ions, reduced longitudinal 
straggling is expected, and consequently, a higher ionization density, leading to lower CCE. 
This result was anticipated considering the relatively lower range of low energy ions in water. 
This is particularly true for high-LET particles such as carbon and oxygen ions. As the CCE 
for protons was found higher than 0.999 in the peak region for the lowest energy investigated, 
no measurements were performed at higher energies. Compared to the peak region, the lower 
LET in the plateau region gave values of CCE even closer to unity. The data presented in 
Kurz et al (2012) were evaluated in the near-saturation region and were in good agreement 
with these findings, with CCE higher than 0.99.  
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Ion 
Energy 
index 
ddd region CCE Ion 
Energy 
index 
ddd region CCE 
p 33 
plateau 1.000 
C 
33 
plateau 0.999 
peak 0.999 peak 0.993 
ddd 1.000 ddd 0.998 
He 
33 
plateau 0.999 
152 
plateau 1.000 
peak 0.998 peak 0.996 
ddd 0.999 ddd 0.999 
255 
plateau 0.999 
255 
plateau 0.999 
peak 0.998 peak 0.997 
ddd 0.999 ddd 0.999 
O 33 
plateau 0.998 
O 152 
plateau 1.000 
peak 0.991 peak 0.993 
ddd 0.997 ddd 0.999 
Table 3.2: Charge Collection Efficiency: Results for the different ions, energy and Bragg 
curve regions investigated. The uncertainty (1 σ) on the CCE was estimated to be at 
maximum 0.4% 
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Figure 3.1: Charge Collection Efficiency for carbon ions at 80.90 MeV/u: Relation between 
1/Q as a function of 1/V (left panel) or 1/V² (middle panel). In the right panel, the CCE is 
expressed as a function of V. “Meas.” stands for measurements, “Meas. near sat. region” 
stands for measurements in the near saturation region. 
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 Distal range 80%   3.3.1.2.
Figure 3.2 displays the acquired ddds without RiFi (left panels), together with the relationship 
between the distal range 80% (R80) and the ion energies (right panels), for protons, helium, 
carbon and oxygen ions. In appendix A are presented the ddds with RiFi (figure A.1). The 
dosimetric properties of the ions are displayed as a function of R80 without RiFi in the 
following figures. The difference in R80 between curves with or without RiFi was consistent 
for every ion, with a mean value of 1.91 mm (σ = +/- 0.08 mm). At small energy a 
dependence was observed, with values ranging from about 1.94 mm for low beam energies 
(R80 ~ 26 mm) to 1.89 mm for higher beam energies (R80 ~ 312 mm). 
 
 Peak-width 3.3.1.3.
The peak-widths of the depth dose distributions are shown in figure 3.3 (top right left) for 
every ion with or without RiFi as function of R80. Without RiFi, a linear trend can be 
observed for all ions with a steeper slope for lighter ions. The range of observed PW is 
between [0.9-8.0 mm] for protons, [0.7-4.4mm] for helium ions and [0.6-2.7 mm] for heavier 
ones. The enlargement of the PW with increasing energy is mainly related to the range 
straggling effect along the path of the ions in addition to multiple coulomb scattering, leading 
to broader peaks at large depths. At higher energies with R80>120 mm, protons and helium 
ions exhibit a PW/R80 ratio 3.5 and 1.9 times larger than oxygen ions, respectively, while 
carbon ions exhibit a PW/R80 ratio 1.1 times larger than oxygen, as seen in Appendix A 
(figure A.2). As a function of particle mass M, the PW/R80 results, relative to oxygen ions, 
suggest a relationship for protons, helium and carbon ions respectively of about 0.85 ×
(√𝑀𝑂 √𝑀𝑝)⁄ , 0.93 × (√𝑀𝑂 √𝑀𝐻𝑒)⁄  and 0.97 × (√𝑀𝑂 √𝑀𝐶)⁄ . These results are close, but 
slightly inferior, to the dependency of 1 √𝑀⁄ , with M the particle mass, of the range 
straggling width over range (Schardt et al 2010) dependency expected without consideration 
of other effects (e.g. density inhomogeneities or initial energy spread). The presence of the 
RiFi increases the PW due to the introduction of an additional range spread resulting from its 
shape. For heavy ions, the PW increases from 1.7 mm for low energy to about 1.1 mm at 
higher energy for carbon ions and 1.6 mm for oxygen ions. For protons and helium ions, the 
increase at low energy is similar to heavier ions, about 1.5 mm and 1.6 mm respectively, but 
decreasing to 0.2 mm and 0.6 mm at higher energies. For lighter ions, when the energy and 
thus the position of the BP in water increase, the effect of the initial energy spread due to the 
RiFi becomes less important regarding the effects of range straggling.  
 
 Entrance-to-peak ratio 3.3.1.4.
 The EPR, is shown in figure 3.3 (top left) for the different ion species (with or without RiFi) 
as a function of R80. For R80 smaller than 52 mm and 80 mm for both measurements with and 
without RiFi, respectively, EPRs are discarded from the analysis, since the entrance dose 
value at 16 mm in water is already on the ascendant part of the BP. Without RiFi for low 
beam energies (R80 < 140 mm), the heavier ions have an advantageous EPR [16-19%] 
compared to protons [20-21%] and helium ions [17-19%], due to a smaller longitudinal 
straggling leading to a narrower PW and thus a higher BP. For energies with R80 >140 mm, 
the advantage of the heavy ions in EPR is lost due to an increase of nuclear interactions, 
reducing the peak height and producing buildup in the plateau, resulting in an increased EPR 
up to 36% for carbon ions (29% for oxygen ions at the highest energy available). The 
fragmentation of helium ions, associated to the enlargement of the PW, yields EPR values 
from 19% to 28%. Protons EPR rises from 21% to 25% at high energy. The introduction of 
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the RiFi, leading to a broader PW as seen previously, changes the ratio between the entrance 
and the peak dose. The heavier the particle, the larger is the impact on the PW, as seen 
previously. This yields an absolute increase in EPR values of 8% to 6% for oxygen ions at 
larger depth, 7% to 4% for carbon ions, 5% to 1% for helium ions and 3% to below 0.5% for 
protons. 
 
 Distal fall-off 3.3.1.5.
The distal fall-off expressed as a function of R80, is shown in figure 3.3 (bottom left) for the 
different ions with and without RiFi. Without RiFi, the evolution of the distal fall-off shows a 
linear trend for every ion species from [0.5-4.3 mm], [0.3-2.4 mm], [0.2-1.7 mm] for protons, 
helium and heavier ions respectively. For lighter ions, due to the range straggling along the 
path, the distal fall-off is larger than for heavier ones. With the introduction of the additional 
range spread due to the RiFi, the distal fall-off increases particularly for heavier ions, where 
the RiFi impact is larger than the one introduced either by range straggling or multiple 
coulomb scattering. This increase was about [1.1-0.7 mm] for heavy ions, [0.9-0.3 mm] for 
helium ions and [0.8-0.2 mm] for protons, for the whole energy range. At low energies and 
thus shallow BP depths the impact on the distal fall-off is higher than at larger 
energies/depths, due to the importance of the energy spread introduced by the RiFi, compared 
to the one introduced by range or lateral straggling.  
 
 Tail-to-peak ratio 3.3.1.6.
The tail-to-peak ratio is shown as a function of R80 in figure 3.3 (bottom right), for each ion 
species with or without RiFi. Without RiFi, the evolution of this relative dose follows a linear 
trend for ions with charge Z>1, due to the fragmentation of the primary beam into lighter 
fragments. The relative tail contribution to the dose, within the available R80 range, was about 
[1-16%] for oxygen ions, [1-14%] for carbon ions and [<0.5-4%] for helium ions. For 
protons, although there is no fragmentation tail due to the primary beam, the tail-to-peak ratio 
was nonzero for R80 superior to 200 mm, due to the large distal fall-off at these energies, and 
up to 4% for high initial beam energies. By introducing the RiFi, a maximal tail-to-peak ratio 
dose enhancement of 3%, 2% and <0.5% was observed for oxygen, carbon ions and the 
lighter ions, respectively. The main reason behind this rise is the normalization with respect to 
the dose in the BP, which is getting broader and smaller, as seen before for the EPR. Thus, 
when normalizing the tail dose to the entrance, no relevant difference was observed between 
the tail-to-entrance curves with or without RiFi.  
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Figure 3.2: Depth dose distributions results for protons, helium, carbon and oxygen ions, 
respectively, from the top to the bottom panels. In the left panels the ddds of the ions in water, 
in the right panels, the dependence of R80 as a function of the ion energy. 
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Figure 3.3: Parameters inferred from the depth dose distributions: PW (top left panel), EPR 
(top right panel), distal fall-off (bottom left panel) and tail-to-peak ration as a function of R80. 
Protons are represented with squares, helium ions with circles, carbon ions with triangles and 
oxygen ions with diamonds. Parameters with the RiFi are shown with filled symbols, while 
without RiFi are not. 
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 Pencil-Beam – Lateral dose profiles  3.3.2.
Profiles measured at the entrance or near the BP position in the water tank are shown in figure 
3.4 for the three energies (low, medium and high) and four ion species investigated without 
RiFi, together with simple and double Gaussian fits. As described in Weber and Kraft (1999), 
RiFi for carbon ions has only a minor influence on the lateral profiles, leading to an increase 
of the FWHM at isocenter for focus 1of about 1.9 and 0.3 mm for low and high energy 
beams, respectively. While the simple Gaussian fit allows to describe the central core of the 
Gaussian and the evolution of σ in depth, the double Gaussian, introduced by Pedroni et al 
(2005) and used in Schwaab et al (2011) for HIT data, describes these profiles more precisely. 
Other parametrizations reviewed in Bellinzona et al (2015), such as a triple Gaussian 
parametrization (Inaniwa et al 2014), could help describing the behavior of the profiles more 
precisely, particularly for the entrance regions and for ions with charge Z>1. In fact, the first 
Gaussian provides a good description of the central core dominated by multiple Coulomb 
scattering with small angles. The second Gaussian gives a good approximation of non-elastic 
interactions in water as well as elastic large-angle single scatters (defines as “halo” in 
Gottschalk et al (2015)). However, with only two Gaussians, the parametrization fails to 
reproduce the “spray” (Gottschalk et al 2015) stemming from large angle scatters from elastic 
interactions in the beamline and air, with an effect more pronounced for protons as it can be 
observed for the entrance profile at high energy (figure 3.4). Nevertheless, at larger depth, the 
contribution of the spray is smeared out by the importance of interaction in water (elastic/non 
elastic) in the lateral field extension relevant for this study.  
In order to compare the evolution of the single or double Gaussian parametrization for the 
different ions, the width of the beam at isocenter was extracted to obtain by a subsequent 
quadratic subtraction the different σcorr as described in 2.2. For the simple and double 
Gaussian parametrization, the extracted σ0-0cm / σ1-0cm and thus the corresponding FWHM0-0cm 
/FWHM1-0cm are compared to the nominal foci values at isocenter from the HIT accelerator 
library and to the values measured by the beam monitors chambers (BAMS, Beam 
Application and Monitoring System), subsequently converted to FWHM at isocenter. In 
figure 3.5 (top panels), it can be seen that for protons, helium and carbon ions, the 
extrapolated FWHM values from the simple and double Gaussian parametrization are similar, 
with the largest difference for low energies where the contribution of the second Gaussian 
leads to a smaller central core for σ1-0cm compared to σ0-0cm. Our measurements and the ones 
from the BAMS are inside the tolerance of +25%/-15% accepted at HIT. The maximum 
deviation between upstream BAMS measurements converted to the isocenter and our data 
acquired in the water phantom was +10%, while the maximum difference between nominal 
value and measurement in the phantom was +7%. However, for oxygen ions, the values 
measured in this study were out of tolerance, due to the fact that the beam foci were not yet 
fully optimized by the accelerator team at the time of our measurement, and no information 
on the irradiation characteristics from the monitoring system was recorded for the highest 
energy. The varying absolute values of FWHM of the ions at the isocenter (e.g. 19.6 mm for 
protons, 5.4 mm for oxygen ions for the lowest energy), due to the different impact of 
scattering in the beamline, justify the need of a correction for this offset to compare the 
evolution of the width distributions parameters. 
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Figure 3.4: Lateral dose distribution: Protons are represented with squares, helium ions with 
circles, carbon ions with triangles and oxygen ions with diamonds. In solid line, the double 
Gaussian (DG) fits are shown, and in dashed line the simple Gaussian (SG) fits. 
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Figure 3.5: FWHM of the extracted σ1-0cm (circles), compared to the extrapolated 
measurements of the BAMS (squares) and the HIT foci library (solid lines, with acceptance 
limits as dashed lines), for protons, helium, carbon and oxygen ions, respectively from left to 
right. 
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For the single Gaussian parametrization, the evolution of σ0corr is shown in figure 3.6 (left 
panels) for all ions, at the three investigated energies, as function of the relative depth (depth 
normalized to the BP position). For the medium energy, compared to the width of the 
clinically used carbon ions, protons and helium ions exhibit a width 3.2 and 1.7 times larger, 
while oxygen ions exhibit a width 1.1 times smaller, as seen in Appendix A (figure A.3). As a 
function of particle mass M, the width relative to carbon ions can be described by the 
following relations for protons, helium and oxygen ions 
respectively: 0.9 × (√𝑀𝑐 √𝑀𝑝)⁄ ,  √𝑀𝐶 √𝑀𝐻𝑒⁄ , and 1.05 × (√𝑀𝐶 √𝑀𝑂)⁄ . As expected, the 
heavier the ion, the smaller is the width of the beam, with a relation close to 1 √𝑀⁄ . After the 
BP, the single Gaussian describes the behavior of the secondary particles produced upstream, 
for ions with Z>1. For helium ions, the beam width distribution of the secondary particles was 
found to be larger than for carbon and oxygen ions, with a steeper increase of the Gaussian 
width with depth. These effects are related to the lighter fragments originating from the 
fragmentation of helium ions compared to heavier primary ions, and the fact that light ions 
produced by heavier ions are more focused in forward direction. A particular behavior of the 
width evolution was observed just after the BP, with a drop of σ0corr that can be interpreted by 
the fact that only the primaries which underwent small straggling (range or lateral) remain 
there and lead to a smaller beam width compared to the upstream depths. Compared to σ0corr 
values for carbon ions at the BP position (relative depth ~1), σ0corr values were found to be 
larger for protons and helium ions by roughly [2.3, 3.4, 5.1 mm] and [0.8, 1.3, 1.8 mm], for 
the low, medium and high energy, respectively The width difference was below 0.3 mm 
between oxygen and carbon ions, except for the highest initial beam energy, where the 
energies were not comparable, as oxygen ions have a range of 231 mm compared to the 308 
mm of carbon ions. 
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Figure 3.6: Fitted single and double Gaussian parameters: the left panels show the evolution 
in water of σ0corr (empty symbols) and σ1corr (filled symbols), the middle panels depict the 
evolution of σ2corr and the right panel displays w for the different ions (protons with squares, 
helium ions with circles, carbon ions with triangles and oxygen ions with diamonds), for low, 
medium and high energy (top to bottom panels). The depth is normalized to the BP position. 
The approximate range of the ions is presented (* stands for the range of the highest oxygen 
energy). 
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Figure 3.6 presents the evolutions of the parameters of the double Gaussian parametrization 
for the different ions and energies investigated. The evolution of σ1corr (figure 3.6 left panels) 
is close to σ0corr before the BP. Due to the contribution of the particles contained in the second 
Gaussian, σ1corr is slightly smaller than σ0corr (maximum difference of 1 mm for high energy 
protons and less than 0.5 mm for all other cases). The value of σ2corr (figure 3.6 middle 
panels) is not starting at zero, regardless of the ion, showing the impact of scattering upstream 
of the phantom entrance window, with higher width values for low energy and light ions. For 
medium and high energies, after an initial build-up (which is not visible for low energies), the 
values of σ2corr remain stable (within the error bar), as already observed for low energies. The 
build-up region can be seen as the propagation of the high energy fragments produced in the 
entrance of the water phantom and in the upstream beamline. The plateau regions of σ2corr can 
be interpreted as the fact that the angular distribution of secondary particles is not changing 
much with depth, as seen in Haettner et al (2013) for carbon ions. Thus, in the plateau region 
in the lateral field investigated and within the dose threshold set, there is an equilibrium 
between the contribution of secondary particles which are already spread from the entrance 
region and the contribution of the newly produced particles (with lower energies and a 
slightly broader angular distribution). The 1 √𝑀⁄  dependency of the secondary Gaussian 
width is no longer valid, as it was for the primary Gaussian, due to the mixed radiation field. 
As seen in Haetnner et al (2013) and Krämer et al (2016), the contribution of the secondary 
particles is mainly due to protons and helium ions. Furthermore, the light swift ions, such as 
protons, from fragmentation processes of primary carbon or oxygen ions are produced with 
smaller angles compared to the one stemming from primary protons or helium ions. As a 
result, the second Gaussian component was found to be broader for protons, followed by 
helium ions and the heavier ions. The evolution of the weight, w (figure 3.6 right panels), was 
stable of around 40% for protons before the BP (from 35% up to a maximum of 45% at high 
energy), regardless of the energy, while for heavier ions w is increasing due to the attenuation 
of the primary beam and the production of secondary particles, particularly at high initial 
beam energies. For oxygen ions, w was about 11% at the entrance, rising up to 25% for low 
energy and up to 30% for high initial energy beams. For carbon ions, w was about 15% close 
to the entrance and up to 25% for low energy and 45% for high energy beams. For helium 
ions, w was about 27% at the entrance, rising up to 30% for low initial beam energy and 56% 
at high energies. The contribution of the secondary particles to the dose halo, stemming from 
helium ions, exceeds the one from protons at high initial beam energies, due to the increased 
productions of secondary protons. Finally, the contribution of the second Gaussian is not 
negligible for heavier ions particularly at high initial beam energies, mainly due to the 
production of secondary particles at large angle and their propagations in water.  
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Figure 3.7: Spread-out Bragg peak: depth dose distributions (left panel), lateral dose 
distributions at the SOBP center (middle panel) and evolution of the lateral dose fall-off in 
water (right panel). Protons are displayed with squares, helium ions circles, carbon ions with 
triangles and oxygen ions with diamonds. 
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 Spread-Out-Bragg-Peak 3.3.3.
The mean dose measured in the SOBP region by the ICs, compared to the planned dose value 
of 1Gy, was -1.5% lower for protons, -1.8% for carbon ions, +4.6% for helium ions and 
+5.5% for oxygen ions. The reason for the larger discrepancy for helium and oxygen ions is 
stemming from the fact that the beam monitor calibration for these two ions was not yet 
completed at the time of this study. Hence, to ensure fair comparisons between the different 
distributions, a normalization of the data was performed, using these deviations as 
normalization factors. The depth and lateral dose profiles (at the entrance and center of the 
SOBP), together with the evolution of the lateral dose fall-offs, are shown in figure 3.7. 
In table 3.3, the entrance-to-plateau ratio, the size in depth of the SOBP, the distal fall-off and 
the dose 10 mm after the distal range (defined as the 90% dose fall-off), the homogeneity and 
the standard deviation of the mean dose value inside the SOBP are shown, together with the 
size of the laterally treated and irradiated volume sizes.  
Protons and helium ions showed favorable entrance doses compared to oxygen and carbon 
ions, which were about 5% higher. These results are consistent with the finding in section 
3.1.4 for the EPR of heavy ions with RiFi compared the light ions without. The distal fall-offs 
of helium ions were found to be smaller than for the other ions, but the distal fall-off values of 
the different ions were rather close to each other, which is consistent with the results found in 
section 3.1.5. However, the results are not as separated as the ones from the water column 
measurements, since the measurement step size in depth here was only about 1 mm 
(compared to 0.05 mm of the PKF), and the sensitive volume of the pinpoint IC (chamber 
radius of 1.45mm) is non-negligible compared to the fall-off values. Furthermore according to 
Karger et al (1999), the uncertainty in the IC measurement position is about 0.5 mm, 
accounting for the step motor and effective point of measurement errors as well as the IC 
position in the water tank. The dose 10 mm after the SOBP was higher for heavy ions 
compared to light ions, with larger values than in the water column results for pencil beam-
like irradiation, due to the summation of the tails of the individual peaks making up the 
SOBP. The size of the SOBPs were similar for the different ions, with a homogeneity <5% 
and a deviation to the mean dose <1%. Regardless of the calibration of the beam monitor, the 
helium and oxygen ions show dosimetric beam qualities comparable to the clinically used 
protons and carbon ions.  
The lateral fall-off for protons was clearly larger than for helium ions by about 6 mm, and 8 – 
8.5 mm compared to carbon and oxygen ions. While the lateral fall-off was slowly increasing 
with depth for protons (from 13.3 to 14.3 mm) and for helium ions (from 7.3 to 8.1 mm), the 
lateral fall-off was found to be between 6.1 and 6.2 mm for carbon ions and around 5.5mm for 
oxygen ions, due to the observed slow evolution of the primary Gaussian core (see section 
3.2). In the SOBP region the difference between the treated and irradiated volume is found up 
to 11.0 mm for protons, 6.7 mm for helium ions, 5.0 mm for carbon ions and 4.4 mm for 
oxygen ions. The uncertainty of the lateral/distal fall-off, SOBP depth size is about 0.8 mm. 
These results are consistent with the trend found for the pencil-beam lateral fall-off results. 
However, it should be noted that SOBP optimization was performed in one dimension (in-
depth), without intensity modulation within the same energy slice. Hence, one can expect 
better results in term of lateral fall-off and conformity to the initial planned lateral size with a 
3D optimization, particularly for protons (Scheib and Pedroni 1992).  
 
 
 
 3.4 Discussion 
49 
 
 
Table 3.3: Spread-out Bragg peak results: For the depth dose distribution analysis: relative 
entrance dose (Rel. ent. dose), SOBP depth size, distal fall-off and relative dose 10 mm after 
the SOBP (Rel. tail dose), homogeneity between minimal and maximal dose and standard 
deviation in the SOBP. For the lateral dose distributions analysis inside the SOBP region: 
Treated and irradiated lateral size. The uncertainty on the distal fall-off, SOBP depth size is 
estimated at 0.7 mm. 
 
 
 Discussion 3.4.
The results shown in this chapter (and Appendix A) give an overview over the dosimetric 
characteristics of all ions available at HIT, complementing previous studies (Schwaab et al 
2011, Parodi et al 2012, Kurz et al 2012). Even if the behavior of the different ions is 
expected from literature (previous experiments or simulations), experimental depth dose and 
lateral distributions are fundamental quantities for validation of Monte Carlo codes (Parodi et 
al 2012, Parodi et al 2013) and analytical engines (Krämer et al 2000, Krämer et al 2016), or 
even for beam parametrization (Grassberger et al 2015, Bellinzona et al 2015). Compared to 
Kurz et al (2012), the CCE for all ions was found to be superior to 99% due to an improved 
number of data points included in this study and an evaluation only in the near-saturation 
region. In the near saturation region, linear fits on 1/V² (continuous beam, general 
recombination) were showing better agreement than for 1/V (initial recombination for 
pulsed/continuous beam, general recombination for pulsed radiation). Even if a mixture of 
these effects due to the synchrotron beam structure is present in the measurements, as 
postulated by Kurz et al (2012), general recombination from the continuous-like spill 
structure seems to be dominant in the presented PKF measurements. A study from Rossomme 
et al (2016) on ion recombination strongly recommends from their results the use of 
corrections for ddd acquisition. However due to the different operating voltage of the PKF 
(400V) compared to the one from their study (-100V), the CCE is found high enough even in 
high dose region, to neglect recombination corrections. The newly measured ddds and lateral 
profiles were used to adjust the modeling of the HIT beamline and the input parameters of 
FLUKA simulations for phase space files generation (Chapter 5), biological dose calculations 
(Mairani et al 2016a), and creation of an experimentally validated physical database input for 
the analytical research TPS used for biological experiments (Dokic et al (2016)) with all 
available ions.  
 
Depth dose distributions 
Lateral dose distributions 
in SOBP 
Ion 
Rel. entr. 
dose 
Size 
Distal fall-
off 
Rel. tail 
dose 
Homogeneity σ 
Treat. lat. 
size  
Irr. lat. 
Size 
p 
63.4%  
(+/- 0.3%) 
42.5 
mm 
1.7 mm 
0% 
(+/- 0.03%) 
3.3% 
(+/-1.4) 
0.6% 
134.6 mm 
+/- 1.0 mm 
156.7 mm 
+/-0.7 mm 
He 
65.2% 
(+/- 0.9 %) 
42.7 
mm 
1.3 mm 
3.1% 
(+/- 0.4%) 
4.7% 
(+/-1.4%) 
0.9% 
138.9 mm 
+/- 0.9 mm 
152.3 mm 
+/-0.9 mm 
C 
68.6% 
(+/- 0.6%) 
42.0 
mm 
1.5 mm 
10.7% 
(+/- 0.2%) 
3.9% 
(+/-1.4%) 
0.8% 
142.4 mm 
+/- 0.9 mm 
152.3 mm 
+/-0.8 mm 
O 
69.6% 
(+/- 0.4) 
42.7 
mm 
2.0 mm 
12.4% 
(+/- 0.6%) 
4.9% 
(+/-1.4%) 
0.9% 
143.8 mm 
+/-1.1 mm 
156.7 mm 
+/-0.7 mm 
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Compared to Schwaab et al (2011), the results are similar for the extracted σ1-0cm for protons, 
even with a different fitting software package. Carbon ions σ1-0cm are not comparable as only 
data with RiFi are presented in Schwaab et al (2011). However, less spread in the σ2 values 
was observed due to the restriction in the lateral field of the values < |25|mm, leading also to 
lower values in this study for σ2. The σ0-0cm values, and corresponding FWHM0-0cm, are for 
protons, carbon ions and helium ions higher than the values at isocenter expected from the 
HIT pencil beam library. In addition to a possible daily variation of the beam spot size, this 
finding can be attributed to the use of a vertically scanned line instead of a single spot. While 
using a line, each single spot contributes to the measured profiles as it is integrated vertically. 
It was already noticed in Tessonnier et al (2016) that profiles integrated vertically are larger 
than profiles sampled at the middle of a single spot due to the non-single Gaussian shape of 
the beam at isocenter, leading to an enlargement between 0.1-0.4 mm for carbon ions and 0.5-
2.5 mm for protons, as it will be also described in Chapter 5. 
Measured ddds for protons, carbon and oxygen ions were consistent (within 0.3 mm range 
agreement) with the ones reported in previous studies at HIT (Parodi et al 2012, Kurz et al 
2012). First ddds for helium ions were characterized by Lawrence et al (1977) at the 
Lawrence Berkeley Laboratory (LBL). The main features reported for 150 and 225 MeV/u 
ion beams, such as R80 and EPR, were found in good agreement with the findings of this 
study: R80 values of [150 mm – 312 mm] and EPR values of [18% - 30%] at LBL, while R80 
[159 mm – 321 mm] and EPR [18% - 29%] for the HIT beamline energy (with extrapolation 
of the values for the 225 MeV/u). As found in Krämer et al (2016), a constant shift of about 9 
mm is to be applied to match the LBL data, probably due to the Berkeley beamline and the 
water equivalent thickness of the detector setup not corrected for their reported range.  
In terms of absolute dosimetry for SOBP scanned beam delivery, the beam monitor 
calibration used at HIT has recently been upgraded after completion of this study, allowing 
dose deviation below 3.5% for all ions and for SOBPs at different depths in water, and will be 
discussed in Chapter 6. Nevertheless, this does not affect the main findings of this study 
regarding the difference in SOBP characteristics for different ions, which seemed to be 
consistent with the observations from the ddds and the lateral dose distributions. However, it 
should be noted that the lateral dose fall-offs and the differences between treated and 
irradiated volumes could be further reduced in theory with 3D intensity modulated 
optimizations, allowing steeper lateral dose gradients. Such a refined approach would 
decrease the differences between light and heavy ions for these parameters. Nevertheless, the 
presented approach allows a more physical comparison of the SOBPs of the different ions, 
without influence of the characteristics and performances of a more complex optimizer. The 
dose at the entrance is particularly interesting for light ions in the case of a physically 
optimized SOBP, however in case of biologically optimized SOBP the physical dose in the 
entrance could drop further due to the higher RBE of heavy ions, thus becoming more 
favorable for heavy ions. 
Regarding the ddds and lateral distribution parameters, for deep seated SOBP, helium ions 
could be advantageous over protons for better distal and lateral fall-off, leading to a better 
conformity while sparing the surrounding healthy tissues. The main drawback of helium ions 
compared to protons in this SOBP study is the dose due to the fragmentation tail, that can be a 
disadvantage for opposite fields irradiation as investigated in Kantemiris et al (2011).  
Compared to heavier ions, helium ions are providing interesting features such as a lower 
fragmentation tail and an advantageous entrance dose, while similar lateral and distal fall-off 
properties. Nevertheless biologically optimized SOBPs might offer smaller fragmentation 
tails and a lower entrance doses for the different ions compared to the results suggested by 
this study using physically optimized SOBPs. While for carbon and oxygen ions the need of 
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the RiFi is commonly accepted, for helium ions it appears that the RiFi could be necessary for 
certain tumor depths to reduce the number of energy slices needed to achieve a homogeneous 
distribution, due to the small peak width for R80 below 170 mm. Some studies, such as 
Furusawa et al (2000), found a shift of the high RBE values toward the low-LET region for 
light ions such as helium ions compared to heavier ones. However, due to the difference in 
achievable LET values, heavier ions remain of clinical interest for certain kinds of tumors 
such as hypoxic tumors.  
The physical characterization reported here and in recent reviews of biological investigations 
(Held et al 2016) suggest that helium ions could regain interest for future therapeutic 
applications, thanks to their overall physical and biological properties. However, as shown in 
Grün et al (2015), the choice of an ion is not straightforward and depends on several criteria 
such as the tumor and healthy tissues types, target localization and the associated beam 
ballistics (number of fields, angles). Thus, more treatment planning comparisons with 
experimentally validated physical and biological model are needed, and this experimental 
might be considered as a reference for dosimetric validation of the employed computational 
models, paving the way to such studies. 
 
 
 Summary 3.5.
This chapter presents a detailed analysis of the dosimetric characteristics of the proton, 
helium, carbon and oxygen ion beams available at HIT. Although the therapeutic use of 
helium ions had been discontinued after the end of the clinical experience at the Berkeley 
National Laboratory in 1992, our experimental results indicate that helium ions could be a 
good candidate for further improvements in particle therapy, with intermediate properties 
between the clinically used proton and carbon ions. The main features are especially a smaller 
lateral scattering compared to protons and a very low tail-to-peak ratio compared to carbon or 
oxygen ions. These experimental results can be exploited for validation of physical models for 
further patient planning studies. Moreover, this study was used to create the first helium ions 
physical database at HIT, enabling accurate design of ongoing biological experiments which 
will ensure proper treatment planning and future fair comparisons between planning studies 
with different ions.  
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 Helium ions at Chapter 4.
HIT: Comparisons 
between FLUKA 
code predictions 
and measurements 
 
 
 
 
We present in this chapter the comparisons and validations of the Monte Carlo FLUKA code 
against in-depth dosimetric measurements acquired at the Heidelberg Ion Beam Therapy 
Center. Future chapters building upon this section will include treatment plan comparisons 
(Chapter 7), using validated biological models (Appendix C), between proton and helium ions 
with a validated Monte Carlo treatment planning engine (Chapter 6) based on the same code 
FLUKA. The work presented in this chapter has been submitted for publication (Tessonnier et 
al 2017b). 
 
 
 
 Background 4.1.
After the end of the clinical experience with helium ions at the Lawrence Berkeley National 
Laboratory (LBL) in 1992, a particular renewed interest for helium emerged as explained in 
Chapter 2. Most of the publications, either based on Monte Carlo (MC) simulations (Kempe 
et al 2007, Kantemiris et al 2011, Burigo et al 2015) or analytical models (Fuchs et al 2015, 
Krämer et al 2016, Grün et al 2015, Knäusl et al 2016), are not relying on detailed dosimetric 
data for models validation. Hence, we present in this chapter a comprehensive validation of 
MC simulations based on the FLUKA code (Ferrari et al 2005, Bohlen et al 2014, Battistoni 
et al 2016) against dosimetric measurements in water with 
4
He ions, based on the data 
presented in the previous chapter. Experimental laterally integrated depth dose distributions 
(ddds), with or without ripple filter (RiFi), lateral dose profiles and their parameterization 
along the depth, as well as a spread-out Bragg peak (SOBP) are compared to MC simulations. 
Through this work, we could provide a thoroughly validated database for input to the 
analytical research treatment planning system (TPS, Krämer et al 2000, Krämer and Scholz 
2000) currently used at HIT for planning radiobiological investigations at HIT, as previously 
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done in Kurz et al (2012) for oxygen ions and Parodi et al (2012, 2013) for protons and 
carbon ions. Furthermore, this work builds the basis for future treatment planning studies 
based on validated physical and biological models (Mairani et al 2016a, Mairani et al 2016b) 
for helium ions, which will be presented in Chapters 7. 
 
 Materials and Methods 4.2.
 The FLUKA Monte Carlo code 4.2.1.
All simulations presented in this chapter are based on the MC code FLUKA (development 
version July 2015) and the following simulation parameters were kept consistent throughout 
the study. In the entire particle therapy energy range (~50-220 MeV/u for 
4
He ion beams), the 
two models handling nucleus-nucleus interactions are RQMD (Relativistic Quantum 
Molecular Dynamics, Sorge et al 1989) for particles below 5GeV/u and BME (Boltzmann 
Master Equation, Cavinato et al 1998) below 120MeV/u (cf. Chapter 2). The defaults setting 
HADROTHErapy was selected, including an accurate modeling of charged particles multiple 
Coulomb scattering, with a particle transport and delta ray production threshold set to 100 
keV. The production of energetic heavy fragments via the coalescence mechanism (Battistoni 
et al 2016) and the evaporation of heavy fragments have been activated through the 
COALESCE and EVAPORATION cards, respectively.  
Regarding the standard geometry of all simulations, a detailed model of the HIT beamline was 
implemented (Parodi et al 2013, Tessonnier et al 2016), describing the vacuum window, the 
beam applications and monitoring systems (BAMS) consisting of three parallel plane 
ionization chambers and two multiple wires proportional chambers, as will be described more 
in detail in Chapter 5. The RiFi model, used in previous work for generation of the carbon 
ions database (Parodi et al 2012, Mairani et al 2010), was added to the simulation geometry, 
if needed.  
To replicate the experimental setup, either a semi-infinite water slab (for ddds) or a water tank 
(with a 5 mm PMMA entrance window for lateral profiles and SOBP) were placed at the 
isocenter as depicted in figure 4.1.  
 
 Depth dose distributions 4.2.2.
Measurements of the pencil-beam ddds were performed in a treatment room at HIT with the 
PeakFinder (PKF) water column in a similar fashion as in previous works for protons, carbon 
and oxygen ions (Parodi et al 2012, Kurz et al 2012) and described in Chapter 3. The ten 
energies presented in Chapter 3, selected from the 255 discrete energies available at HIT, are 
summarized in table 4.1 and will be compared to MC predictions in this Chapter. As 
described in Chapter 3, quasi-monoenergetic beams along the central axis were delivered with 
or without RiFi and clinical-like beam spot sizes (foci). The measurements were ranging from 
depths in water of 16 mm up to at least 20 mm after the BP position. The charge collection 
efficiency over the whole Bragg curve for low (82.33 MeV/u) and high (220.51 MeV/u) 
energies was studied in the previous Chapter 3 and was found higher than 0.998 +/- 0.4%. 
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Initial Energy 
(MeV/u) 56.4 79.8 103.1 122.9 140.7 157.0 172.3 190.9 210.9 220.5 
Focus size (mm) 16.7 11.6 9.2 7.9 7.1 6.3 5.8 5.3 5.0 4.9 
Intensity (ions/s) 8.0 x 10
7 
 
IC Voltage (V) 400  
RiFi with / without 
Table 4.1: Depth dose irradiation parameters: Initial energy of the beam, beam spot size 
without RiFi (FWHM) and intensity used for the different acquisitions (with and without 
RiFi). Voltage used by the ICs of the PKF. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Different setups used in the simulations: the top panel shows the geometry used 
for the depth dose distribution simulations (A) with the scoring region of 4.08cm radius inside 
a water slab, with or without RiFi. The middle panel (B) depicts the setup used to extract the 
FWHM of the primary particles fluence at isocenter without RiFi for an initial infinitely 
narrow beam impinging on the BAMS. The bottom panels (C) illustrates the setup used with 
the water tank, for both lateral profiles and SOBP simulations. 
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For reproducing the experimental setup in the simulations, a water region is added at isocenter 
(112.6 cm downstream from the last elements of the BAMS) to the standard geometry of the 
simulation described in section 3.2.1, as seen in figure 4.1. The beam Gaussian size in 
vacuum was defined as 2.5 mm, as used in Parodi et al (2012) for the smallest spot size of 
protons and carbon ions. However, as evaluated in Kurz et al (2012) with measurements, spot 
sizes do not have influence on the recorded ddds. Scoring bin size was set to 25µm in depth 
while integrating the dose on a radius of 4.08 cm laterally, consistently with the ICs in the 
PKF. The number of primary particle histories was set to 1×10
6
. The water density value used 
for the simulations was set to 0.998g.cm
-3
, in order to reproduce more accurately the 
experimental temperature conditions (~20°C). To determine the optimal configuration of the 
simulation (e.g. water ionization potential (Ipot) and relative initial beam momentum spread 
(dp/p) values), an iterative process of trial-and-errors was applied for simulations without 
RiFi. The Ipot value was kept fixed for all energies, while the dp/p values were tuned 
individually. First the Ipot value was adjusted in order to reduce the shift between measured 
and simulated Bragg curves over the entire therapeutic interval. The BP position was 
determined from a 5
th
 polynomial order function fit to the Bragg curves above 80% of the 
maximum values (BP). Both the distal range at 80% (R80) of the maximum dose and the BP 
position were evaluated as a function of Ipot. The advantage of R80 over the BP position is a 
lower sensitivity to momentum spread variations, as described in Bortfeld (1997) and 
therefore already used in Kempe et al (2007) with MC simulations, as well as in the previous 
Chapter 3. After the determination of the optimal Ipot value, the simulated curves were 
aligned to the measurement curves, using the newly calculated shifts between their respective 
R80, for further comparisons. Then, both measured and simulated ddds were normalized by 
their area. For the investigated energies, the dp/p tuning was performed by minimizing an 
objective function χ² (Kurz et al 2012), defined as: 
 
χ² =  ∑ [
∆𝑚𝑒𝑎𝑠
𝑠𝑖𝑚 (𝑧𝑖)²
𝑑𝑖
⁄ ] × ∆𝑧𝑖
𝑖+1 𝑖  ,                                   (4.1) 
 
where ∆𝑚𝑒𝑎𝑠
𝑠𝑖𝑚  is the difference between the simulated and measured ddds at the depth zi. The 
1/di and ∆𝑧𝑖
𝑖+1 are weighting factors accounting for both the increased absolute error at higher 
dose levels and the varying spacing of the measurement positions, along the Bragg curves.  
From this set of parameters, final ddds, with and without RiFi, were simulated for comparison 
with measurements. Several parameters were extracted: 
- The R80 and BP position as described previously, 
- The entrance dose difference at 16 mm between measurement and simulation, relative 
to the maximum measured dose for the normalized ddds, 
- the highest dose difference in the BP region (i.e., above 90% of the maximum dose) 
between normalized ddds,  
- the entrance-to-peak ratio (EPR), defined as the ratio between the entrance dose to the 
dose at the BP position, 
- the tail-to-peak ratio (TPR), defined as the ratio between the dose found 10 mm after 
the BP position relative to the BP dose, 
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- the peak-width (PW) at 80%, defined as the distance in mm between the proximal and 
distal position at 80% of the BP, 
- the distal fall-off (FO), defined as the distance in mm between the 80% and 20% distal 
dose position, 
- The dose-weighted average dose-difference 𝛥𝐷/𝐷̅̅ ̅̅ ̅̅ ̅̅  (Battistoni et al 2016), defined as: 
 
𝛥𝐷/𝐷 ̅̅ ̅̅ ̅̅ ̅̅ ̅ = 100 ×  
∑ 𝐷𝑖
𝑚𝑒𝑎𝑠 ×∆𝑧𝑖−1
𝑖+1 × |(𝐷𝑖
𝑚𝑒𝑎𝑠−𝐷𝑖
𝑠𝑖𝑚) 𝐷𝑖
𝑚𝑒𝑎𝑠|⁄𝑖
∑ 𝐷𝑖
𝑚𝑒𝑎𝑠 × ∆𝑧𝑖−1
𝑖+1
𝑖
 ,                             (4.2) 
 
with Di being the normalized dose at the depth zi from simulation or measurements and Δz the 
mean step size between the zi+1 and zi-1 depth, giving an index of the overall agreement 
between simulated and measured Bragg curves.  
While the entrance dose difference and the highest dose difference give information about 
discrepancies between normalized ddds, EPR, TPR, PW and FO are representative of relative 
dose comparisons. 
 
 Lateral dose profiles 4.2.3.
 Beam size in vacuum 4.2.3.1.
The beam size in vacuum for the different foci available was determined for helium ions using 
a narrow beam approach as defined in Tessonnier et al (2016) for protons, as it will be 
explained in detail in Chapter 5. For all energies, the primary particle fluence at the isocenter 
was recorded for an infinitely narrow initial beam. Subsequently, the FWHM of the primary 
particles fluence distribution was extracted and the FWHM of the beam in vacuum for each 
focus was estimated using the following equation: 
 
𝐹𝑊𝐻𝑀𝑣𝑎𝑐𝑢𝑢𝑚,𝑓𝑜𝑐𝑢𝑠 = √𝐹𝑊𝐻𝑀𝑖𝑠𝑜𝑐𝑒𝑛𝑡𝑒𝑟,𝑓𝑜𝑐𝑢𝑠
2 − 𝐹𝑊𝐻𝑀𝑖𝑠𝑜𝑐𝑒𝑛𝑡𝑒𝑟,𝛿
2
,           (4.3) 
 
with FWHM being the full-width half maximum of the particles distributions either at the 
isocenter or before the BAMS in vacuum, for an infinitely narrow beam δ or a selected focus 
spot size. 𝐹𝑊𝐻𝑀𝑖𝑠𝑜𝑐𝑒𝑛𝑡𝑒𝑟,𝛿 is extracted from the simulation, while 𝐹𝑊𝐻𝑀𝑖𝑠𝑜𝑐𝑒𝑛𝑡𝑒𝑟,𝑓𝑜𝑐𝑢𝑠 is 
known from the HIT accelerator library.  
The energies investigated were [50.57, 55.30, 60.80, 79.78, 103.05, 122.93, 140.71, 157.03, 
172.28, 190.85, 210.92, 220.51 MeV/u] for 1×10
6
 primary histories per run. Using the 
estimated 𝐹𝑊𝐻𝑀𝑣𝑎𝑐𝑢𝑢𝑚,𝑓𝑜𝑐𝑢𝑠 , new simulations for focus index 1 were performed and the 
primary fluences FWHMs at isocenter were compared to the values of the HIT library for the 
same energies. 
 
 Comparison of measurements and simulations 4.2.3.2.
Lateral dose profile measurements of vertically scanned line irradiations were performed in a 
water tank at the HIT experimental room, as described in Chapter 3. Details on the setup and 
energy used can be found in Chapter 3, section 3.2.2. The range R80 for the low, medium and 
high energies is about 54, 172 and 308 mm, respectively. Simulations were performed for the 
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same irradiation configuration described above. The geometry of the water tank, featuring a 5 
mm PMMA entrance window placed at the isocenter before a 30 cm × 30 cm × 29.5 cm
 
water 
cube, was exactly modelled (see figure 4.1). The optimal input parameters described in the 
previous sections were used (Ipot, dp/p, beam size in vacuum). Dose depositions were scored 
using FLUKA built-in scoring capabilities in Cartesian voxels of 1 mm × 1 mm × 1 mm size 
for 200 independent runs of 1×10
6
 primary histories each.  
Qualitative comparisons between measurements and simulations were realized through visual 
inspection of the data, with normalization to the maximum of each profile. Quantitative 
assessments were achieved through lateral Gaussian parameterizations (single and triple 
(Inaniwa et al 2014)) along the depth. To extract the parameters, lateral profiles were 
processed with the MINUIT minimization package (James and Roos 1975) of ROOT 
(root.cern.ch, Brun and Rademakers 1997) using least square optimization. The fitting 
weights were defined as 1 (√𝐷𝑖/100)
2⁄  as in Schwaab et al (2011) and Chapter 3.  
The simple single Gaussian (SG) describes the central core of the profiles, restricted to values 
(simulated or measured) above 20% of the profiles normalized to their local maximum (for 
each depth), and is defined as: 
 
𝑑(𝑥, 𝑦) = 𝑛 × 
1
2𝜋𝜎𝑆𝐺²
 ×  𝑒
− 
(𝑥−𝑠ℎ)2
2𝜎𝑆𝐺
2
 .                      (4.4) 
 
For line irradiation, y is assumed to have a constant value of y=0, while d stands for the 
relative dose, x denotes the position on the lateral profile, σSG is the width (standard deviation) 
of the Gaussian, n is a normalization factor and sh indicates the shift to the central position, 
either due to uncertainties in the IC block or beam position as well as the water tank 
alignment for the measurements. 
In the triple Gaussian (TG) parametrization, the same lateral extension was selected keeping 
only the measurements/simulations with a lateral position |x| < 25 mm with respect to the 
maximum IC position from all chambers. Measured/simulated points with a relative dose 
contribution to the profile maximum below 0.5% were excluded to avoid noisy data. The 
triple Gaussian is defined as: 
 
𝑑(𝑥, 𝑦) = 𝑛 ×  [
𝑤1
2𝜋𝜎12
 ×  𝑒
− 
(𝑥−𝑠ℎ)2
2𝜎1
2 +  
𝑤2
2𝜋𝜎22
 ×  𝑒
− 
(𝑥−𝑠ℎ)2
2𝜎2
2 +
𝑤3
2𝜋𝜎32
 ×  𝑒
− 
(𝑥−𝑠ℎ)2
2𝜎3
2 ],     (4.5) 
𝑤1 = 1 − 𝑤2 − 𝑤3,          (4.6) 
 
with d being the relative dose, x the position of the lateral profile, σx the widths of the narrow 
(σ1) and broader Gaussians (σ2 and σ3). Moreover, wx stands for the relative weight of the 
different Gaussians, n is a normalization factor and sh is the shift to the central position (as 
introduced for the single Gaussian). As described previously, y is assumed to be equal at 0. 
As described in Chapter 3, a fair comparison of the evolutions of the different σ, regardless of 
possible uncertainties of the initial beam spot size, is allowed by quadratically subtracting 
from the depth-dependent σ(z) the width at the phantom entrance window placed at isocenter, 
σ0cm, which is extrapolated for the smallest Gaussian (σSG or σ1): 
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𝜎𝑐𝑜𝑟𝑟(𝑧) = √𝜎(𝑧)2 − 𝜎0𝑐𝑚
2
,                    (4.7) 
 
This approach yields σcorr, i.e., the Gaussian widths (σSG, σ1, σ2 or σ3) corrected by the initial 
beam width at isocenter, which can be interpreted as the evolution along the depth z of an 
infinitely narrow beam impinging on the water tank. The single Gaussian through the 
evaluation of σSGcorr allows following the main evolution of the beam width in depth. The 
analysis of the triple Gaussian with its parameters enables disentangling the dose 
contributions to the lateral profile from the primary beam and its small and large angle 
emission/scattering secondary particles, and their evolution along the depth in water. 
       
 Spread-out Bragg peak 4.2.4.
As example of a more complex geometry, a laterally and longitudinally extended SOBP was 
also studied. The SOBP was planned to deliver 1 Gy absorbed dose to a 140 mm × 140 mm × 
140 mm target centered at 80mm depth in water, as in Chapter 3. The optimization was 
performed using a pre-clinical database generated from section 4.2.2, and the SOBP was 
optimized only in depth without RiFi. The experimental setup is described in detail in Chapter 
3, section 3.2.3. 
Simulations were performed using the same setup described previously (cf. section 4.2.2), 
scoring the dose in 1 mm × 1 mm × 1 mm voxels in the transport of 2×10
8
 primary histories. 
The ICs finite sensitive volume was taken into account in the data analysis. 
Besides the dose comparison between simulations and measurements, assessment of different 
lateral field parameters and their evolutions along the depth in water was carried out, such as 
the evolution of the local 90% SOBP size (defined as the distance between the lateral 
positions where the dose reaches 90% of the SOBP mean dose within the investigated 
profile), the lateral FO (defined as the 80%-20% distance) or the evolution of the irradiated 
lateral size (identified by the 50% isodose, in this study 0.5 Gy). 
 
 Results 4.3.
 Depth dose distributions 4.3.1.
A value of 76.8 eV for the first simulation parameter investigated, Ipot, was found to 
minimize the range shift for all energies below +/- 0.1mm. The optimal relative momentum 
spread dp/p values, giving the lowest χ² scores, were extracted individually for the ten 
investigated energies, as seen in Appendix B (figure B.1), and then interpolated to the whole 
energy range as seen in figure 4.2 (left panel). All simulations presented in the next part of 
this chapter were performed with these parameters. 
The simulated Bragg curves plotted against the measured data are shown in figure 4.3 (top 
panel) without RiFi and figure 4.4 with RiFi (top panel), normalized to their area. The range 
differences (from either BP position or R80) between MC predictions and measurements are 
below 0.1mm for both investigated cases with and without RiFi (figure 4.2, right panel), 
centered around 0 mm with no evident trends. For the data without RiFi, the EPR is shown in 
figure 4.3 (middle left panel), indicating a good agreement between MC and measurements up 
to an energy corresponding to a R80 of 120mm, while differences get as large as 1.9% at 
higher depths. Regarding the PW (figure 4.3, middle central panel) and the distal FO (figure 
4.3, middle right panel), measurements and simulations show good agreement with 
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differences below the measurement uncertainties. The TPR (figure 4.3, bottom left panel) 
shows discrepancies from less than 0.2% at R80 around 120mm up to 0.7% for the highest 
energies. The 𝛥𝐷/𝐷̅̅ ̅̅ ̅̅ ̅̅ , shown in figure 4.3 (bottom center panel), indicates that the overall 
agreement between the measured and simulated data is deteriorated, mainly at higher 
energies, with a trend from 0.6% at low energy up to 2.3% differences at higher energy. When 
normalizing the Bragg curves to their area, the entrance dose differences are below 0.5% for 
all investigated energies, while in the high dose regions dose differences up to 5.5% can be 
encountered for high energies as shown in figure 4.3 (bottom right panel). In the comparisons 
of the Bragg curves with RiFi, the same trends were observed, starting with an EPR in good 
agreements up to a R80 of 120mm, but then reaching differences of about 2.2% at high 
energies (figure 4.4, middle left panel). Differences in TPR (figure 4.4, bottom left panel) 
were evolving in a similar way as well, from 0.3% at R80120mm up to 0.9% at high energies. 
PW (figure 4.4 middle center panel) and FO (figure 4.4 middle left panel) evolutions as a 
function of energy show good agreement within 0.1mm between simulations and 
measurements. The 𝛥𝐷/𝐷̅̅ ̅̅ ̅̅ ̅̅  evolution with RiFi, shown in figure 4.4 (bottom center panel), 
indicates a better agreement at low energies than at higher ones, with differences rising up to 
2.3%. Regarding the comparisons of the curves normalized to their area, dose differences in 
the entrance region were below 0.5%, while in the high dose region differences below 0.6% 
were observed for low energies, rising up to 5.9% at high energies (figure 4.4, bottom right 
panel). 
 
 
 
 
Figure 4.2: Left panel: initial relative momentum spread found during the error-and-trial 
process (square) for the ten investigated energies (without RiFi), then interpolated (line) to the 
entire energy range. Right panel: range (R80) shift differences between simulations and 
measurements, as a function of R80 of the measured energies, with and without RiFi. 
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Figure 4.3: Measured/simulated depth dose distributions and extracted parameters 
comparisons without RiFi. In the top panel, measured (squares) depth dose distributions and 
simulated (lines) are shown after shift and normalization to the area (cf. section 2.1), and then 
normalized to the maximum of the measured curve for display purpose only. The middle left 
panel depicts the EPR as a function of R80, the middle central panel shows the PW as a 
function of R80 and the middle right panel illustrates the FO as a function of R80. The bottom 
left panel shows the TPR, the bottom central panel the 𝛥𝐷/𝐷̅̅ ̅̅ ̅̅ ̅̅  and the bottom right panel the 
maximum dose difference of the normalized curve as a function of R80. Parameters derived 
from measurements appear with squares, while circles refer to simulations. 
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Figure 4.4: Comparisons of measured/simulated depth dose distributions and related extracted 
parameters with RiFi, as described in Figure 4.3 for a delivery without RiFi. Parameters 
derived from measurements appear with squares, while circles for simulations. 
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Figure 4.5: In the left panel, different FWHM at isocenter are compared. HIT-Fx stands for 
the beam spot size at isocenter (index 1 to 4) from the HIT accelerator library. “Narrow beam 
– FWHM” (red square) is the simulated FWHM of the primary particles fluence starting from 
an infinitely narrow beam before the BAMS. “Est. beam appr. –F1 FWHM” (blue circle) 
stands for the FWHM from the estimated beam approach for the smallest focus (focus 1). It 
represents the FWHM obtained from simulations using the estimated beam FWHM in 
vacuum for focus 1 (right panel). In the right panel are presented the FWHM values in 
vacuum for the four first HIT focus indices estimated from the infinitely narrow beam 
approach simulation and the HIT accelerator library. 
 
 
 Lateral dose profiles 4.3.2.
The results of the Gaussian beam width parameters extracted from data and simulations in 
vacuum and its verification are shown in figure 4.5. The FWHM of the primary particles 
fluence at isocenter for a simulated infinitely narrow beam was extracted for the investigated 
beam energies (figure 4.5 - left panel with squares), then interpolated. Subsequently, the size 
of the beam in vacuum, for the different helium ion spot sizes, was estimated (figure 4.5 – 
right panel). New simulations using these estimated values were finally performed for the 
smallest HIT focus size. The FWHM of the primary particle fluences for the ten energies 
investigated was found in excellent agreement with the expected values from the HIT library, 
with differences below 0.2 mm (figure 4.5 - left panel with circles). 
Lateral dose profile measurements overlaid with simulation results are shown in figure 4.6, 
for the three different investigated energies and two positions in depth, at the entrance of the 
water phantom and near the Bragg peak position. The profiles are normalized to their local 
maximum. The absolute water-equivalent thickness of the measurement position is about 19 
mm at the entrance of the phantom, and about 53 mm, 169 mm and 300 mm (near the BP) for 
the low, medium and high energy, respectively. For all investigated energies the entrance 
profiles, restricted to values above the 1% dose level with respect to the profile maximum, are 
found in good agreements between simulations and measurements. Thus, knowing that the 
EPR is about 20-25%, these agreements are found for dose levels above 0.3% of the 
maximum dose delivered to the BP. However, when looking at differences for lower dose 
levels in the entrance, it can be noticed that for the higher beam energies, larger discrepancies 
can be found in the halo comparing the local value between simulation and measurement, 
with local deviation up to 45% (for a relative dose level of 0.2% with respect to the profile 
maximum) for the highest energy, up to 42% (0.2%) for the mid-range energies, and 14% 
(0.4%) for the lowest energy. 
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Figure 4.6: Lateral profiles for the three investigated energies, namely low, medium and high 
from left to right, sampled both at the entrance of the phantom (top) or near the BP (bottom). 
Profiles are normalized to the local maximum and depicted in semi-logarithmic scale. 
Simulations are displayed with lines, while the measurements with circles. 
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Near the BP position, the underestimation of the halo dose in the FLUKA simulations 
increases, with discrepancies up to 26% (1.3%) for the highest energy and 23% (0.4%) for the 
intermediate one. For the lowest energy, a good agreement is kept with differences up to 9% 
(0.3%). In the high dose regions, all points agree within the experimental uncertainty either 
due to the positioning of the IC or beam as well as the dose measurement. The statistical 
uncertainties on the simulation are below 0.1% in the high dose region and about 1% at the 
extreme positions of the investigated profiles, for all energies and depths investigated.  
The SG parametrization for the three energies is shown in figure 4.7 for σSGcorr as a function of 
the relative depth in water (normalized to the BP position) and corrected by the σSG value 
extrapolated at 0cm. Error bars for measurements are taking into account the uncertainty on 
σSGcorr due to the retrieval process and the positioning uncertainty during the measurements, 
while for simulation only uncertainties related to the fitting procedure are shown. The values 
of σSGcorr-0cm are about 5.19 (+/- 0.72) mm, 3.16 (+/- 0.71) mm, 2.31 (+/- 0.71) mm for 
measurements and about 5.21 (+/- 0.04) mm, 3.13 (+/- 0.02) mm, 2.39 (+/- 0.03) mm for 
simulations, respectively, for low, medium and low energies. The agreement between these 
values is good, below 3.1% (0.07 mm) difference, and below 16.9% (0.45 mm) in comparison 
to the HIT spot size library. The evolution of σSGcorr along depth in water is similar for both 
measurements and simulations, with differences below 0.2 mm in average for low energy, 0.2 
mm for medium energy, and 0.3 mm for the highest energy. 
 
 
 
 
Figure 4.7: Single Gaussian parametrization of beam width evolution with depth in water 
(relative to the BP position) for the three investigated energies (low, medium and high from 
left to right). Simulations are displayed with circles and measurements with squares. 
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The TG parametrizations was performed for the three energies and the results for the highest 
energies are shown in figure 4.8 or in Appendix B (figure B.2 and figure B.3). Error bars are 
displayed in a similar way as for the SG. Regarding the first Gaussian width extrapolated at 0 
cm, σ1-0cm, for the different energies, it was found to be 4.44 (+/- 0.86) mm, 2.90 (+/- 0.71) 
mm and 2.13 (+/- 0.70) mm for measurements and 4.74 (+/- 0.31) mm, 2.91 (+/- 0.21) mm 
and 2.27 (+/- 0.13) mm for simulations, thus showing an agreement within 0.3 mm. The 
evolution of the different Gaussian widths in water depicted in figure 4.8 is corrected by these 
values. For low energies, the three corrected Gaussian widths are in good agreement within 
the error bars, with less than 0.02 (+/- 0.94) mm difference on average for σ1corr. The same 
behavior is found for the highest energies as well, with differences in σ1corr values below 0.08 
(+/- 0.18) mm for medium energies and 0.02 (+/- 0.13) mm on average for the highest energy. 
For σ2corr and σ3corr no direct comparisons can be performed due to the larger fluctuations of 
the results, as can be seen for the highest energy in figure 4.8. Nevertheless, the comparisons 
between simulation and measurements follow the same trends with similar values within the 
error bars, and this is true for all investigated energies. Regarding the weight of the different 
Gaussians, for the lowest energy investigated no particular differences between measurements 
and simulations were found. However, for medium and high energies, larger discrepancies 
were found as seen in figure 4.8. The weight of the 1
st
 Gaussian is overestimated in FLUKA 
simulations by about 6% - 11%, while the 2
nd
 Gaussian is underestimated by about 2 – 4%, 
and the 3
rd
 Gaussian by about 4% - 7% for medium and high energy, respectively. 
 
 Spread-Out Bragg Peaks 4.3.1.
The results of the dose measurements, corrected for the beam monitor calibration deviation of 
4.6% (cf. Chapter 3), and FLUKA simulations of the SOBP are shown in figure 4.9. For the 
depth dose distribution (figure 4.9 top right panel), the dose differences in the SOBP regions 
are below 1% and in the entrance region below 2% compared to the maximum. The range 
difference is below the positioning uncertainty of the IC chambers of 0.5 mm. In the lateral 
dose profiles, an overall good agreement is observed as seen in figure 4.9 (top right panel) at 
the middle of the SOBP. The dose deviations are below 1% in the plateau region and below 
3% in the high dose gradient regions. The extracted local SOBP size (90% of the local 
maximum profile dose) shows a similar trend along depth in water, with maximal difference 
of 0.9 mm. In the lateral FO evolution a similar behavior is observed between simulations and 
measurements, with an underestimation of the simulated values of about 0.3 mm, however 
being still within the measurements error bars. The evolution of the SOBP irradiated size 
(isodose 50%, i.e., 0.5 Gy in the presented case) is consistent between measurements and 
simulations, with a maximum difference of 0.6 mm in the SOBP region and of 0.3 mm in the 
entrance. 
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Figure 4.8: Triple Gaussian parametrization for the highest beam energy. Simulations are 
displayed with circles and measurements with squares. The top panels depict the Gaussian 
widths evolution in water (relative to the BP position), from the smallest Gaussian to the 
broader one from left to right. The bottom panel shows the corresponding weights. 
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Figure 4.9: Spread-out Bragg-peak results: the top panels depict the depth (left) and lateral 
(right) dose distributions (simulations displayed with continuous line, measurements with 
squares). In the bottom panels, the SOBP size (between the local 90% dose) is shown on the 
left, the FO in the center and the SOBP irradiated dose (isodose 50%) in the right panel. 
Simulations are displayed with circles, measurements with squares. 
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 Discussions 4.4.
In terms of the modelling parameters, the initial beam momentum spread is consistent with 
dp/p values obtained for the HIT synchrotron in prior works for carbon ions and protons, 
which were ranging in the same order of magnitude from approximately 0.3% at low energies 
up to 0.1% at high energies (Parodi et al 2012, Kurz et al 2012). The value of Ipot of 76.8 eV 
is different from the values reported in those two studies. However, those works were 
assuming a water density of 1.0 g.cm
-
³ and performed with a previous version of FLUKA. 
New simulations using the detailed model of the beamline and a density of 0.998 g.cm
-
³ were 
compared to the experimental measurements presented in those works, and were found in 
excellent agreement for an Ipot value of 76.8 eV for carbon and oxygen ions, and 77.3 eV for 
protons. Thus, the water Ipot values needed by FLUKA for simulation of HIT ddds for 
different ions can be brought closer to each other, close to the most recent ICRU 
recommendation (78 eV ICRU 2009, Andreo et al 2013) and similar to the value of 77.0 eV 
suggested by Krämer et al (2000). The estimated beam size in vacuum is experimentally 
validated regarding the small differences found between the extracted σSG-0cm from simulations 
which are close (within 0.1 mm) to the σSG-0cm of measurements. The differences from these 
values to the HIT library ones are due to the way of performing the irradiation. As the 
delivery is made as a line scan and not as a single spot, the contributions of the different spots 
lead to a larger value of σSG at isocenter, as already observed in Tessonnier et al (2016). 
The depth dose distributions of individual pencil beams are showing an overall good 
agreement between simulations and measurements, however the differences are increasing for 
higher initial beam energies of the particles. Both the relative value to the maximum (EPR, 
TPR, 𝛥𝐷/𝐷̅̅ ̅̅ ̅̅ ̅̅ ) and the maximum difference while normalizing to the area are increasing as a 
function of the beam energy. This could hint at a possible underestimation of the secondary 
particle production or secondary particle angular distribution at large angles from the FLUKA 
code. However, the excellent agreement of the range, PW and distal FO, mainly linked to the 
dose contribution of the primary helium ions, shows that the FLUKA code is able to 
accurately reproducing energy loss and range straggling of 
4
He ions. In order to better 
understand the dose underestimation problem observed at high energies, the attenuation of the 
primary beam was also investigated, by reproducing the same experimental setup presented in 
Krämer et al (2016) and Rovituso et al (2017) for a 200MeV/u helium ions beam. The 
simulated attenuation results shown in the Appendix B (figure B.6) were found to be 
consistent with the experimental findings for 
4
He attenuation. Thus, the dose differences 
could be ascribed to the secondary particles (
3
He, 
3
H, 
2
H or 
1
H) behaviors, such as their 
angular distributions or nuclear interactions, rather than a deficit of nuclear interactions and 
fragmentation of 
4
He. Investigations on the angular distribution of 120 and 200MeV/u helium 
ions and secondary particles in the FLUKA MC code are presented in Appendix B (figure 
B.7), compared to experimental data from Rovituso et al (2017). The lateral dose profiles are 
showing similar trends for higher energies at the entrance, with discrepancies on the halo dose 
indicating an underestimation of the FLUKA simulations compared to the measurements, and 
even higher differences at larger depths at the BP position. However, even if local deviations 
can show differences up to 26% at a dose level of 1.6% for the highest energy investigated, it 
should be noticed that all the discrepancies are below 1% with respect to the profile maximum 
(global deviation). The evolutions of the σSGcorr shows good agreement between simulations 
and measurements for the three investigated energies, and are a direct indicator of the 
evolution of the core beam along the depth. In fact, the primary beam is the main contributor 
to the central Gaussian core and leads to the observed good agreement on the FWHM 
broadening in depth, which is mainly due to multiple Coulomb scattering processes. For the 
highest energy at large depths before the BP, a slight difference of 0.7 mm appears which is 
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due to the enhanced contribution of the secondary particles at such depths. When using the 
TG parametrization at this energy, the σ1corr is not showing anymore these discrepancies, as it 
is removing the dose contribution of fragments to the central core. The TG parametrization is 
thus leading to good agreement on the Gaussian widths evolution between measurement and 
simulations within the uncertainties of both measurements and parametrization processes. 
However, FLUKA simulations for medium and high energies are underestimating the weight 
of the second and third Gaussians, thus again suggesting a possible lack of secondary 
emissions at large angles or scattered particles. For the highest energy, the possibility of a 
non-single-Gaussian beam in vacuum was investigated for different double-Gaussian shapes 
in vacuum as explained in Appendix B (figure B.4). The main Gaussian width corresponds to 
the width extracted in section 4.3.2, while the second one is related to the range of widths of 
the second and third Gaussian. It allowed forcing the MC and measurements lateral profiles to 
match at the phantom entrance, however the dose underestimation with MC predictions at 
larger depths compared to measurements could not be eliminated, thus still hinting on a 
possible room of improvement for the models of the MC code FLUKA. Additional 
investigations were performed in Appendix B, weighting the dose contributions of the 
secondary particles in order to retrieve better ddds or lateral profiles. 
The results of the SOBP are overall encouraging, with good agreement between corrected 
measurement and simulations even in the high dose gradient regions. Furthermore, more 
recent measurements for SOBPs at different depths with an updated dose calibration have 
shown differences between measurements and simulations below 1% in the SOBP region 
without any dose corrections in the analysis (data not shown). The reported differences on the 
lateral FO and irradiated size could originate from the halo dose contributions of the large 
number of spots used to build the SOBP lateral extension, as well as from IC and/or beam 
positioning uncertainties. The better agreement found for the SOBP lateral dose compared to 
previously presented lateral dose profiles is linked to the fact that the investigated SOBP is 
not as deep seated as the medium and high energies investigated. This implies that for greater 
depths a larger disagreement in the investigated parameters of lateral FO and irradiated size 
are to be expected. In addition to the dosimetric validation of the FLUKA MC code for 
modeling helium irradiation, the possibility to link the simulations to validated biological 
models as presented in Mairani et al (2016a, 2016b) will allow MC treatment planning 
optimization (Mairani et al 2013, Böhlen et al 2013) and comparison between different ions, 
as will be shown in Chapters 6 and 7. Furthermore, this work enabled the creation of a 
validated physical database of helium ion ddds for input into the analytical research TPS at 
HIT, which is regularly used for planning biological studies (Dokic et al 2016), as well as the 
creation of phase space files as in Tessonnier et al (2016) for external user applications, in an 
identical way that what will be presented for protons and carbon ions in the next Chapter 5. 
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 Summary 4.5.
We presented in this chapter an in-depth validation of the FLUKA MC code against 
dosimetric measurements of 
4
He ion beams. The results are overall satisfactory even in the 
case of a 3D SOBP, which is a more complex scenario than ddds and line irradiations. 
Differences in the high dose region were below 1% and below 3% for the entire dose 
distribution, which demonstrate that the FLUKA code is reliable enough for future clinical 
use and further studies. Despite the overall very promising agreement, some model 
improvements could be foreseen to reduce the discrepancies observed in the contribution at 
large angles of the secondary particles, impacting both ddds and lateral profiles, particularly at 
large energies. By using the experimentally validated MC code in conjunction with validated 
biological models, it is now feasible to conduct reliable treatment plan comparisons between 
helium ions and protons (or heavier ions) to investigate the possibility of improving dose 
distributions and thus patient treatment outcome, in view of the foreseen clinical deployment 
of helium ion therapy at HIT. A research MC-based treatment planning system and related 
plan comparisons will be presented in Chapters 6 and 7. 
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 Phase space generation Chapter 5.
for proton and carbon ion 
beams for external users’ 
applications and in-house 
simulation framework 
implementation 
 
 
 
 
 
This chapter deals with the generation of phase-space files created using the beamline model 
previously presented in Chapter 4, and their implementations within the Monte Carlo 
framework presented in Bauer et al (2014). After describing the theory behind the proposed 
approach to generating phase-space files for protons and carbon ions and validating against 
measurements and simulations with the beamline, an example of the application within the 
framework is shown. The method of phase-space files generation was then extended to helium 
and oxygen ions, completing the characterization of all available ions at HIT. Further 
applications of this work are presented in the next chapters. A part of this work was published 
in (Tessonnier et al 2016). 
 
 
 Background 5.1.
In the particle therapy field, MC codes provide a powerful tool to perform accurate 
calculations, with a precise description of the transport and interactions of the beam with the 
traversed materials, compared to the current treatment planning systems (TPS) as the one used 
at HIT (Syngo RT Planning TPS, Siemens AG Healthcare), which is based on analytical 
algorithms using fast pencil-beam dose calculation algorithms (Krämer et al 2000). At HIT, 
the FLUKA MC code was chosen to support the creation of the TPS basic input data (Parodi 
et al 2012), as exlpained in Chapter 2, section 2.7 and performed for helium ions based on the 
work presented in Chapter 4. The beamline has been modeled in great details, particularly the 
vacuum window and the Beam and Application Monitoring System (BAMS), composed of 
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two multiwire proportional chambers and three ionization chambers which are monitoring the 
beam, providing accurate data for the parametrization of the lateral dose spread for additional 
input to the analytical clinical TPS (Parodi et al 2013, Chapter 4). A MC framework, without 
using the beamline model but a beamline approximation closely resembling the TPS 
approach, has been also developed and is used to perform both dose forward calculation and 
range verification (Bauer et al 2013a, 2013b, 2014), providing a powerful computational tool 
to complement the clinical TPS. 
The use of modeled beamlines in MC applications has been described in many works for 
beam delivery with active energy selection (Parodi et al 2013, Molinelli et al 2013, Mairani et 
al 2013, Magro et al 2015), for passive energy selection with pencil-beam scanning 
(Grassberger et al 2015, Paganetti et al 2008), or for passive scattering (Paganetti et al 2004, 
Stankovskiy et al 2009). In our case, due to confidential issues with the beamline geometry, 
the model is not available for external users in need of precise simulation, neither for data 
analysis comparisons after irradiation at HIT nor for simulation-related researches. 
This chapter proposes a solution to this problem with the creation of phase space (PS) files 
containing the characteristics (charge, mass, energy, coordinates and direction cosines, history 
number) of all particles (primary protons and carbon ions as well as secondaries) at the end of 
the beamline, for each of the 255 available initial beam energies. Furthermore, the adaptation 
to the delivery pattern from the raster scanning system has to be possible with these PS, as 
well as the accommodation of the 4 different foci used clinically at HIT, i.e. the FWHM of the 
lateral beam sizes in air at isocenter according to the accelerator database (LIBC, as seen in 
Chapter 3). PS files created from beamline geometries, in the particle therapy field, have 
already been investigated for proton beam applications with passive beam delivery or scanned 
beams of fixed lateral size (Paganetti et al 2008, Stankovskiy et al 2009, Ramos-Méndez et al 
2015, Schümann et al 2012, Parodi et al 2007). The approach presented in this chapter 
proposes a novel narrow beam approximation to generate PS which can be accurately adapted 
to reproduce all the foci available at HIT and scanning pattern of irradiation plans for both 
protons and carbon ions. Several validation steps against simulation with the full beamline 
geometry will be presented. Simulations using the PS approach will be compared to 
measurements in a water phantom. After implementation of the PS within the in-house 
simulation framework, an application of the proposed approach to a small target patient plan 
will be shown and compared to the results of the simplified MC framework. For this plan, the 
two approaches will be evaluated against measurements in a water phantom. 
 
 Materials and Methods 5.2.
 Phase space generation 5.2.1.
 Monte-Carlo code and modeling approaches of the HIT 5.2.1.1.
beamline 
Different approaches have been used concerning the modeling of the beamline for MC 
simulation at HIT. The detailed geometrical model (Parodi et al 2013) allows simulating 
transport and interactions occurring in the beamline more precisely, particularly inside the 
BAMS, for accurate prediction of lateral beam scattering (figure 5.1). The different foci are 
representative of the spread of an initially small (millimeteric) beam in vacuum into the 
beamline and air. In the simplified MC framework the beamline is approximated by an energy 
reduction before the propagation of the particles in vacuum, according to the water equivalent 
thickness of the beamline and air distance to the isocenter. The focus is then adapted 
geometrically to its nominal value at the isocenter (Parodi et al 2012, Bauer et al 2014), 
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similar to the TPS approach dealing with a beam impinging on the target in vacuum. With this 
simplified approach, forward recalculation of planned treatments could well predict 
dosimetric measurements in most of the cases, with differences below 3% (Bauer et al 2014). 
However, the approximations made in such MC framework (so called TPS-like approach 
(Bauer et al 2014)) could have limitation for extreme cases e.g. small fields, due to an 
underestimation of large angle lateral scattering in the elements before the target. 
Furthermore, with the explicit modeling of the beamline geometry, information on the 
primary and secondary particles exiting the BAMS could be tracked, as well as their impacts. 
Hence, in order to give the possibility to external users to perform precise simulations using 
the detailed geometrical modeling of the beamline, without disclosing its confidential 
components, we developed an original PS approach (see next section). 
 
 
 
 
Figure 5.1: Schematics of different MC approaches for simulation transport: on the upper 
panel, the detailed beamline allowing precise description of the particle interactions, from a 
proton beam with an initial energy E0 and an initial focus FWHMvac; on the bottom panel the 
simplified TPS-like approach propagating the particle in vacuum to the isocenter, with an 
initial energy E’0 taking in account the energy reduction of E0 due to the BAMS water 
equivalent thickness and adapted geometrically to the same FWHMiso used by the TPS at 
isocenter. 
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The FLUKA version used in this chapter was the 2011.2c. The version used in the other 
chapters is the development version to include the latest physics related to helium ions. 
However, between these two versions, no particular differences were found for protons and 
carbon ions due to the changes in models, as verified on test cases such as depth dose 
distributions, as presented in the following. In order to reproduce the HIT reference Bragg 
curves presented in Chapter 3 and with a similar process as that presented in Chapter 4 for 
helium ions, several optimizations have been made on the initial beam momentum spread for 
every energy as well as the ionization potential in water, analogue to prior studies using older 
FLUKA versions (Parodi et al 2012, Kurz et al 2012). The optimal ionization potential value 
in water was found at 77.3 eV for protons and 76.8 eV for carbon ions, as previouly 
mentioned in Chapter 4. The “HADROTHErapy” settings with the “EVAPORation” physics 
model were used for both phase space generation and dosimetric verification. These two 
settings were described in detail in Chapter 4. In consideration of time and data storage 
efficiency during PS file generation, photons and electrons were not transported, thus 
depositing their energy at the production point.  
 Phase space requirements 5.2.1.2.
The PS files characterize the beam on a plane perpendicular to its propagation at a defined 
position along the beam path, by describing the properties of every crossing particle (charge, 
mass, energy, coordinates and direction cosines, history number). 
Several goals were defined prior to the generation of the PS: (1) for every initial beam energy 
of proton and carbon ions, a unique PS should be generated and adapted to all the possible 
foci available at HIT, (2) the FWHM in air at isocenter obtained with the PS should not be 
different from the reference foci values of the TPS basic data or LIBC (i.e., FWHM in air at 
isocenter) within the tolerances defined internally at HIT to account for possible daily 
variations of the beam shape ([-15 , 25 ] % of the reference). The same tolerances are defined 
for comparing the simulations using the new PS approach to measurements of FWHM in 
water at different depths. For the comparisons between the full beamline geometry (BL 
approach) and the PS approach, we decided that the differences in FHWM at isocenter in air 
should be inferior to 3%. (3) Additional requirements included a consistent propagation of the 
primary and secondary particles, meaning that particles generated from the same primary 
history must be transported together. Also, the PS approach should lend itself to beam 
propagation according to the raster scanning pattern of the treatment plan. (4) A reasonable 
compromise between the size of the PS files and the number of simulated particles has to be 
found, in order to have enough available statistics per energy and also saving all the needed 
information. 
 
 Phase space narrow beam approach 5.2.1.3.
In order to respect the requirements on the adaptability of a unique PS to different foci we 
develop an original narrow beam approach for PS files generation. It can be explained by 
analogy with a homogeneous analytical system, whose response Rδ to a Dirac signal δ is its 
impulse response S. In addition, the response RG of this system to a Gaussian signal G will be 
the convolution between the signal G and the impulse response S.  
 
𝑅𝛿 =  𝑆 ∗  𝛿 = 𝑆 ,           (5.1) 
𝑅𝐺  =  𝑆 ∗  𝐺,           (5.2) 
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In this way, when using an infinitely narrow (“zero-width”) beam propagated in the beamline 
(by analogy δ), the PS scored at the end of the BAMS of the beamline (by analogy the 
system), specifically the information on the particles position, represents the impulse response 
S of this system.  
Therefore, an adaptation to every focus is possible by convoluting the PS with the information 
on the particle position, using a Gaussian distribution G to represent the beam in vacuum 
before entering the beamline. It is known that the result of the convolution between two 
Gaussian functions is still a Gaussian, with a width (standard deviation) σ(G1*G2) 
corresponds to the quadratic addition of the widths of the two Gaussians G1 and G2, σ(G1) 
and σ(G2). Assuming that the fluence distribution of this PS is Gaussian-like, this approach is 
consistent with the quadratic addition as in Parodi et al (2013), with σ the beam focus at 
isocenter, σ0 the beam broadening at isocenter due to a ‘zero-width’ beam and σini the 
estimated initial beam in vacuum: 
 
𝜎(𝐺1 ∗ 𝐺2)2 =  𝜎(𝐺1)2 +  𝜎(𝐺2)2,        (5.3) 
𝜎² =  𝜎0² +  𝜎𝑖𝑛𝑖²,           (5.4) 
 
For every focus a different value of the beam initial size in vacuum is needed and has to be 
estimated. The theoretical Gaussian FWHM of the beam in vacuum (before the beamline) is 
investigated as a function of the energy using this narrow beam approach. By scoring the 
position of the primary particles at the isocenter, for several energies in the therapeutic range, 
and evaluating the FWHM of their distributions at the center of the beam spot along the 
horizontal axis, the FWHM of the vacuum Gaussian beam FWHMVacuum(focus) can be 
retrieved using the following equation for every focus: 
 
𝐹𝑊𝐻𝑀𝑉𝑎𝑐𝑢𝑢𝑚(𝑓𝑜𝑐𝑢𝑠)
2 = 𝐹𝑊𝐻𝑀𝐼𝑠𝑜𝑐𝑒𝑛𝑡𝑒𝑟(𝑓𝑜𝑐𝑢𝑠)
2 −  𝐹𝑊𝐻𝑀𝐼𝑠𝑜𝑐𝑒𝑛𝑡𝑒𝑟(𝛿)²,    (5.5) 
 
where FWHMIsocenter(focus) is the FWHM size at isocenter in air for one focus extracted from 
the HIT LIBC database, FWHMIsocenter(δ) is the FWHM size in air at isocenter after the 
propagation of an infinitely narrow beam. The energies investigated are {48.12, 54.19, 80.90, 
106.82, 132.30, 157.43, 182.66, 221.05} MeV/u for protons and {88.83, 100.07, 150.42, 
200.28, 250.08, 299.94, 350.84, 430.10} MeV/u for carbon ions. 
Calculated FWHMVacuum(focus) are compared to the expected values from previous work 
(Parodi et al 2012) and are used for the final validation of the PS approach, as well as for the 
rest of the study. A total of 1×10
7
 primary histories are simulated for each run. 
With the beam records of the irradiation, where the information about the size of the focus at 
the isocenter are recorded, a new estimated focus size in vacuum could be calculated by 
replacing the nominal FWHMIsocenter(focus) with the value extrapolated from the upstream 
measurement of the BAMS. 
 
 Phase space scoring 5.2.1.4.
PS files are generated for protons and carbon ions at every energy in the HIT accelerator 
library, using an optimized beam momentum spread, transporting 1×10
7
 primary histories in 
total, resulting in files with a total size of about 500Mb each. The initial lateral size of the 
beam is set to a zero-width distribution (see section 5.2.1.3). The scoring is done on a 4m² 
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square plane perpendicular to the beam direction at the end of the BAMS, just after the last 
element of the beamline, i.e., the second multiwire proportional chamber, at about 112 cm 
before the isocenter.  
Two files are created. The first file corresponds to the scoring of the primary beam with the 
information about the energy, the position in the plane (X,Y position) and the direction 
cosines (dX, dY direction cosines). The second file contains the information about the 
secondary particles (except photons and electrons) in terms of energy, position, direction 
cosines, charge and mass information of every particle. Last information to be saved in both 
files is the generation number of the primary, which allows linking primary to secondary 
particles during the propagation process. To ensure that the PS is representative of the 
different interactions occurring in the beamline, the starting positions of the narrow beam are 
randomly selected in a 5mm x 5mm square around the central axis. Information on these 
starting positions is kept during the beam propagation in the beamline to the scoring position, 
and then subtracted to the scored position of every particle in the PS files.  
 
 
 
 
 
Figure 5.2: PS propagation process: on the left panel, convolution results (red) between the 
PS from the narrow beam (black) and the Gaussian in vacuum (blue): new position (Xvac+XPS) 
obtained from the original position on the phase space (XPS) and the selected position on the 
Gaussian in vacuum (Xvac); on the right panel, rotation of the beam to the expected position: 
transformation from the X/Y position at the BAMS with a direction cosine d to the new 
X’Bams/Y’Bams position at the BAMS with the direction cosines d’ in order to reach the 
X’iso/Y’iso position at isocenter. 
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 Phase space propagation for scanned beam delivery 5.2.1.5.
While performing a treatment plan simulation using the PS, so called PS approach, the 
propagation process is divided in 5 steps:  
- Reading the plan used for irradiation and segmenting the requested number of primary 
histories for the simulation run among the different energy slices according to the 
weight of the number of particles per slice compared to the total number of particles of 
the plan. This is the only step of the process which is not random in order to read the 
PS files only one by one, not to overload the computer memory. 
- Reading the PS file of the current energy slice and linking primary and secondary 
particles. 
- Selecting randomly a generation number among the 10 million possible, to be handled 
as the next primary history. Then loading all the particles related to this primary 
history into the stack of particles to be propagated. Every possibility can be handled (a 
primary with no secondaries, only secondaries, primary and secondaries, no particles 
scored in the PS). 
- The convolution process at the single particle level is performed by adding the 
position information (XPS, YPS) of each particle of the stack (loaded from the PS) to 
respectively 2 distinct random positions (XVac, YVac) selected from a Gaussian 
distribution with a FWHM size corresponding to the expected Gaussian size of the 
beam in vacuum for the selected focus (see figure 5.2 and section 5.2.1.3). This initial 
Gaussian distribution in vacuum is assumed to have the same FWHM in X and Y. The 
final position of the particle to be transported is then XPS + XVac, YPS + YVac. 
- Selecting randomly one of the planned positions at isocenter (X’iso,Y’iso) in the 
current energy slice, with probability weighted by the number of particles to be 
delivered to this spot compared to the total one of the energy slice. In order to reach 
this position the PS have to be rotated from the original position (Xiso ,Yiso, 
corresponding to the position of the central beam axis at isocenter) to the selected 
coordinate (X’iso,Y’iso). This means finding a new position on the PS plane 
(X’Bams,Y’Bams) with respect to the original one along the central axis (XBams,YBams) 
and adapting the new direction cosines (d’) from the original one of the selected 
particles (d) in order to target the selected isocenter position after propagation (figure 
5.2). 
This method holds the advantage that even with only 10 million particles in the PS, the 
convolution with random positions of the beam Gaussian shape in vacuum increases the 
number of combinations of position and energy, thus decreasing the probability to have the 
same event repeated twice.  
 
 Validation and comparisons 5.2.2.
 Validations of the PS approach 5.2.2.1.
Validations of the PS approach are performed against the BL approach, i.e., propagation with 
the beamline geometry, for different cases. The first pencil-beam validation step is focused on 
the differences between the two approaches in terms of fluence distributions and particle 
spectra for a central beam delivery without scanning. For the additional validation steps with 
scanned beam delivery featuring line scans and spread out Bragg-peak (SOBP) distributions, 
the comparisons are made on the dose results. 
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 Pencil-Beam validation 5.2.2.1.1.
For both protons and carbon ions, two energies have been investigated, namely the lowest 
(respectively 48.12 and 88.83 MeV/u) and the highest (respectively 221.06 and 430.10 
MeV/u), for the largest and smallest foci (i.e., focus index 1 and 4) used in clinical routine. 
Different PS files were generated at different positions along the beam path in order to 
investigate the beam propagation in air for a fixed central pencil beam: PSBAMS is recorded on 
a 4m² plane at the BAMS exit at the same position as the one generated with the narrow beam 
approach, while PSiso is recorded on a 4m² plane at the isocenter. Three scenarios are 
compared for the different energies: 
- Simulations with BL approach with different focus sizes: PSBAMS,BL(focus) and 
PSiso,BL(focus), starting from a beam in vacuum with the estimated beam size in vacuum 
before the beamline 
- Simulations with BL approach for the narrow beam propagation: PSBAMS,BL(δ) and 
PSiso,BL(δ), starting from an infinitely narrow beam in vacuum before the beamline, as 
in the PS generation process  
- Simulations with the PS approach for different focus sizes: PSiso,PS(focus), starting from 
the PS in air at the BAMS exit position (where the PS have been generated) 
The fluence and energy distributions are investigated for both primary and secondary 
particles.  
On the planes perpendicular to the beam propagation, at the BAMS exit position and the 
isocenter, the FWHM of the fluence distributions at the center of the pencil-beam spot along 
the horizontal axis are reported, as well as the FWHM of the vertically integrated profiles.  
For the vertically integrated profiles at the isocenter, the absolute global differences are also 
analyzed. It corresponds to:  
 
𝐷𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒𝑔𝑙𝑜𝑏𝑎𝑙(𝑥) = 100 ×
|𝐹𝑙𝑢𝑒𝑛𝑐𝑒𝑃𝑆(𝑥)−𝐹𝑙𝑢𝑒𝑛𝑐𝑒𝐵𝐿(𝑥)|
max(𝐹𝑙𝑢𝑒𝑛𝑐𝑒𝐵𝐿)
,                (5.6) 
 
with Fluence(x) the fluence on the profile at the position x (for both approaches), and 
max(FluenceBL) the maximum fluence along the profile. The mean, standard deviation and 
maximal deviation of these differences are reported. These values are calculated in a region of 
the profiles where the fluence is superior to 0.1% of the maximal fluence. The bin size of the 
profile is 0.2 mm. 
For the energy spectrum, the same analysis is performed on the different PS files acquired at 
the isocenter, however the x variable corresponds to an energy bin in the energy distribution. 
The bin size is 0.04 MeV/u. The energy spectrum of the secondaries is qualitatively analyzed 
as their proportion compared to the primaries is low (maximum probability for an energy bin 
around 0.05% per primaries), hence only the trend and similarities of the spectrum are 
compared. 
For the BL and the PS approach scenarios 1×10
7
 and 5×10
6
 primary histories are simulated 
respectively. For quantitative purposes, only 5×10
6
 primary histories are used for the analysis, 
for both approaches, in order to have a fair comparison. 
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 Line scan validation 5.2.2.1.2.
For both protons and carbon ions we designed plans corresponding to a vertical line scan, 
extending from -5 cm to +5 cm with a 1mm step and centered horizontally (i.e., at 0 cm), in a 
similar way as presented in Chapter 3 and Chapter 4. Three initial beam energies within the 
therapeutic range are investigated, a low energy (80.90 and 150.42 MeV/u for protons and 
carbon ions, respectively), a middle energy (157.43 and 299.94 MeV/u, respectively) and the 
highest energy (221.06 and 430. MeV/u), in combination with each of the four foci used in 
clinical routine, thus resulting in a total of 24 line scans. The geometry of the simulated target 
represents the water phantom used for plan verification measurements, positioned at the 
treatment isocenter, with a 5 mm PMMA entrance window, as presented in Chapter 4, section 
4.2.3.2 . The bin size of the dose scoring grid is set to 0.5 mm x 0.5 mm x 0.5 mm. To ensure 
enough statistics, 1×10
8
 primary histories were simulated for both approaches in 100 
statistically independent runs. Both laterally integrated depth dose profiles, scored along the 
beam penetration in water, and lateral dose profiles, sampled at the entrance of the target, are 
compared between the BL and PS approach. For every dose profile, we investigate both the 
absolute local dose relative difference:  
 
𝐷𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒𝑙𝑜𝑐𝑎𝑙(𝑥) = 100 ×
|𝐷𝑜𝑠𝑒𝑃𝑆(𝑥)−𝐷𝑜𝑠𝑒𝐵𝐿(𝑥)|
𝐷𝑜𝑠𝑒𝐵𝐿(𝑥)
,       (5.7) 
 
and the absolute global dose relative difference: 
 
𝐷𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒𝑔𝑙𝑜𝑏𝑎𝑙(𝑥) = 100 ×
|𝐷𝑜𝑠𝑒𝑃𝑆(𝑥)−𝐷𝑜𝑠𝑒𝐵𝐿(𝑥)|
max (𝐷𝑜𝑠𝑒𝐵𝐿)
,       (5.8) 
 
with Dose(x) being the dose of the profile at the position x (for both approaches), and 
max(DoseBL) being the maximum dose along the profile. 
 
  SOBP validation 5.2.2.1.3.
SOBP plans have been simulated with both the PS and the BL approaches for protons and 
carbon ions, in the latter case using the ripple filter geometry (RiFi, as seen in Chapter 4). 
SOBP plans are designed to deliver 1 Gy to a 5 cm x 5 cm x 3 cm target, centered at 10cm 
depth in water. The same MC geometry with the water phantom is used, as described in 
section 5.2.2.1.2. The dose scoring grid is set to a bin size of 1 mm x 1 mm x 1 mm. A total of 
1×10
8
 primary histories are used to simulate these plans. In this more clinical-like scenario 
only the absolute global differences of the doses between the BL and PS approaches are 
investigated along the central depth dose profile and for the lateral dose profiles sampled at 
the entrance of the target and in the middle of the SOBP.  
 
 Comparisons of the PS approach with measurements 5.2.2.2.
The line scan plans, presented in section 5.2.2.1.2, have also been irradiated in the 
experimental room at HIT. The measurements were performed in the water phantom equipped 
with 24 motorized pinpoint ionization chambers, previously described in Chapter 3. For each 
block position in depth, six measurements were performed with a 2 mm horizontal shift 
perpendicular to the beam direction to complete the lateral profiles. The lateral extension of 
each profile is 46 mm. The block was put at three positions along the beam path in order to 
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sample lateral profiles at the entrance of the phantom, in the plateau of the Bragg peak and 
near the Bragg peak. The measurements were acquired for every combination of particle type 
/ energy / focus presented previously in section 5.2.2.1.2.  
For this comparison, the MC simulations using the PS approach are the same as the one 
presented previously. However, in order to have a fair comparison between the PS approach 
and the measurements, the sensitive volume of the ionization chamber has been taken into 
account in the MC dose results, by averaging the dose value of the voxel of interest with the 
surrounding ones to obtain a resulting integration volume close to the one of the ionization 
chamber. 
The lateral profiles are analyzed quantitatively at three different depths, for each energy and 
focus, and the FWHM of both measurements and simulation are compared. For the lowest 
energy, with a range of around 53 mm, the depths analyzed are 15.7 mm, 30.7 mm and 45.7 
mm. For the middle energy, with a range around 172 mm, the depths analyzed are 15.7 mm, 
85.7 mm and 151.7 mm. For the highest energy, with a range around 308 mm, the depths 
analyzed are 15.7mm, 195.7mm and 267.7mm. The mean and the standard deviation of the 
absolute differences are reported for protons and carbon ions. 
 
 Implementation of the PS in the MC framework 5.2.3.
In order to take advantage of the beamline model in the in-house MC framework, PS files 
were implemented in the simulations. Several changes regarding the original framework using 
the PS approach were made, also taking advantage of new capabilities of FLUKA, and are 
schematized in figure 5.3: 
- The direction of the beam is fixed in contrast to the original simulations, where the 
beam was rotated around the patient as a function of the beam angle and the couch 
position (rotation, pitch and roll). 
- The patient CT voxelized geometry is moved (via rotations) to adapt to the movement 
of both the gantry (beam angle) and the couch position, while it was fixed in the 
previous version for both parameters. 
- More precise description of the interactions in the beamline, as seen in figure 5.2, with 
air instead of vacuum between the PS plane (end of BAMS) and the patient. 
Several tests were designed with different levels of complexity and compared to the TPS as 
gold standard. These tests need to describe all the possibilities allowed by the use of a gantry 
(rotation around the table with respect to a horitontal axis centered on the isocenter), the 
rotation of the treatment table (rotation of the couch in the horizontal plane around a vertical 
axis at isocenter, and pitch and roll rotation around an axis centered at isocenter and oriented 
along either the lateral or longitudinal axis of the treatement table). The plans included the 
following: 
- one to several beams,  
- fix table with different beam angles,  
- fix beam angle with rotation of the couch,  
- the previous case with pitch and/or roll,  
a combination of the different precedent possibilities. 
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Figure 5.3: Schematic of different framework approaches for simulation: on the upper panel, 
the TPS-like approach with a fixed patient geometry and a rotating beam as a function of the 
plan parameters. In the lower panel the PS implementation approach with a fixed origin at the 
PS plane and a rotating voxelized patient geometry as a function of the beam plan parameters. 
 
 
 
 
 
 Application to a small target clinical case 5.2.3.1.
A challenging clinical case has been selected for testing the PS application: an arterio-venous 
malformation (AVM). AVM are congenital malformation assumed to not undergo 
modification in time (implying then low αx/βx from LQ model as explained in Chapter 2, 
section 2.3), which are mostly treated following hypofractionation scheme. Some studies 
demonstrate that AVM yield a high αx/βx which should support hyperfractionation 
(Vernimmen et al 2010), however αx/βx are elusive for smaller target. At HIT, the selected 
AVM are a small targets, inferior to 20 ml in most of the cases and below 3 ml in our study, 
treated at HIT with protons in one fraction of 18 Gy RBE at the isodose 80%. Magro et al 
(2015) found for small targets at shallow depth discrepancies between TPS and measurements 
in water up to ~19%. 
Among the four beams of the plan, we selected the plan delivering the highest dose. 
Dosimetric measurements for this beam were performed in the same water phantom described 
in section 5.2.2.2, and compared to the dose calculations resulting from the PS approach and 
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the simplified MC framework using the TPS-like approach. Several lateral profiles in the 
horizontal direction, with a 1mm lateral step, are acquired at different depths of 19.7mm, 
29.7mm 39.7mm and 49.7mm.  
Furthermore, using the information from the irradiation beam records registered by the 
BAMS, it was found that all foci were on average 1mm larger than the values of the TPS 
database, used in both the PS (in terms of the beam vacuum size added to the narrow beam 
approach) and TPS-like simulations. Hence, new expected Gaussian sizes of the beam in 
vacuum were generated and an additional simulation was performed for the PS approach with 
these new parameters for comparison to the measurements and the previous simulations. 
The geometry for the MC simulations is using the same water phantom target as for the SOBP 
simulations. The dose scoring grid is with a bin size of 1mm x 1mm x 1mm and the number 
of primary histories is set to 5% of the beam total number of particles, which is five time 
higher than the recommend statistics according to Bauer et al (2014).  
In a second step, forward dose calculations of the whole plan in the patient CT geometry have 
been performed for both the TPS-like and PS approach, using the reference LIBC foci value 
at isocenter. The results are compared in term of dose profiles sampled within the target 
region (planning target volume, PTV) region and PTV dose volume histograms. 
 
 Results 5.3.
 Validation of the PS approach  5.3.1.
 Gaussian shape in Vacuum 5.3.1.1.
For Carbon ions, the calculated FWHM values of the Gaussian lateral beam distribution in 
vacuum are within 0.2 mm to the ones expected: 2.5 mm, 5 mm, 7.5 mm, and 9.5 mm for the 
foci from 1 to 4. For focus 1, the mean calculated FWHM (µ) is 2.46 mm with a standard 
deviation σ of 0.15 mm, µ=5.02 +/- 0.09 mm, µ=7.47 +/- 0.07 mm and µ=9.49 +/- 0.06 mm 
for focus 2, 3 and 4 respectively. As the focus increases, the σ decreases due to an easiest 
FWHM evaluation in regards to the bin size. Considering the bin size of 0.2 mm and the small 
difference to the expected value, the nominal values are kept for the whole work. 
In constrast, the calculated FWHM for protons are far different from the initial values of {2.5, 
6, 8 and 10} mm assumed in a previous work, which involved only using a simplified 
beamline modeling to guide the LIBC generation at a time when beamline details had not 
been yet disclosed by the vendor (Parodi et al 2012). It should also be noted that for foci 
higher than focus 1, the FWHM foci values for the low energy region (<100 MeV/u) do not 
correspond to the cited values, due to an asymptotical convergence used to avoid too large 
beam width at the isocenter (Parodi et al 2012). From the simulated eight energies in the 
therapeutic range, an interpolation is done (figure 5.4). For focus 1, we found µ=6.46 +/- 2.05 
mm on the whole energy range. For energies above 100 MeV/u, for focus 2 we obtained 
µ=7.69 +/- 0.37 mm, for focus 3 µ=9.40 +/- 0.30 mm, for focus 4 µ=11.16 +/- 0.26 mm. 
These new values are used for the whole study in order to reach with the PS simulation a good 
agreement to the LIBC foci values at isocenter, which are also used by the TPS.  
 Pencil-Beam validation 5.3.1.2.
 Fluence distributions 5.3.1.2.1.
For the two extreme foci analyzed, the lateral profiles obtained at isocenter with the PS and 
BL approaches are similar, regardless of the considered energy and ion species (figure 5.5). 
The absolute global differences between the two approaches are under 2.5% for protons and 
under 1.3% for carbon ions (Table 5.1). The FWHM values of the lateral profiles, for the 
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profiles in the center of the pencil beam spot and for the vertically integrated profiles, at the 
BAMS exit positions and at isocenter, are reported in Table 5.2. For protons (for both 
energies and foci) the maximal difference is equal to 0.1mm for the vertically integrated 
profiles and 0.2 mm for the horizontal profile along the spot center. For carbon ions (both 
energies and foci) the maximal difference is equal to 0.1 mm for the vertically integrated 
profile and 0.2 mm for the profile sampled along the spot center. For both particles type, the 
difference to the nominal expected values at the isocenter from the database is under 3.5% 
and 0.5mm with the FWHM values in vacuum obtained from section 5.3.1.1.  
 
 
Figure 5.4: Calculation of the protons Gaussian FWHM in vacuum: on the left panel, the 
different FWHM size of the proton foci at isocenter from the LIBC are displayed as a function 
of the energy, as well as the calculated FWHM size for the narrow beam approach (star) and 
its interpolation; on the right panel, the results of the quadratic subtraction between the two 
previous quantities yielding the initial beam size in vacuum for the different foci as function 
of the energy. 
 
 
 
  
 Protons Carbon ions 
48.12MeV/u 221.06MeV/u 88.83MeV/u 430.10MeV/u 
µ(%) σ(%) max(%) µ(%) σ(%) max(%) µ(%) σ(%) max(%) µ(%) σ(%) max(%) 
F1 0.33 0.32 2.30 0.06 0.13 0.91 0.07 0.13 0.93 0.02 0.06 0.83 
F4 0.35 0.34 2.20 0.08 0.17 1.30 0.10 0.18 1.26 0.05 0.12 0.85 
Table 5.1: Primary particle fluence differences at the isocenter (absolute global differences 
with mean µ, standard deviation σ and maximum value) between the PS and the BL 
approaches for both focus 1 and 4 for the vertically integrated lateral profile distributions, in 
percentages compared to the maximum fluence (calculated for spectra regions with a 
corresponding fluence >0.01% of the maximum one). 
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Figure 5.5: Energy spectra difference for protons and carbon ions at the isocenter in air: on the 
left panels, absolute differences in primary spectra obtained with the PS and BL approaches 
are displayed for focus 1 and 4 (blue and green) together with the primary spectra shape (in 
black, similar for focus 1 and 4 and both approaches). On the right panel, secondary spectra at 
isocenter are displayed for the beamline approach (narrow beam and focus 1) and the PS 
approach. The upper panels correspond to protons, energy 48.12MeV/u, and the bottom 
panels correspond to carbon ions, energy 88.83MeV/u. 
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   48.12MeV/u 221.06MeV/u 
  position Profiles(mm) 
Int. 
profiles(mm) 
Profiles(mm) 
Int. 
profiles(mm) 
P
ro
to
n
s 
DB-F1 Isocenter 32.4 / 8.7 / 
DB-F4 Isocenter 32.6 / 12.6 / 
BL-Narrow 
BAMS 4.1 4.2 0.9 0.9 
Isocenter 32.0 34.1 6.8 6.8 
BL-F1 
BAMS 8.6 8.6 5.0 5.0 
Isocenter 32.4 (0 %) 34.5 8.9 (2.3%) 9.1 
BL-F4 
BAMS 9.4 10.6 10.8 10.8 
Isocenter 32.5 (-0.3%) 35.0 13.0 (3.2 %) 13.5 
PS-F1 Isocenter 32.3 (-0.3 %) 34.6 9.0 (3.4%) 9.2 
PS-F4 Isocenter 32.6 (-0.6 %) 35.0 12.8 (1.6 %) 13.5 
       
   88.83MeV/u 430.10MeV/u 
  position Profiles(mm) 
Int. 
profiles(mm) 
Profiles(mm) 
Int. 
profiles(mm) 
C
ar
b
o
n
 i
o
n
s 
DB-F1 Isocenter 9.8 / 3.4 / 
DB-F4 Isocenter 13.4 / 9.8 / 
BL-Narrow 
BAMS 1.3 1.3 0.4 0.4 
Isocenter 9.6 9.6 2.5 2.5 
BL-F1 
BAMS 2.9 2.9 2.7 2.7 
Isocenter 10.0 (2%) 10.4 3.5 (3%) 3.6 
BL-F4 
BAMS 9.7 10.3 9.6 9.6 
Isocenter 13.7 (2.2%) 14.2 9.9 (1%) 9.9 
PS-F1 Isocenter 9.8 (0%) 10.4 3.5 (3%) 3.5 
PS-F4 Isocenter 13.6 (1.5%) 14.2 9.8 (0%) 9.9 
 
Table 5.2: FWHM, in mm, of the different fluence distributions for protons and carbon ions, 
with respect to the reference one from the LIBC: FWHM values for profiles sampled at the 
center of the beam spot and for vertically integrated profiles (Int. profiles), for two positions 
in depth in air (exit of the BAMS and isocenter) for both focus 1 and 4. For the different foci 
at isocenter, the variations in percentage to the LIBC foci value are shown in bracket. DB- 
stands for the LIBC database values, BL- for the BL approach values and PS- for the PS 
approach. 
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 Energy spectrum 5.3.1.2.2.
From visual analysis, the different energy spectra for the primary particles of both carbon ions 
and protons at the isocenter are similar for the different foci simulated with the BL (focus 1, 4 
and narrow beam) or while using the PS approach for the focus 1 and 4. Quantitatively, the 
energy spectra at the isocenter of the BL and the PS approaches are highly similar regarding 
their differences (figure 5.6). The absolute global differences between the BL and the PS 
approaches are reported in the Table 5.3. The maximal deviation for protons is 0.46% and for 
carbon ions 0.68%. 
For the less abundant secondary particles, the different approaches show profiles with the 
same trend for both protons and carbon ions (figure 5.6). 
 Line scan validation 5.3.1.3.
The line scan validation step exhibits similar results for the simulations performed with the 
BL and the PS approaches, both in terms of depth as well as lateral dose profiles (figure 5.7). 
For both type of particles and all explored combinations of energy and focus values, the 
absolute global dose relative difference between the PS and the BL approaches is below 0.5% 
for the laterally integrated depth dose profiles, and the local dose relative difference is below 
0.8%. For the lateral profiles, the maximal absolute global dose relative differences are less 
than 0.5%, while the absolute local dose relative differences reach higher values in low dose 
regions, but still well below the MC percentage errors (figure 5.7), as calculated over the 100 
statistically independent runs. 
 SOBP validation 5.3.1.4.
In terms of extended SOBP fields, both the simulated approaches yield depth and lateral dose 
profiles in excellent agreement with each other (figure 5.8), with absolute global dose relative 
differences below under 0.5% regardless of the considered ion species. 
 
 
 
 
 
 
 Protons Carbon ions 
48.12MeV/u 221.06MeV/u 88.83MeV/u 430.10MeV/u 
µ(%) σ(%) max(%) µ(%) σ(%) max(%) µ(%) σ(%) max(%) µ(%) σ(%) max(%) 
F1 0.05 0.07 0.41 0.04 0.06 0.31 0.06 0.08 0.44 0.07 0.08 0.35 
F4 0.06 0.10 0.46 0.05 0.07 0.30 0.06 0.10 0.68 0.08 0.10 0.42 
 
Table 5.3: Primary particles energy spectra differences at the isocenter (absolute global 
differences with mean µ, standard deviation σ and maximum value) between the PS and the 
BL simulation approaches for both focus 1 and 4, in percentages compared to the maximum 
fluence (calculated for spectra regions with a corresponding fluence >0.01% of the maximum 
one). 
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Figure 5.6: Fluence distributions for protons and carbon ions at the isocenter in air – vertically 
integrated profiles: on the left panels, vertically integrated profiles (projections of X profiles) 
from BL and PS approaches are displayed for focus 1 and 4 in semi-logarithmic scale; on the 
right panels, absolute relative differences between lateral distributions from PS and BL 
approaches are displayed for focus 1 and 4 of the smallest energy (blue/green) together with 
their respective shapes (black). The upper panel corresponds to protons (48.12MeV/u), the 
bottom panel corresponds to carbon ions (88.83MeV/u). 
 
 
 
 
 
 
 
5.3 Results   
90 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7: Lateral dose profiles for line scan validations: Lateral dose profiles for the lowest 
energy studied for both protons (upper panels, 80.90 MeV/u) and carbon ions (bottom panels, 
150.42 MeV/u) at the isocenter in water. The left panels display the profiles from focus 1 and 
focus 4 for the PS (full line) and the BL approaches (stripes) in a semi-logarithmic scale; On 
the right panels, the profiles (black lines) together with their local relative difference (cross) 
and MC percentage errors (dashed lines) for focus 1 and 4 are shown. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 5.8: SOBP Profiles in water: on the left panel, the depth dose profiles of both the PS 
(full line) and the beamline (dot line) approaches are plotted together; on the right panel the 
lateral dose profiles at the center of the SOBP for both the PS (full line) and the BL (dot line) 
approaches are shown. 
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Figure 5.9: Dose calculations and measurements for lateral dose profile comparisons from line 
scans: half-profiles of the different foci are plotted for the same low energy, from left to right 
for focus 1 to focus 4 at 15.7 mm in water, and for two other depths for focus 1 (30.7 and 40.7 
mm). The upper panels correspond to protons comparisons (energy 80.90MeV/u), the bottom 
panels to carbon ions comparisons (energy 150.42MeV/u). Results are normalized to the 
maximum. 
 
 
 
 
 
 Comparison of PS-based simulations with 5.3.2.
dosimetric measurements 
The different water phantom dosimetric measurements show good agreements with the PS 
approach simulations (figure 5.9). In terms of lateral profiles sampled at three different depths 
in water, the differences (in mm and percentage) of the fitted FWHM values are displayed in 
Table 5.4 for both particles types, and all investigated combinations of energies/foci. The 
maximum relative FWHM differences found for protons are about 6.5% and 5.8% 
corresponding respectively to FWHM differences of 0.8 mm and 1.1 mm. The mean absolute 
difference of the value is 0.5 mm with a standard deviation of 0.3 mm. The maximal absolute 
difference found for carbon ions is of -0.9 mm (relative difference of -7.5%), the mean 
absolute difference is 0.2 mm with a standard deviation of 0.2 mm. 
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  Protons Carbon ions 
 Depth 
(mm) 
F1 F2 F3 F4 F1 F2 F3 F4 
L
o
w
 e
n
er
g
y
 
15.7 -0.2mm 
-1.0% 
0.5mm 
2.2% 
0.4mm 
1.8% 
-0.9mm 
-3.7% 
-0.4mm 
-5.7% 
-0.2mm 
-1.8% 
-0.2mm 
-1.5% 
-0.3mm 
-2.1% 
30.7 -0.3mm 
-1.3% 
-0.4mm 
-1.5% 
-0.3mm 
-1.1% 
-0.8mm 
-3.1% 
-0.3mm 
-3.5% 
0.0mm 
0.0% 
0.0mm 
0.0% 
-0.1mm 
-0.1% 
45.7 -0.5mm 
-2.2% 
0.0mm 
0.0% 
0.2mm 
0.8% 
-0.7mm 
-2.8% 
-0.2mm 
-3.2% 
0.1mm 
0.9% 
-0.1mm 
-0.5% 
-0.2mm 
-1.4% 
M
id
d
le
 e
n
er
g
y
 
15.7 -0.1mm 
-0.7% 
0.2mm 
1.2% 
0.4mm 
3.1% 
-0.5mm 
-2.8% 
-0.1mm 
-2.8% 
0.1mm 
2.0% 
-0.2mm 
-1.7% 
-
0.9mm 
-7.5% 
85.7 0.3mm 
2.1% 
0.4mm 
2.7% 
0.6mm 
3.5% 
0.2mm 
1.0% 
0.3mm 
6.6% 
0.4mm 
5.44% 
0.0mm 
0.0% 
-0.7mm 
-5.7% 
151.7 0.3mm 
2.0% 
0.8mm 
5.0% 
0.8mm 
4.4% 
0.5mm 
2.6% 
0.2mm 
2.7% 
0.4mm 
6.1% 
0.3mm 
3.6% 
-0.1mm 
-1.3% 
H
ig
h
 e
n
er
g
y
 
15.7 0.3mm 
2.9% 
0.4mm 
4.1% 
0.8mm 
6.5% 
0.2mm 
1.3% 
0.2mm 
3.7% 
0.1mm 
2.0% 
0.0mm 
0.0% 
-0.1mm 
-1.1% 
195.7 0.3mm 
2.4% 
0.7mm 
4.6% 
0.1mm 
0.3% 
0.9mm 
5.2% 
-0.1mm 
-1.5% 
0.1mm 
1.6% 
0.1mm 
1.0% 
-0.3mm 
2.7% 
267.7 0.3mm 
1.8% 
0.7mm 
3.8% 
1.1mm 
5.8% 
0.9mm 
4.5% 
-0.1mm 
-1.1% 
0.3mm 
4.0% 
0.4mm 
4.4% 
0.1mm 
1.0% 
 
Table 5.4: FWHM differences (in millimeter) and percentages differences (%), between the 
PS simulation approach and dosimetric measurements, at different depths in water, for all 
investigated combinations of particles/energies/foci. Measurements are the reference FWHM. 
“Low energy” corresponds, respectively for protons and carbon ions, to 80.90 and 
150.42MeV/u, “Middle energy” to 157.43 and 299.94 MeV/u, and “High energy” to 221.06 
and 430.10 MeV/u. Numbers in bold represent the maximal differences found for protons and 
carbon ions. 
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 Application to a small target clinical case 5.3.3.
After validation of the PS approach against dosimetric experiments as presented previously in 
a water phantom, the PS implementation in the framework was tested successfully against the 
TPS for several scenarios. Rotation of the CT geometry emulates the adjustments made to the 
patient table (as explained in section 5.2.3) and of the gantry during treament. Subsequently, 
the framework was tested for the challenging clinical case selected.  
The comparison of the measurements acquired at different depths in water exhibits absolute 
global differences below 6% with the conventional PS approach (i.e. utilizing the beam width 
in vacuum discussed in section 5.2.3.1.), while under 2% with the optimized PS approach 
which takes into account the actual deviation of +1 mm for the delivered foci with respect to 
the nominal TPS (LIBC) values. In such extreme scenarios, the TPS-like approach 
implemented in the MC framework, using the nominal TPS FWHM values, yields deviations 
up to 25% (figure 5.10) consistent with the expectations from previous work (Magro et al 
2015, Parodi et al 2012). 
Using the nominal FWHM values at isocenter the results of the dose predictions for the full 
plan projected on the CT patient geometry show the same tendency in terms of the lateral 
profiles and dose volume histogram (figure 5.11). Specifically, the main findings can be 
summarized as follows: 
- 95% of the volume receives 16.9 Gy for PS approach against 19.44 Gy for the TPS-
like one. 
- 5% of the volume receives 22.5 Gy for PS approach against 26.1 Gy for TPS-like one. 
 
 
 
 
Figure 5.10: PS approach against TPS-like approach for a small target clinical case – dose 
verification in a water phantom : dose verification measurements (stars) are displayed against 
simulations with the TPS-like approach using the database foci values (black), the normal PS 
approach (red) with the foci in vacuum estimated from the database foci values, and the 
modified PS approach (blue) using the foci values in vacuum calculated from the beam 
records, at two different depths in water (19.7 mm and 49.7 mm); 
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Figure 5.11: PS approach against TPS-like approach for a small target clinical case – dose 
predictions on the CT geometry: the dose profile at the PTV level in the CT patient geometry 
is plotted in red for the TPS-like approach and black for the PS approach, using the reference 
LIBC foci, for one beam; the bottom right panel displays dose volume histograms of the dose 
calculated with the two studied approaches.  
 
 
 
 Discussions 5.4.
 Validation of the PS 5.4.1.
MC simulations using the proposed PS approach are overall in good agreement with results 
using the the explicit beamline modeling approach, typically within 0.5% for the absolute 
global dose difference.  
The initial sampling of the infinitely narrow beam randomly spread within a 5 mm x5mm area 
before the beamline allows to include into the PS the information of the different interactions 
which can occur in the beamline, particularly between the impinging particules and the 
multiwire proportional chambers, where the wires are separated by a 1mm distance. Without 
this sampling, the spectra of the particles would have been different between the PS and the 
BL approaches, since some particles of the narrow beam approach would not interact as 
expected with the beamline. This would also cause to the fluence distribution and dose 
deposition deviations due to incorrect direction cosines, reducing the FWHM for the fluence 
distributions of the PS approach, ultimately boosting dose deposition in the center of the beam 
spot. The energy spectra of the particles obtained with the BL approach were found to be 
similar for both focus 1 and 4, regardless of the sampling position at the end of the BAMS or 
at the isocenter. This means that either with a small or a large FWHM Gaussian size in 
vacuum, there is no major impact on the energy spectra, thus confirming that the used initial 
sampling area 25mm² is adequate. Furthermore, while investigating the impact of the 
sampling area in more detail, new PS were generated for a 100mm² area. The fluence 
distribution comparison between the original and new PS did not show any relevant 
differences. No major differences were found for the director cosines distribution or the 
energy spectra either for the PS generated with the different foci or PS generated with the 
different sampling area, since in all these cases the initial beam is large enough to cover the 
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multiwire proportional chambers pattern, where the wires are separated by 1mm in the 
horizontal and vertical directions. 
The absolute differences for the vertically integrated fluence distributions, obtained for the 
pencil-beam validation, are mainly due to the bin size and the resulting lower statistics per 
bin. When changing the bin size from a 0.2 mm to 0.6 mm, the maximal differences drop 
from 2.5% to 0.6% for protons and from 1.3% to 0.5% for carbon ions.  
The dose differences between the PS and the BL simulation approaches for the line scans and 
the SOBP validation are within the statistical uncertainties. 
These results show that we could fulfill the initial requirements on the adaptation of a unique 
PS to the different foci and the consistency of the propagation starting from the PS sampling 
plane, including the handling of the raster scanning process. 
 
 Comparisons of the PS-based simulations to 5.4.2.
dosimetric measurements 
Overall, there was good agreement between the PS approach simulations to the lateral profile 
measurements in water, with a maximal FWHM deviation of -7.5 % or 1.1 mm for the 
extreme cases and a mean deviation below 0.5 mm, which corresponds to the bin size. These 
results are well within the range of acceptability, taking into account the even larger tolerance 
of experimental foci deviations at HIT, which is from +25% to -15%. For larger foci, 
particularly for carbon ions, the measured profiles exhibit asymmetric shapes in the horizontal 
directions, which are not modeled in our simulation. This shape is the resulting effect of the 
knock-out extraction process of the beam in the synchrotron, occurring in the horizontal 
plane, which is of trapezoidal shape (Ondreka and Weinrich 2008). However, its effects are 
smeared out due to the scattering in the beamline, air and water, particularly for small foci and 
lower energies. 
 
 Application to a small target clinical case 5.4.3.
The PS approach shows good results compared to dosimetric measurements in the water 
phantom, with an acceptable maximal deviation of 5.8%, taking into account uncertainties in 
the dose gradient for such an extreme case of a small target volume. Moreover, our findings 
also prove the power of the PS approach to adapt easily to the “real” conditions of irradiation 
as monitored by the BAMS, improving the results significantly. In particular, we show that 
MC simulations with the PS approach can use the record of the irradiation to refine from the 
measured foci the estimate of the actual beam size in vacuum for each energy slice. Combined 
with the approach used in Tessonnier et al (2013), using the measured positions of every 
single raster scanning spot and its associated number of particles, it could provide a powerful 
tool for forward calculation closer to the “real” irradiation conditions.  
On the other hand, the simplified TPS-like approach of the MC-framework exhibits a large 
overestimation of the dose with a smaller size of the irradiated volume. This is because it 
underestimates the large angle spread of the beam due to the BAMS and the air between the 
end of the beamline and the target position, resulting in higher dose values in the center of 
every spot. This is shown in the comparison for the lowest beam energy and focus for protons 
used in the line scan comparisons between the new PS approach, the TPS-like one and 
measurements (figure 5.12). These results show that beyond the accurate transport of particles 
in the target, the initial conditions of the beam are also fundamental. This observation is 
consistent with the results of Magro et al (2015) between the same TPS and MC simulations 
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for small targets at shallow depths, and as expected from Parodi et al (2012) evaluating the 
TPS-like approach against a more detailed approach (accounting for the BAMS elements but 
without the at that time not yet available detailed modeling). Beamline approximations used 
for MC simulations are giving in general good results, as shown in Bauer et al (2014) for the 
MC-framework, where the differences between simulations and measurements are in average 
below 3% or in Grassberger et al (2015 where their model compared to a full beamline 
propagation show differences inferior to 1% in the middle of a SOBP. As mentioned in 
section 5.2.1.1, the previous TPS-like approach was implemented for consistency and 
validation of the TPS beam modeling, and before the MC modeling of the beam nozzle (cf 
section 5.3.1.1). However a precise model is fundamental for extreme cases of small targets 
sensitive to the exact modeling of the few individual pencil beams.  
In addition to the advantages provided by a good description of the beamline, the new MC 
framework using the PS provides a full description of the patient set-up as well as the 
possibility to readily take into account all rotations related to the plan. These features were 
made possible by the new capabilities of the MC code FLUKA for handling geometry 
implemented in the newest version (version 2011 and above). The implementation of 
additional elements such as RiFi, or range shifter is facilitated due to the fix geometry of the 
upstream beam.  
 
 
 
 
Figure 5.12: Dose results and measurements at 15.7 mm in water, for lateral dose profiles 
from line scans for the lowest energy protons and focus 1 with a semi-logarithmic scale. The 
TPS-like approach is displayed in red, the PS approach in blue and the measurements with the 
star dots 
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 Summary 5.5.
In this chapter, a novel PS approach has been successfully introduced, validated against 
simulations with the full beamline geometry and implemented in the in-house MC framework. 
It provides an accurate description of the beam to be propagated to a target (phantom/patient) 
as it includes the information of the interaction in the beamline in a generic way (so called 
narrow beam approximation), allowing adaptation to different beam foci with the same data. 
The PS approach can bring significant improvement to the dose calculation compared to the 
simplified approach implemented in the current MC framework (for consistency with the 
TPS). This is especially important, for similar extreme situations of a small target at shallow 
depths, as the patient case investigated in this chapter. 
The generation of PS files for other particles (helium and oxygen ions) has been carried out 
successfully to allow a full description of the particle species available at HIT. 
The generated phase spaces were made available for external teams upon request and have 
been used for several projects (Kelleter et al 2017, Bellinzona et al 2016, Meyer et al 2017). 
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 Dosimetric verification Chapter 6.
in water of a Monte 
Carlo treatment 
planning tool for 1H, 
4He, 12C and 16O ion 
beams at HIT 
 
 
 
In this Chapter, the validation of a Monte Carlo treatment planning tool will be presented. 
This work is using the phase space files created for every ion, presented in Chapter 5, after 
tuning the simulation parameters as explained in Chapter 4. The validation of this tool is the 
mandatory step toward application for patient planning, to be presented in Chapter 7. After 
SOBP optimizations in water for each ion available at HIT, Monte Carlo predictions will be 
compared to dosimetric measurements. The difference between ion dosimetric characteristics 
will be highlighted for challenging SOBP cases, closer to clinical-like scenario compared to 
the SOBP presented in Chapter 3. The introduction of the biological model coupled to the 
Monte Carlo treatment planning tool used for patient planning is shown in Appendix C, 
together with its validation against biological experiments. A part of the work presented in 
this Chapter has been submitted for publication (Tessonnier et al 2017c). 
 
 
 Background 6.1.
The previous Chapter 3 and 4 introduced the particular interest of the particle therapy 
community into other ions than the therapeutically used protons and carbon ions. At the 
Heidelberg ion beam therapy center, as previously seen, recent efforts aim to provide further 
ions species such as helium and oxygen for future clinical use.  
In Chapter 3, thorough dosimetric characterization of these particle species was performed 
(Tessonnier et al 2017a). Validation of the MC code FLUKA against experimental dose 
measurements in water and air was presented in previous published works for protons, carbon 
and oxygen ions (Parodi et al 2012, Parodi et al 2013, Kurz et al 2012), and in Chapter 4 of 
this thesis for helium ions (Tessonnier et al 2017b).  
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Prior to clinical deployment, treatment planning studies have to be performed with an 
experimentally validated engine. As already mentioned in Chapters 3 few works are available 
in literature (Kantemiris et al 2011, Kempe et al 2007, Fuchs et al 2015, Grün et al 2015), 
based on either analytical or MC dose engines, which compare physical properties of different 
ions and treatment-like plans. These works have been performed, however, without any or 
with a limited number of experimental dosimetric benchmarks supporting their predictions. 
Therefore this Chapter addresses the validation of a novel FLUKA-based Monte Carlo 
Treatment Planning tool (MCTP, Mairani et al 2013, Böhlen et al 2013) against dosimetric 
measurements for challenging targets, i.e., small spread-out Bragg peaks (SOBPs) of 3 cm × 3 
cm × 3 cm size, or larger SOBPs of 6 cm × 6 cm × 6 cm, at different depths in water (5, 12.5 
and 20 cm), which are representative for clinically-relevant scenarios. Furthermore, the 
experimental dosimetric SOBP properties collected for the different ions, such as distal/lateral 
fall-off or the entrance/tail doses, were compared to complete the dosimetric studies presented 
in Chapter 3.  
 
 Materials and Methods  6.2.
 Monte Carlo Treatment Planning tool 6.2.1.
The physical optimization of the SOBPs was performed with the FLUKA-based MCTP tool. 
The optimization was carried out for 3 cm × 3 cm × 3 cm and 6 cm × 6 cm × 6 cm
 
targets, 
centered at 5 cm (SOBP1), 12.5 cm (SOBP2) and 20 cm (SOBP3), with a planned 
homogeneous absorbed dose of 1 Gy within the SOBP. The step in depth between two 
consecutive energy slices was about 2 mm, while the lateral spacing between two pencil 
beams was 3mm. The simulations were performed using a detailed model of the HIT 
beamline as described in Parodi et al (2013) and Tessonnier et al (2016), with a water tank 
positioned with its entrance window at the isocenter, as seen in Chapter 4 and Chapter 5. As 
investigated in Parodi et al (2012) and Kurz et al (2012), the optimal initial energy 
momentum spread and ionization potential values in water (76.8 eV for helium, carbon and 
oxygen ions and 77.3 eV for protons) were used for simulation, for a water density of 
0.998g.cm
-3
, reproducing the experimental conditions as seen in Chapter 4. The ripple filter 
(RiFi) was implemented for carbon ions and oxygen ions as routinely applied for patient 
treatment with carbon ion beams. For protons and helium ions, the beam spot size at isocenter 
was chosen following the clinical practice with protons, i.e., using the lowest focus available 
in the HIT accelerator library, thus meaning full-width at half-maximum (FWHM) at 
isocenter of [24.2-16.8] mm and [13.7-10.0] mm for SOBP1, [13.1-11.7] mm and [7.9-7.0] 
mm for SOBP2, [10.3-9.3] mm and [6.0-5.5] mm for SOBP3 for protons and helium ions, 
respectively. For carbon and oxygen ions, the third focus value was chosen as generally 
performed in clinical routine of carbon ion therapy. Thus, this choice means FWHM values at 
isocenter without RiFi of [10.4-9.0] mm and [9.9-8.9] mm for SOBP1, [8.4-8.2] mm and [8.5-
8.4] mm for SOBP2, [8.0] mm and [8.2-8.1] mm for SOBP3 for carbon and oxygen ions, 
respectively. In the optimization, a constraint on the maximum dose in the target was set to 
107% of the planned dose. The scoring grid for dose calculation was set to 1 mm × 1 mm × 1 
mm, smaller than used in routine with the clinical treatment planning system (generally 
between 2 mm × 2 mm × 2 mm and 3 mm × 3 mm × 3 mm). After optimization, the final plan 
for each SOBP and for each beam modality was re-calculated using the full beamline and a 
model of the water tank used at HIT for measurement verification (Tessonnier et al 2016 and 
Chapter 5), with 2x10
8
 primary histories in 200 statistically independent parallel runs. A 
summary of the optimization workflow is provided in Appendix C. 
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 Dosimetric Measurements 6.2.2.
The measurements of the MCTP-optimized plans were acquired in the experimental room of 
HIT. The delivery was performed with the active beam scanning system available at HIT 
(Chapter 2), with the beam impinging on a water tank positioned with its entrance window at 
isocenter and equipped with a block of 24 pinpoint ionization chambers (ICs, 0.030cm
3
; 
PTW) as described in Chapter 5 and Tessonnier et al (2016).  
Depth dose measurements were recorded from 16 mm depth to at least 20 mm after the 80% 
dose fall-off position (R80) of the SOBP. Depth measurement step size in both regions of high 
dose and sharp gradients was about 1 mm. For each irradiation, six depth positions were 
acquired at the same time, with at least two ICs within the radiation field per depth. Depth 
dose positions are relative to the entrance window and expressed in water-equivalent depth. 
Lateral dose measurements were performed at several depths. Measurements from -25 mm to 
+30 mm were achieved with a particular emphasis on the 0 to +30 mm region with step sizes 
of about 1 mm for 3 cm × 3 cm × 3 cm SOBPs. For 6 cm × 6 cm × 6 cm SOBPs, 
measurements were acquired from -25 to +50 mm, with a special focus on the 15 to 50 mm 
region and are presented in Appendix C. 
 
 Analysis of the experimental results and 6.2.3.
comparisons to MC predictions 
From the experimental dosimetric measurements, for each ion and SOPB, parameters were 
extracted for both depth and lateral dose distributions, similar to Chapter 3.  
For each depth dose distribution, the mean dose in the inner 80% of the SOBPs was compared 
to the planned dose of 1 Gy. Subsequently, the mean dose was used as a normalization factor 
for all measurements for all comparisons (depth and lateral), thus being independent of beam 
monitor calibration or daily dose delivery deviation. The dose homogeneity, defined as the 
ratio between the lowest and the highest measured dose within the inner 80% of the SOBP, 
was calculated. The R80, the distal position of the SOBP reaching 80% of the planned dose, 
and the 90% SOBP size, defined as the distance between the proximal and distal position 
reaching 90% of the planned dose, were estimated. The dose distal fall-off 80%-20% 
(DFO80/20), defined as the distance between the 80% and 20% distal dose positions, was 
assessed. The distal fall-off 80%-40% (DFO80/40), free from the influence of the fragmentation 
tail, was also evaluated. The entrance-to-plateau region (EPLR) ratio, between the absorbed 
dose at 16 mm and the mean dose in the inner 80% of the SOBP, as well as the tail-to-plateau 
ratio (TPLR) ratio, between the dose 10 mm after the R80 and the SOBP mean dose, were 
extracted.  
For the lateral dose distributions, the following parameters were extracted from each lateral 
profile within the SOBP region, and then averaged: 
- the 90% lateral SOBP size defined as the distance between the lateral position 
reaching 90% of the planned dose,  
- the lateral fall-off 80%-20% (LFO),  
- the lateral irradiated size defined as the distance between the position reaching the 
50% dose. 
The dosimetric parameters described above were then extracted from the MC predictions as 
well, with the exact same procedure, and compared to the experimental results. 
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 Results 6.3.
 Small SOBP (3 cm × 3 cm × 3 cm) 6.3.1.
The next sections present detailed results related to the 3 cm × 3 cm × 3 cm SOBPs. As 
described in Magro et al (2015), this scenario represents a challenging target for a treatment 
planning system, with high sensitivity to delivery uncertainty and beam modifications (e.g. 
spot sizes). 
 Depth dose distributions 6.3.1.1.
Measured and predicted depth dose distributions are shown in figure 6.1 for the three 3 cm × 
3 cm × 3 cm
 
SOBPs for protons, helium, carbon and oxygen ions.  
 Measurements results and comparisons between ions 6.3.1.1.1.
The experimental depth dose SOBPs parameters are displayed in table 6.1 (left column). The 
error on the dose is the standard deviation of the measurements. The positioning error, linked 
to the IC position uncertainty, is about 0.5 mm, accounting for the 0.1 mm accuracy of the 
step motor, the uncertainty in water tank position of the IC and the error on the position of the 
effective measurement point (Karger et al 1999). Deviations between planned and measured 
dose were below about 3.5% for every ion species and SOBP sizes. For proton and helium ion 
SOBPs, the absolute dose deviations were below 1.1% and below 1.0%, respectively. For 
heavier ions, the differences to the planned dose were below 3.5% with the largest 
discrepancies found for the deepest 
12
C ion SOBP. The homogeneity was in general above 
95% except for the shallowest helium ion SOBP with a registered homogeneity of around 
93%. The range was found to be similar between ions: about 65.5 mm for SOBP1, about 
140.2 mm for SOBP2 and about 215.4 mm for SOBP3. For SOBP1 the DFO80/40 was around 
1 mm for protons, oxygen- and carbon ions, and 0.3 mm for helium ions. For SOBP2 the 
DFO80/40 was around 1.7 mm for protons, oxygen and carbon ions, while being 0.8 mm for 
helium ions. For SOBP3 the DFO80/40 was around 2.6 mm for protons and 1.7 mm for helium, 
oxygen and carbon ions.  
The SOBPs size was similar for all depths and ions with an average size of 31.6 mm with a 
maximum difference of about 1 mm. The EPLR of the different ions for the SOBP1 were 
similar and around 72.3%. For the SOPB2 the EPLR was around 54% for the lighter ions and 
63.5% for the heavier ions. At the largest depth, greater differences were found with EPLR 
values of 49.7% for protons, 54.3% for helium ions, 66.9% for carbon ions and 73.7% for 
oxygen ions. The TPLR for protons were 0% except for the deeper SOBP with 0.4%. From 
the shallowest to deepest SOBPs the TPLRs were about 1.6%, 2.9%, and 3.4% for helium 
ions, 6.0%, 12.9%, and 17.9% for carbon ions, and 6.6%, 16.7%, and 24.9% for oxygen ions. 
 Simulations results and comparisons to measurements 6.3.1.1.2.
The depth dose SOBPs parameters extracted from the simulations are shown in table 6.1 
(right columns) and the deviation of the main parameters to the measurements are 
summarized in figure 6.2. The errors for the R80, DFO and size parameters take into account 
the errors on the simulated position, about half of the dose scoring bin-size (0.5 mm). The 
uncertainties on the dose parameter (EPLR, TPLR, homogeneity and absolute dose deviation 
to the planned dose) were linked to the standard deviation of the underlying dose. The Monte 
Carlo statistical uncertainty was below 0.1% in the high dose region and below 0.5% in the 
low dose regions for all investigated ions and SOBPs. Consistently with the experimental 
results, the homogeneity was in general above 96% except for the shallowest helium ion 
SOBP with homogeneity around 92.1%.  
The differences in mean dose were close to those found between experimental and planned 
dose since simulated mean absolute dose deviations to planned dose were found to be about -
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0.3 ±0.6%. EPLR and TPLR differences between simulations and measurements were within 
3% with the largest difference observed for the deepest SOBPs and heavier ions (carbon ions 
EPLR for the SOBP3 was about 2.9% larger for simulations). Concerning variation in R80, the 
differences were below 1 mm for every ion/SOBP combination. Similar results were found 
for the SOBP size, with differences below 1 mm except for He SOBP1, with a difference of 
1.9 ± 1.0 mm. The DFO80/20 differences were below 1 mm except for the 
16
O SOBP3 with 2.3 
±1.0 mm difference.  
The figure 6.3 presents dose comparisons between measurements and simulations along the 
depth for all ions investigated, after normalization of both depth dose curves to the dose in the 
inner 80% of their respective SOBP. Dose deviations are presented in units of percent 
difference (Δ %), with the display of the ±1% difference in green and ±3% difference in red, 
as well as the blue vertical lines which represent the SOBP target region. The four ions are 
presented: protons, helium, carbon and oxygen ions from left to right panels respectively, for 
the three SOBPs investigated from top to bottom panels, respectively). After normalization of 
each SOBP to the mean dose within 80% of their sizes, for both measurements and 
simulations, all measurement points in the high dose region were found with differences for 
protons below 1% in the target region and below 2.5% in the whole distribution for all 
SOBPs. For helium and oxygen ions, the differences were found to be below 2% for the 
whole distribution, while being below 2.1% in the target for carbon ions and below 3% for the 
overall distribution. 
 
 
 
6.3 Results   
104 
 
 
Table 6.1: 3 cm × 3 cm × 3 cm SOBP depth dose distribution parameters: the different 
parameters are shown for the ions investigated at the different SOBP positions, for both 
measurements (left columns) and simulations (right columns).  
 
 
 
 
 
 
 
 
mean σ mean σ mean σ mean σ mean σ mean σ
EPLR (%) 71,3 2,6 53,1 0,6 49,7 1,1 71,0 0,3 52,3 0,2 49,3 0,4
R80 [mm] 65,0 0,7 140,5 0,7 216,4 0,7 64,8 0,7 140,3 0,7 216,0 0,7
Size [mm] 31,8 0,7 32,5 0,7 32,8 0,7 31,9 0,7 32,7 0,7 33,0 0,7
TPLR (%) 0,0 0,7 0,0 0,3 0,4 0,5 0,0 0,3 0,0 0,2 0,5 0,4
DFO80/20 [mm] 1,5 0,7 2,8 0,7 4,1 0,7 1,8 0,7 2,8 0,7 4,3 0,7
DFO80/40 [mm] 0,9 0,7 1,8 0,7 2,6 0,7 1,0 0,7 1,8 0,7 2,7 0,7
Hom. [%] 97,0 1,2 99,0 1,1 97,8 1,1 98,7 0,1 99,3 0,1 97,9 0,1
Dose dev. -1,1 0,7 0,1 0,3 -0,3 0,5 -0,2 0,3 0,0 0,2 0,2 0,4
EPLR (%) 70,5 1,9 55,3 0,8 54,3 2,4 71,7 0,2 55,4 0,1 54,0 0,1
R80 [mm] 66,1 0,7 140,0 0,7 214,4 0,7 65,9 0,7 140,0 0,7 214,6 0,7
Size [mm] 30,0 0,7 31,9 0,7 31,8 0,7 31,9 0,7 32,0 0,7 31,6 0,7
TPLR (%) 1,6 1,9 2,9 0,7 3,4 0,8 1,2 0,2 2,0 0,1 2,7 0,1
DFO80/20 [mm] 0,5 0,7 1,3 0,7 2,3 0,7 0,8 0,7 1,4 0,7 2,0 0,7
DFO80/40 [mm] 0,3 0,7 0,8 0,7 1,3 0,7 0,4 0,7 0,9 0,7 1,2 0,7
Hom. [%] 93,0 1,2 97,8 1,1 96,9 1,1 92,1 0,1 99,5 0,1 99,3 0,1
Dose dev. -0,1 1,9 0,2 0,7 0,8 0,8 0,0 0,2 -0,3 0,1 -0,9 0,1
EPLR (%) 72,9 0,9 62,1 0,9 66,9 1,1 73,4 0,3 63,1 0,1 69,7 0,6
R80 [mm] 65,5 0,7 140,2 0,7 214,9 0,7 65,4 0,7 140,1 0,7 214,7 0,7
Size [mm] 31,1 0,7 31,5 0,7 31,0 0,7 31,9 0,7 32,0 0,7 31,4 0,7
TPLR (%) 6,0 0,7 12,9 0,8 17,9 1,1 6,4 0,3 12,8 0,1 17,6 0,6
DFO80/20 [mm] 1,8 0,7 3,1 0,7 4,8 0,7 2,0 0,7 2,9 0,7 4,2 0,7
DFO80/40 [mm] 1,1 0,7 1,5 0,7 1,6 0,7 1,4 0,7 1,4 0,7 1,4 0,7
Hom. [%] 97,7 1,0 96,3 1,3 95,2 1,2 98,8 0,1 99,4 0,1 96,7 0,1
Dose dev. 1,7 0,7 2,7 0,8 3,5 1,1 -0,6 0,3 -0,3 0,1 0,0 0,6
EPLR (%) 74,3 0,6 65,0 1,5 73,7 1,3 73,6 0,2 65,6 0,2 75,3 0,5
R80 [mm] 65,4 0,7 140,1 0,7 216,0 0,7 65,2 0,7 140,1 0,7 215,9 0,7
Size [mm] 31,5 0,7 31,4 0,7 32,3 0,7 31,7 0,7 32,3 0,7 33,2 0,7
TPLR (%) 6,6 0,5 16,7 1,0 24,9 0,9 6,5 0,2 15,8 0,2 23,6 0,5
DFO80/20 [mm] 1,5 0,7 4,2 0,7 14,7 0,7 1,8 0,7 3,3 0,7 17,0 0,7
DFO80/40 [mm] 0,9 0,7 1,7 0,7 1,5 0,7 1,2 0,7 1,7 0,7 1,5 0,7
Hom. [%] 97,7 1,1 96,9 1,1 96,6 1,2 99,3 0,1 99,2 0,1 96,9 0,1
Dose dev. 1,7 0,5 3,0 1,0 2,8 0,9 -0,7 0,2 -0,5 0,2 -0,5 0,5
5,0 12,5 20,0 5,0 12,5
C
O
20,0
Experimental measurement parameters FLUKA simulation parameters
SOBP position
H
He
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Figure 6.1: Depth dose distributions in water of the 3 cm × 3 cm × 3 cm SOBPs centered at 5, 
12.5 and 20 cm for protons, helium, carbon and oxygen ions (from top to bottom panels). 
Measurements are shown as points with circles (with error bars) while MC predictions are 
represented by solid lines. 
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Figure 6.2: Difference between SOBP parameters extracted from the measured and simulated 
depth dose distributions. SOBP centered at 5 cm are represented by the square, at 12.5 cm by 
the triangle, and at 20 cm by the circle. From top to bottom the differences are displayed for 
protons, helium, carbon and oxygen ions. The dotted lines stand for difference of either 0 % 
or 0 mm, the dashed lines represent successively the 1, 3 and 5 difference in % or mm. 
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Figure 6.3: Dose differences along the depth between MC and measurements in water, after 
normalization, for the 3 cm × 3 cm × 3 cm SOBPs presented in Chapter 6. The 1% deviation 
line is displayed in red, the 3% in green. The target region is within the blue vertical lines. 
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  Lateral dose distributions 6.3.1.2.
Lateral profiles in the middle of the SOBP for measurements and simulations are shown in 
figure 6.4, for all three cases of the small 3 cm × 3 cm × 3 cm SOBP (left to right: SOBP1, 
SOBP2 and SOBP3), for all ion species (top to bottom: protons, helium, carbon and oxygen 
ions).  
Parameters for the lateral distributions extracted from the measurements are shown in the 
table 6.2 (left columns). The errors have been estimated as described for the depth dose 
distributions. The LFO values for protons were ranging from 12.7 mm for the shallowest 
SOBP to 9.6 mm for the deepest one. The LFO values for helium ions were ranging from 6.9 
mm for SOBP1 down to 5.4 mm for SOBP3. The LFO values for carbon ions were ranging 
from 6.3 mm down to 4.9 mm. The LFO values for oxygen ions were about 5.2-5.4 mm for 
all SOBPs. The average SOBP sizes were similar for every ion, with a better conformity for 
oxygen ions of about 30.3 mm, followed by carbon ions with 30.6 mm, then helium ions with 
31.4 mm and finally protons with 31.7 mm. The irradiated SOBP size was about 51.7 mm at 
the shallowest depth for protons and around 45 mm for other depths. For helium ions, the 
irradiated size was about 41.2 mm for SOBP1 and around 38.3 mm for the other two SOBPs. 
In case of carbon- and oxygen ions, the irradiated size was around 38.5-38 mm for all SOBPs. 
The parameters of the lateral distributions extracted from the SOBP simulations are shown in 
table 6.2 (right columns) and the difference to the parameters extracted from the 
measurements are summarized in figure 6.5. 
The differences between measured and simulated parameters are below 1 mm except for the 
SOBP size of the proton SOBP1 and SOBP2, where variations of about 2 mm are observed. 
 
 
 
 
 
Table 6.2: 3 cm × 3 cm × 3 cm SOBP lateral dose distribution parameters: the different 
parameters are shown for the ions investigated at the different SOBP positions, for both 
measurements (left columns) and simulations (right columns) 
 
mean σ mean σ mean σ mean σ mean σ mean σ
Irrad. Size [mm] 50,4 1,3 44,9 0,7 45,3 0,8 49,4 0,8 44,6 0,7 44,9 0,8
Lat. Size [mm] 31,8 0,9 31,1 0,7 32,2 0,8 33,7 0,7 32,7 0,7 32,7 0,7
LFO80/20 [mm] 12,9 1,4 10,1 0,8 9,6 0,9 12,2 0,8 9,3 0,7 9,6 0,8
Irrad. Size [mm] 41,2 0,7 37,7 0,7 38,9 0,7 41 0,7 37,4 0,7 38,2 0,7
Lat. Size [mm] 31,7 0,8 30,5 0,7 32 0,7 31,5 0,7 30,6 0,7 31,8 0,7
LFO80/20 [mm] 7 0,8 5,4 0,7 5,4 0,8 7,2 0,7 5,3 0,7 5,1 0,8
Irrad. Size [mm] 38,9 0,8 38,3 0,7 38,3 0,7 38,5 0,7 37,9 0,7 37,8 0,7
Lat. Size [mm] 29,9 0,9 30,7 0,7 31,2 0,7 30,7 0,7 30,9 0,7 30,5 0,7
LFO80/20 [mm] 6,3 0,7 5 0,7 5 0,7 6 0,7 5,3 0,7 5,6 0,7
Irrad. Size [mm] 38,7 0,7 37,8 0,7 38,6 0,7 38,1 0,7 37 0,7 37,7 0,7
Lat. Size [mm] 31 0,7 29,7 0,7 30,1 0,8 31,2 0,7 30,2 0,7 30,6 0,7
LFO80/20 [mm] 5,2 0,7 5,3 0,7 5,4 0,7 5,3 0,7 5,2 0,7 5,4 0,7
H
He
C
O
SOBP position
Experimental measurement parameters FLUKA simulation parameters
5,0 12,5 20,0 5,0 12,5 20,0
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Figure 6.4: Lateral dose distributions at the mid-SOBP position for the 3 cm × 3 cm × 3 cm 
SOBPs centered at 5, 12.5 and 20 cm (from left to right panels) for protons, helium, carbon 
and oxygen ions (from top to bottom panels). Measurements are shown as points with circles, 
while MC predictions are represented by the solid lines. 
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Figure 6.5: Difference between parameters extracted from the simulated and measured lateral 
dose distributions in the SOBP region. From the left to the right panels, the irradiated lateral 
size, the SOBP lateral size and the lateral dose fall-off are presented for protons, helium, 
carbon and oxygen ions (from top to bottom panels). The dotted lines stand for 0 mm 
difference, the dashed lines represent differences of 1 and 3 mm, respectively. 
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 Large SOBP (6 cm × 6 cm × 6 cm) 6.3.2.
The next sections present detailed results related to the 6 cm × 6 cm × 6 cm SOBPs.  
 
 Depth dose distributions 6.3.2.1.
 Measurements results and comparisons between ions 6.3.2.1.1.
Measured and predicted depth dose distributions are shown in figure 6.6 for the three SOBPs 
for protons, helium, carbon and oxygen ions. The experimental depth dose SOBPs parameters 
are displayed in table 6.3 (left column). The error on the dose and positioning are similar to 
those previously seen in section 6.3.1. Absolute dose deviations between planned and 
measured dose were below about 3.5% for every ion species and SOBP.  
For proton and helium ion SOBPs, the absolute mean dose deviations within the SOBP were 
below 0.5% and below 1.5%, respectively. For heavier ions, the differences to the planned 
dose were below 3.3% with the largest discrepancies found for the deepest 12C ion SOBP. 
The homogeneity was in general above 95% except for the shallowest helium ion SOBP 
centered at 5cm, with an homogeneity of about 94.7%. The range was found to be similar 
between ions: about 79.5 mm for SOBP1, about 153.5 mm for SOBP2 and about 229 mm for 
SOBP3, except for oxygen ions with 226mm. For SOBP1, the DFO80/40 was roughly 1 mm 
for all ions, around 1.3 mm for SOBP2 and around 2.0 mm for SOBP3. The SOBPs size was 
similar for all depths and ions with an average size of 62.5 mm with a standard deviation of 
about 1.5 mm. The EPLR of the different ions for the SOBP1 were similar and around 93.2%. 
For the SOPB2 the EPLR was around 66% for the lighter ions and 76% for the heavier ions. 
At the largest depth, greater differences were found with EPLR values of 61% for protons, 
66% for helium ions, 82% for carbon ions and 89% for oxygen ions. The TPLR for protons 
were about 0% except for the deeper SOBP with 2.6%. From the shallowest to deepest 
SOBPs the TPLRs were about 2.1%, 4.5%, and 6.0% for helium ions, 10.6%, 17.4%, and 
23.3% for carbon ions, and 9.5%, 20.5%, and 29.7% for oxygen ions.  
 
 Simulations results and comparisons to measurement 6.3.2.1.2.
The depth dose SOBPs parameters extracted from the simulations are shown in table 6.3 
(right columns) and the deviation of the main parameters to the measurements are 
summarized in figure 6.7. The errors on the extracted parameters are calculated in a similar 
way as previously explained. The MC statistical error was below 0.1% in the high dose region 
and below 0.5% in the low dose regions for all the ions and for all the SOBP. Consistently 
with the experimental results, the homogeneity was in general above 98% except for the 
shallowest helium ion SOBP, showing homogeneity of about 96.5%, and the oxygen ion 
SOBP3, at about 94.8%. The differences in mean dose were close to those found between 
experimental and planned dose, since simulated absolute mean dose deviations to planned 
dose were found to be about +0.01 +/-0.3%. EPLR and TPLR differences between 
simulations and measurements were within 3%, with the largest difference observed for the 
deepest SOBPs and heavier ions (carbon ions EPLR difference for the SOBP3 was about 
3.3% larger for simulations). Concerning variations in R80, the differences were below 1 mm 
for every ion/SOBP combination. Regarding the SOBP size, the differences are below 1 mm 
for SOBP1 but larger for SOBP2 and SOBP3. The DFO80/20 differences were below 1 mm 
except for protons, helium ions and the SOBP1 from carbon and oxygen ions. For SOBP2 and 
SOBP3 of oxygen and carbon ions larger differences are found up to12mm. However, the 
DFO80/40 is showing excellent agreements within 1 mm for all investigated ions. 
After normalization of each SOBP to the mean dose within 80% of their sizes, for both 
measurements and simulations, all measurement points in the high dose region were found 
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with differences for protons below 1.5% in the target region and below 3% in the whole 
distribution for all SOBPs, as seen in figure 6.8. For helium, carbon and oxygen ions, the 
differences were found below 3% on the whole distribution, except for the entrance 
measurements of carbon ion SOBP at 3.3%, as seen in figure 6.8.  
 
 
 
Table 6.3: 6 cm × 6 cm × 6 cm SOBP depth dose distribution parameters: the different 
parameters are shown for the ions investigated at the different SOBP positions, for both 
measurements (left columns) and simulations (right columns). 
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Figure 6.6: Depth dose distributions of the 6 cm × 6 cm × 6 cm SOBPs centered at 5, 12.5 and 
20 cm for protons, helium, carbon and oxygen ions (from top to bottom panels). 
Measurements are shown as points with error bars while MC predictions are represented by 
solid lines. 
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Figure 6.7: Difference between simulations and measurements for the 6 cm × 6 cm × 6 cm
 
SOBP parameters extracted/calculated from the depth dose distributions. SOBP centered at 5 
cm are represented by the square, at 12.5 cm by the triangle, and at 20 cm by the circle. From 
top to bottom the differences are displayed for protons, helium, carbon and oxygen ions. The 
dotted lines stand for difference of either 0 % or 0 mm, the dashed lines represent 
successively the 1, 3 and 5 difference in % or mm. 
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Figure 6.8: Dose differences along the depth between MC and measurements in water, after 
normalization, for the 6 cm × 6 cm × 6 cm SOBPs 6. The 1% deviation line is displayed in 
red, the 3% in green. The target region is within the blue vertical lines. 
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 Lateral dose distributions 6.3.2.2.
Lateral profiles in the middle of the SOBP for measurements and simulations are shown in 
figure 6.9, for all three 6 cm × 6 cm × 6 cm SOBP cases (left to right: SOBP1, SOBP2 and 
SOBP3) and for all ion species (top to bottom: protons, helium, carbon and oxygen ions). 
Parameters for the lateral distributions extracted from the measurements are shown in the 
table 6.4 (left columns). The errors have been estimated as described for the depth dose 
distributions. The LFO values for protons ranged from 12.7 mm for the shallowest SOBP to 
about 10.0 mm for the SOBP2 and SOBP3. The LFO values for helium ions ranged from 6.5 
mm for SOBP1 down to 5.6 mm for SOBP2. The LFO values for carbon ions varied from 6.1 
mm down to 5.1 mm. The LFO values for oxygen ions were about 5.0-5.7 mm for all SOBPs. 
The average SOBP sizes were similar for every ion and about 61.5 mm. The irradiated 
protons SOBP size was about 76 mm. For helium and carbon ions, the irradiated size was 
about 69 mm. For oxygen ions, the irradiated size was about 68 mm.  
The parameters of the lateral distributions extracted from the SOBP simulations are shown in 
table 6.4 (right columns) and the difference to the parameters extracted from the 
measurements are summarized in figure 6.10. 
The differences between measured and simulated parameters are below 1 mm for most of the 
SOBP parameters except the for the irradiated sizes of the protons SOBP2 and helium ions 
SOBP3, and the lateral size and lateral fall off of protons SOBP1.  
 
 
 
 
Table 6.4: 6 cm × 6 cm × 6 cm SOBP lateral dose distribution parameters: the different 
parameters are shown for the ions investigated at the different SOBP positions, for both 
measurements (left columns) and simulations (right columns). 
 
mean σ mean σ mean σ mean σ mean σ mean σ
Irrad. Size [mm] 76,1 0,97 76,5 1,72 75,9 1,15 76,2 0,7 75,1 0,8 75,3 0,8
Lat. Size [mm] 59,9 0,75 62,5 1,44 62,3 1,1 62,8 0,8 63,4 0,7 63,3 0,7
LFO80/20 [mm] 12,7 0,75 9,8 0,85 10 0,75 11 0,8 9,2 0,7 9,7 0,8
Irrad. Size [mm] 68,5 0,85 68,3 0,85 70,5 0,97 69,1 0,7 68,4 0,7 69,1 0,7
Lat. Size [mm] 60,6 0,75 61,2 0,97 63,1 0,97 61,2 0,8 62 0,7 62,6 0,7
LFO80/20 [mm] 6,5 0,85 5,6 0,71 6,2 0,6 6,4 0,7 5,1 0,7 5,3 0,8
Irrad. Size [mm] 67,7 0,79 69,3 0,97 69,5 0,97 67,2 0,9 68,9 0,7 69,4 0,7
Lat. Size [mm] 59,3 1,02 62,3 1,33 62,9 0,85 59,9 1,1 62 0,7 62,2 0,7
LFO80/20 [mm] 6,1 0,71 5,1 0,85 5,6 0,85 5,8 0,7 5,3 0,7 5,7 0,7
Irrad. Size [mm] 65,6 1,98 69 0,85 69,2 1,55 66,1 0,7 68,3 0,7 68,9 0,7
Lat. Size [mm] 60 0,85 62,5 1,21 61,3 0,85 59,3 0,7 61,7 0,7 61,9 0,7
LFO80/20 [mm] 5 0,71 5,2 0,85 5,7 0,71 5,3 0,7 5,1 0,7 5,4 0,7
FLUKA simulation parametersExperimental measurement parameters
20,0
H
He
C
O
SOBP position 5,0 12,5 20,0 5,0 12,5
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Figure 6.9: Lateral dose distributions at the mid-SOBP position for the 6 cm × 6 cm × 6 cm 
SOBPs centered at 5, 12.5 and 20 cm (from left to right panels) for protons, helium, carbon 
and oxygen ions (from top to bottom panels). Measurements are shown as points with error 
bars, while MC predictions are represented by the solid lines. 
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Figure 6.10: Difference between parameters extracted from the simulated and measured 
lateral dose distributions in the 6 cm × 6 cm × 6 cm SOBP region. From the left to the right 
panels, the irradiated lateral size, the SOBP lateral size and the lateral dose fall-off are 
presented for protons, helium, carbon and oxygen ions (from top to bottom panels). The 
dotted lines indicate a 0 mm difference, while the dashed lines represent differences of 1 
(blue) and 3 mm (green), respectively. 
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 Discussion 6.4.
As previously stated, the small 3 cm × 3 cm × 3 cm is the most challenging case and will be 
discussed into details. Uncertainties in the planning, delivery and measurements of the the 6 
cm × 6 cm × 6 cm will be described to explain discrepancies in the results, compared to the 
trend reported in detail for the small SOBP. 
 Dosimetric parameters comparisons between the 6.4.1.
different ions and to MCTP plans 
 Depth dose distributions 6.4.1.1.
On the depth dose distribution parameters for the 3 cm × 3 cm × 3 cm SOBPs, for the EPLR 
at 5 cm no particular differences were observed between the different ions with an EPLR 
value of around 72%. For deeper SOBPs, light ions were showing net advantages with at least 
10% less EPLR at 12.5 cm and up to around 20% for protons and helium ions compared to 
oxygen ions at 20 cm. These effects of increased EPLR, already described in Chapter 3 with 
the entrance-to-peak ratio for pristine Bragg peaks measured at HIT, are mainly due to the 
higher fragmentation of ions. Additionally, the RiFi used for heavy ions is increasing the peak 
width of the pristine peaks, thus leading to an increase of EPLR. In Chapter 3, the difference 
between the entrance-to-peak ratio of pristine peaks at about 20 cm of oxygen ions with RiFi 
and protons without RiFi was about 9%. For SOBP3, this difference was found larger (~20%) 
due to the overlapping contribution of each Bragg curve building up the SOBP. For physical 
SOBPs optimized for a 6 cm × 6 cm × 6 cm target the contribution of more Bragg curves 
increased this difference, up to 29%.  
For the 3 cm × 3 cm × 3 cm SOBPs the DFO80/20 of SOBP1 showed similar results for protons 
without RiFi and carbon/oxygen ions with RiFi. A value of about 1.5 mm has been found 
which is in agreement with the results shown in Chapter 3 for pristine peak of the same range 
(~1.3 mm). Helium ions were showing for this depth a reduced DFO80/20 of 0.5 mm due the 
reduced range straggling compared to protons and steeper fall-off than heavier ions using 
RiFi. The RiFi, in fact, increases the range spread. For larger depths, the DFO80/20 were not 
comparable due to the contribution of the fragmentation tail to the 20% fall-of dose, thus 
making DFO80/40 the preferable parameter for comparisons. The DFO80/40 of the 12.5 cm 
centered SOBP were similar (~1.7 mm) for protons, carbon- and oxygen ions, while it was 
smaller (~0.8 mm) for helium ions (without RiFi). For the deepest SOBP helium, carbon and 
oxygen ions exhibit the same DFO80/40, in agreement with the trend of the DFO80/20 at this 
depth for pristine peaks, while the range straggling of protons led to a larger DFO. However, 
it can be observed that the DFO80/40 values are found larger than the DFO80/20 of pristine peaks 
for carbon and oxygen ions. For the lighter ions, the SOBP DFO80/20 is larger than the one 
with pristine peaks. This could be explained by the sum of the Bragg curves and their dose 
contributions to the fall-off of the most distal ones. Thus, for protons the DFO80/20 of the 
SOBP, compared to the corresponding highest energy pristine Bragg peak, was raised by 
about 0.3 mm at 5cm, 0.8 mm at 12.5 cm and 1.3 mm at 20 cm. For helium ions, the increase 
was about 0.1, 0.5 and 0.6 mm for the SOBP1, SOBP2 and SOBP3, respectively. The effect is 
enhanced at greater depth since the DFO80/20 gets larger than the distance between two 
consecutive Bragg peaks in depth. Experiments with 6 cm × 6 cm × 6 cm optimized SOBPs, 
centered at the same investigated depths, showed similar values for the DFO parameters. 
Concerning the TPLR, for the 3 cm × 3 cm × 3 cm SOBPs, the light ions showed advantages 
with null TPLR for protons except small values of 0.4% at large depths due to the enhanced 
distal fall-off, and reaching a maximum of around 3.5% for helium ions for SOBP3. The 
heavier ions showed significantly larger TPLR values up to 18% and 25% for carbon- and 
oxygen ions, respectively. The fragments produced all along the beam paths for each Bragg 
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curves are summed up in the SOBP, leading to TPLR results larger than the ones found in 
Chapter 3 for pristine peaks, exhibiting at 20 cm tail-to-peak ratios of about 10% for carbon 
ions and 15% for oxygen ions. For experiments using 6 cm × 6 cm × 6 cm SOBPs the TPLR 
got even higher due to the contribution of a larger number of Bragg curves, resulting in TPLR 
of about 23% and 29% for carbon- and oxygen ions, respectively, in the case of SOBP3. 
Except for the R80 of the oxygen 6 cm × 6 cm × 6 cm SOBP3, the range of the different 
SOBPs are similar. For the large oxygen SOBP3, this discrepancy in range results from the 
high dose region observed at the end of the SOBP, impacting the range evaluation. It results 
from a lack of constraint on the optimizer for maximal dose within the target (cf. Appendix 
C), which was corrected for the 3 cm × 3 cm × 3 cm SOBPs optimization.  
The size of the small SOBPs in depth was found similar with a value of about 31.6 mm, 
showing good conformity of all ions to the target, except for the shallowest helium SOBP 
(~30 mm) where, due to the ripples, the proximal 90% position is overestimated. Due to the 
same effect, the homogeneity of helium ions for SOBP1 is lower than that of other ions or at 
other depths. In order to achieve homogeneous distribution with low energy helium ions, the 
RiFi should be used as proposed in Chapter 3 and used in Krämer et al (2016). However, it 
could degrade some parameters such as EPLR, TPLR, DFO and LFO, thus bringing more 
doses to the surrounding tissues. Furthermore, even though the homogeneity was found below 
95%, the maximum and minimum doses differ less than 4% from the planned dose value, 
which could still make a delivery without RiFi acceptable. Dose planning using a reduced 
depth separation between consecutive Bragg peaks of about 1mm could provide also an 
improved dose distribution homogeneity within the target. The main drawback of such an 
approach is the increase delivery time. For the larger 6 cm × 6 cm × 6 cm SOBPs, the SOBP1 
size was found consistent between all ions. However for the deepest SOBP2 and SOBP3, 
differences to the planned size of 60mm were observed. The large difference up to 5 mm in 
size can be attributed to the lack of measurement points in the proximal rising edge region of 
the SOBP, as seen in figure 6.6, translated into the large standard deviations reported in table 
6.3.  
 
The observed absolute dose deviations between measurements and MC predictions below 
3.5% for all investigated SOBPs, as well as the overall homogeneity higher than 95%, are 
promising results indicating a proper beam monitor calibration in the experimental room for 
all ions. 
In Chapter 3, larger deviations between planned and delivered dose were found, before 
performing a refinement of the beam monitor calibration, with about 5% dose difference in 
the SOBP region for helium ions and 8% for oxygen ions. Also, the dose differences between 
measurements and plans performed with the research analytical TPS were found about -1.8% 
for carbon ions, while being about +2.7% for the small SOBP2 planned with the research 
MCTP. The small carbon SOBP2 is similar in longitudinal size and close to the range of the 
SOBP presented in Chapter 3. The main reason is ascribed to the fact that the beam monitor 
calibration is tuned for the clinical and research analytical TPS. MC dose prediction of the 
SOBP described in Chapter 3 was found to deviate by about -4.5% from the planned dose, as 
shown in Appendix C. Therefore, a similar disagreement of about 3% is found with respect to 
measurements, consistent with the findings of this work with deviations between 1.7 and 
3.5%. 
Regarding the evolution of the differences between measurement and simulations shown in 
figure 6.3 and 6.8 for small and large SOBPs respectively, due to dose gradient effects and 
position uncertainties, large deviation are observed for all ions near the blue lines representing 
the SOBP limits. Compared to the measurements of the 3 cm × 3 cm × 3 cm SOBPs, the 
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measurements were noisier and presented unexpected values due to measurement drift 
(helium SOBP2 tail, measurements above 3% for protons), mainly due to the delivery time at 
least 8 times higher than for the small SOBPs, associated to a higher number of measurement 
points to cover the whole SOBPs.  
While for protons, carbon and oxygen ions the dose difference is relatively stable around the 
line of 0% deviation (after normalization) in the SOBP region, helium ions show trends of 
increasing dose difference in the SOBP with increasing depth. This could be the effect of the 
beam monitor calibration performed with only two parameters. One is applied to adjust the 
level of the calibration for all energies, while the other one is used to introduce a linear 
dependency between dose and energy. A possible modification of this second component 
could flatten out the dose difference within the SOBP. However, this would lead to a larger 
dose difference in the entrance channel, similar to the trend observed with carbon ions in 
figure 6.3 and 6.8 before the SOBPs position. The beam monitor calibration for helium ions 
could be refined in future, even though the results presented are dosimetrically acceptable. 
 
 Lateral dose distributions 6.4.1.2.
For the lateral dose distributions of the 3 cm × 3 cm × 3 cm SOBPs, due to the use of different 
spot-sizes, the LFO values of helium and heavy ions were found quite similar in the SOBPs 
region while being larger by about 5 mm for protons due to a non-negligible lateral scattering. 
In the entrance of the water tank, smaller LFO values were found for helium ions compared to 
heavier ions. This finding results from (1) the delivery of helium ions without RiFi compared 
to heavier ions with RiFi and (2) due to the use of a different focus size at isocenter (first 
focus size for helium, third focus for heavier ions) as stated in section 6.2.1, being the 
nominal focus size smaller by about 3mm for helium ions at high energies (without taking 
into account the additional broadening effect from the RiFi for heavier ions). In the tail, the 
lateral fall-off of carbon ions was found larger than the one for oxygen ions due to the 
production of heavier fragments with less lateral spread for oxygen ions. Similar LFO results 
were found for the 6 cm × 6 cm × 6 cm SOBPs. 
The irradiated lateral size was found to be similar for helium, carbon and oxygen ions, while 
being up to 8-12 mm larger for protons, respectively, for the large and small SOBPs, as a 
direct consequence of their reported larger LFO.  
Concerning the SOBP sizes, the results were in agreement with the planned size of 30 mm 
and 60mm, with better conformity to the target for oxygen ions, followed by carbon ions, 
helium ions and protons.  
These results are consistent with the trend of the mono-energetic pencil-beams data 
investigated in Chapter 3. Compared to the 4 cm SOBP centered at 10 cm which is presented 
in Chapter 3, optimized only in depth, similar DFO were observed than the small SOBP2. 
However the LFO values of SOBPs optimized with 3 dimensional techniques is improved, 
particularly for light ions. The LFO reported in Chapter 3 was about 4 mm larger for protons, 
3 mm larger for helium ions, about 1 mm larger for carbon ions and 0.5 mm larger for oxygen 
ions, compared to the small and large SOBP2 reported in this Chapter.  
These results indicate that helium and oxygen ions are provided with a similar clinical quality 
than the therapeutic protons and carbon ion beams used at HIT. It also shows that the MCTP 
engine is able to optimize correctly different regular fields with the requested size, depth and 
dose for both small and large targets, respecting as well the constraints of the HIT delivery 
system. 
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 Dosimetric parameters comparisons between MC 6.4.2.
predictions and measurements 
In the comparisons between MC predictions and measurements after dose normalization to 
the mean dose inside the inner 80% of the SOBP, the dose parameters EPLR and TPLR were 
found all in good agreement within 3% for both SOBP sizes. The MC absolute dose deviation 
with respect to the measurements were similar to those presented previously for SOBP dose 
measurements and planned doses, with a maximum absolute dose deviation of 3.5%, since the 
simulated dose agreed within 1% with the dose planned from the MCTP. 
R80 values from simulations and measurements were found to be in excellent agreement, for 3 
cm × 3 cm × 3 cm and 6 cm × 6 cm × 6 cm SOBPs. 
Similar agreement was found for the 3 cm × 3 cm × 3 cm SOBP size comparisons, with the 
exception of the shallowest SOBP for helium ions. As explained previously, this is owed to an 
overestimation of the position of the 90% proximal dose due to the pronounced ripples, thus 
reducing the calculated size of the experimental SOBP. For the 6 cm × 6 cm × 6 cm SOBPs 
difference in size for all ions deepest SOBP2 and SOBP3 were found due to the lack of 
measurement points in the SOBP proximal rising edge region, as seen in figure 6.6. However 
the measurements and simulations depth dose curves are matching in the SOBP region. 
For 3 cm × 3 cm × 3 cm, the agreements on the DFO80/20 are within 1 mm except for the 
deepest oxygen SOBP, due to the worsening of the agreement between measurements and 
predictions in the fragmentation tail. For the 6 cm × 6 cm × 6 cm SOBPs, while the agreement 
remains good for light ions, for SOBP2 and SOBP3 of oxygen and carbon ions, the DFO80/20 
parameter is not reliable due to the dose measurement fluctuation of the tails and the hot spots 
at the end of the SOBP regions. However for both SOBP sizes, when comparing the DFO80/40, 
the difference between measurement and simulation was found to be below 0.5 mm. 
Concerning the comparisons of the geometrical lateral dose parameters of the small SOBP 
size, all investigated quantities were found within 1 mm between MC and experiments, except 
for protons. For protons differences up to 1.9 mm were found for SOBP1 and SOBP2. It was 
found that for these two SOBPs the spot size delivered at isocenter was larger than the one 
expected from the HIT library by about 10%, which is still within the tolerance of HIT. It has 
already been investigated in Parodi et al (2010) that, on small targets, spots size deviations 
can impact the target dose distribution. By adjusting the spot size to the actual measurements, 
as described in Chapter 5 and Tessonnier et al (2016), the newly calculated dose distributions 
were matching well the measurements, resulting in an agreement of the new parameters 
within 1mm (figure 6.11, referring to the small SOBPs). For the largest SOBPs, relevant 
difference on the lateral parameters were observed only for the shallowest proton SOBP1, due 
to the reason previously explained for the small SOBP1 and SOBP2.  
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Figure 6.11: Lateral dose distributions at the mid-SOBP position of the 3 cm × 3 cm × 3 cm 
SOBPs centered at 5, and 12.5 cm (from upper left to right panels) for protons. Measurements 
are shown with dots while MC predictions are represented by the lines. The simulations using 
planned parameters are displayed with dashed lines (“Sim.”) while the simulations using 
larger spot sizes are represented with solid lines (“Sim. Large”). The bottom panels depict the 
evolution of the extracted parameters from the lateral dose distributions in the SOBP region 
for protons. From the left to the right panels the irradiated lateral size, the SOBP lateral size 
and the lateral dose fall-off are presented. Circles depict the comparisons between normal 
simulations against measurements, while square symbols represent the comparisons between 
simulations with larger spot sizes and measurements.  
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The high level of agreement between MC predictions and measurements is encouraging and 
supports the possibility of patient plan comparisons, as addressed in Chapter 7 for protons and 
helium ions. The quality of the predictions is relying on both the FLUKA physics models as 
well as the detailed model of the HIT irradiation system (beamline, focus size). As shown in 
Parodi et al (2010), Parodi et al (2012) and Chapter 5 changes in the description of the 
beamline model, such as the spot size, can highly impact the dose distribution in small and 
challenging targets. In Krämer et al (2016), for helium ions SOBP, disagreement has been 
observed in the lateral fall-off distributions, using their analytical TPS compared to 
measurements. In our study, MC predictions were found to match the data within 1.5 mm for 
all helium ion SOBPs, ensuring a correct estimate of the absorbed dose in surrounding healthy 
tissues for future planning studies. A previous FLUKA-based MC work from Kantemiris et al 
(2011) was estimating DFO80/20 values of about 2.4, 1.6, 1.6, 1.6 mm, respectively, for 
protons, helium, carbon and oxygen ions for a 5cm SOBP centered at 10.5 cm optimized in 
depth. For light ions these values are close to the measurements and simulation predictions 
presented in this work for the 12.5 cm SOBP, with differences most likely due to the variation 
in the initial beam setup (beamline, initial momentum spread) or to the different position of 
the investigated SOBP. However, an underestimation of the fragmentation can be observed in 
the work of Kantemiris et al (2011), as no dose contribution from the tail to the DFO80/20 is 
seen for carbon and oxygen ions, contrary to the expectations. Actually an even enhanced 
fragmentation tail would have been anticipated for that work compared to the small SOBP2 
reported in this Chapter, as a result of the sum of a higher number of pristine Bragg curves 
needed to cover the considered larger target. This effect is probably linked either to a previous 
version of the FLUKA code or different simulation settings. Hence, these observations are 
highlighting the importance of the validation of calculation engines (either analytical or MC) 
against measurements before performing in-depth planning studies. 
This physically validated MCTP system can be interfaced with experimentally validated 
biological models, such as phenomenological (Wedenberg et al 2013, Mairani et al 2016a, 
Mairani et al 2016b) or biophysical (Elsässer et al 2010, Inaniwa et al 2010) models. 
Appendix C shows results of biological calculations performed with FLUKA using the model 
from Mairani et al (2016a, 2016b, 2017a). Thus, the MCTP tool can be used to calculate 
biologically optimized treatment plans. As already explained in Grün et al (2015) and Burigo 
et al (2015) and anticipated in Chapter 3, the superiority of one ion species over another for 
clinical scenarios is not trivial and may depend on various parameters, involving amongst 
others the beam ballistics (number of fields, angles), the fractionation and the tissue types and 
condition (oxygenation) of the target and the surrounding healthy tissues. Thus, the validated 
FLUKA-based MCTP engine presented in this Chapter will provide a solid platform for plan 
comparisons with the available ions at HIT. 
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 Summary 6.5.
In this part of the thesis work, thorough comparisons between the measured dosimetric 
properties of SOBPs physically optimized with the FLUKA-based MCTP tool for different 
ion species were presented, considering small targets of 3 cm × 3 cm × 3 cm
 
and larger targets 
of 6 cm × 6 cm × 6 cm
 
placed at different depths in water. The FLUKA forward recalculation 
of the SOBP plans was validated against measurements with satisfactory agreement for all 
investigated parameters. Using clinical-like irradiation settings, the dosimetric properties of 
helium ions are found close to those of heavier ions. Between protons and helium ions, which 
are in the same low LET range, helium ions could provide better sparing of surrounding 
healthy tissues through better dosimetric characteristics. Oxygen ions show similar dosimetric 
characteristics as clinically used carbon ions. Due to their high LET characteristics, oxygen 
ions could be of particular interest in treatment of radio-resistant tumors such as high-risk 
meningiomas in combination with conventional radiotherapy as discussed by Combs et al 
(2010). Planning studies with patient data are foreseen with this tool in combination with 
recently validated biological models, as will be shown in Chapter 7, thus paving the way 
towards the envisioned clinical introduction of these new ions at HIT. Furthermore, 
investigations on the combination of several ions within the same plan can also be performed 
using this validated platform, following the work of Böhlen et al (2013). 
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 Proton and helium ion Chapter 7.
radiotherapy for 
meningioma tumors: a 
Monte Carlo-based 
planning study 
    
 
 
A comparison of proton and helium ion treatment plans is shown in this chapter. It relies on 
validated Monte Carlo simulations as presented in Chapter 4 for helium ions, as well as the 
Monte Carlo Treatment planning tool described in Chapter 6. With the improved simulation 
framework described in Chapter 5, treatment plans for four patients with meningioma tumor 
were biologically optimized for both protons and helium ions. This biological optimization 
takes into account the different tissue-types of tumorous and normal tissues (based on the 
biological modeling presented in Appendix C for helium and protons). Two tissue-types were 
considered for the target, meningioma and arterio-venous-malformation, representing an 
example of biological diversity of treated brain tissues which yields varying biological dose 
outcomes during optimization. 
 
 
 
 
 Background 7.1.
Clinical application of helium ions with state-of-the-art delivery techniques has the potential 
to improve particle therapy, i.e., patient treatment outcome. Compared to the first clinical 
experience at the Berkeley institute with passively scattered beam delivery (Castro et al. 1994, 
Kaplan et al. 1994), treatments at HIT can be achieved with a fully active beam delivery, as 
presented in Chapter 2.  
The physical advantages of helium ions with reduced range and lateral straggling in 
comparison to protons could result in greater healthy tissue sparing and improved dose-to-
target conformity, as presented in the previous Chapters 3 and 6. As already introduced in 
Chapter 4, compared to protons, helium ions exhibit a higher linear energy transfer (LET) and 
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therefore a higher relative biological effectiveness (RBE), as well as a smaller oxygen 
enhancement ration (OER). Compared to heavier ions, such as carbon and oxygen ions, 
presenting higher LET values, higher RBE and reduced straggling than helium ions, helium 
ions can be still considered favorable in terms of reduced fragmentation after the Bragg peak 
and subsequently lower dose after the target, as seen in the dosimetric results from Chapter 4 
and 6. Even though differential RBE effects between tumor and normal tissues are reduced 
compared to the heavier ions, the reduced RBE range makes biological dose predictions of 
helium ions less prone to uncertainties, particularly in normal tissues. Moreover, possibilities 
of dose escalation seem promising for helium ions, owing to their reduced penumbra 
compared to protons and the low dose fragmentation tail compared to heavier ions. Thus, the 
helium ion treatment modality could effectively reduce dose in cases where organs at risk 
(OAR) are commonly found in proximity to the target, e.g., brain tissue, as well as reduce the 
integral dose delivered to the patient and the related risk of radiation induced secondary 
cancer. Vernimmen et al. (2001) noted the particular interest of proton beam therapy for 
complex brain tumour cases such as meningiomas, where helium ions could further improve 
the therapeutic gain with respect to proton therapy.  
As stated in the previous Chapter 4 and 6, recent works investigated the advantages of helium 
ions for planning studies (Grün et al. 2015, Knäusl et al. 2016) with research platforms not 
validated against experimental dosimetric data. A thorough dosimetric investigation of helium 
ions and in-depth validation of the MC code FLUKA with related MC-based treatment 
planning tool has been achieved in this thesis, as presented in the previous Chapter 4 and 6. In 
combination with a validated phenomenological biological model (Appendix C), which has 
been benchmarked against data for proton and helium ions and considers the entire mixed 
radiation field generated in nuclear interaction (Mairani et al. 2016a, Mairani et al. 2016b, 
Mairani et al 2017), this chapter presents a treatment plan comparison of four different brain 
meningioma cases, using protons and helium ions. Additional MC investigations were 
performed, replacing the target with arteriovenous malformation (AVM) tissue in order to 
evaluate the influence of different brain tissue types on dose optimization and biological 
outcome. AVMs, even if being non-tumorous tissues as described in Chapter 5, represent a 
tissue type which could be related to a high αx/βx in comparison to meningioma (Vernimmen 
et al 2010) and hence is used as a high αx/βx tissue surrogate in the MC study. The effect of 
dose fractionation scheme was investigated for one challenging patient case with helium ions 
for both target tissue types. Additionally, the impact of the ripple filter (RiFi) presence was 
evaluated for a patient case with a target at shallow depth. In Appendix D, a comparative 
study between helium ions and protons for a prostate case is additionally presented.  
 
 Patient selection and methods 7.2.
 Optimization and dose calculation methods 7.2.1.
Four meningioma patient cases irradiated with protons at HIT were used in this study. In 
clinical practice, treatment planning with protons assumed a RBE of 1.1. Details of each 
treatment are presented in table 7.1: 
- three brain meningiomas with two beams (patients A-C); 
- one optical meningioma (patient D), at shallow depth, with a single beam. 
Critical OARs for each case are listed in table 7.1 and their spatial locations relative to the 
planned target volume (PTV) are displayed in figure 7.1. The original proton plans from the 
commercial TPS (SyngoPT, Siemens) were re-optimized with MCTP (cf. Chapter 6) for both 
protons and helium ions, using a variable RBE model for both ions, as well as a fixed RBE 
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value of 1.1 for protons. Proton RBE in clinical practice is defined at 1.1 (Paganetti et al 
2002), since, as explained in Carabe et al (2012), data are not sufficient to support a variable 
RBE approach. However some studies against cell data have shown a rise in RBE with the 
increase of LET (Wedenberg et al 2013, Mairani et al 2017) justifying the implementation of 
such variable model in the MCTP, as also supported by the recent work from Peeler et al 
(2016) showing clinical evidence for pediatric patient brain treatments. In our study, for 
variable RBE calculation, different αx and βx terms from the linear quadratic equation (Fowler 
1989 as seen in Chapter 2) for photon irradiations were attributed to OAR and PTV. For PTV, 
two different tissue types were investigated as explained in the following.  
The optimization process was performed as follows. Firstly, the optimization constraints were 
determined by initially running the proton plans in the MCTP with a fixed RBE of 1.1 in 
order to obtain similar or better dose volume histograms (DVH) than the original plan from 
the analytical TPS. After determination of the various constraints and obtaining the resulting 
plan for protons with fixed RBE, optimizations for protons and helium ions with a variable 
RBE model were performed. The two main advantages of finalizing the constraints for 
protons using a fixed RBE are: (1) it makes the DVH results readily comparable to those of 
the clinical TPS plans and (2) no additional changes will occur on biological dose while 
changing tissue type or fractionation size. The different constraints are shown in table 7.2 
with their respective weights required to achieve dose levels comparable to the ones presented 
in table 7.3 for the TPS proton plans taking into account all treatment fractions (full plan 
delivery, i.e., planned fraction dose times the number of fractions). For the PTV, a constraint 
to achieve a biological dose of 1.8 GyRBE per fraction was initially applied, as well as a 
constraint on the maximum dose where 5% or more of the volume (D5PTV) should not receive 
more than 107% of the planned dose. For the OAR, a constraint on D5OAR was set as seen in 
table 7.2, close to the D5OAR extracted from the TPS plan DVH. The D5 is chosen instead of 
D2 to define the maximum dose, since this indicator is less prone to statistical variation in the 
MC simulation (Paganetti et al. 2008). Additionally to the constraint on the OAR maximum 
dose, low dose constraints were applied with smaller weights. The goal is to reduce as much 
as possible the volume of OAR receiving low dose, and thereby the integral dose, by 
increasing the dose gradient between PTV and surrounding normal tissue. DVH constraints 
on dose and volumes can be easily applied in the clinical TPS, however this feature for the 
MCTP tool is currently under development. 
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Figure 7.1: The four panels above display the complex relation between the contoured PTV 
and OARs for the four considered patient cases on the X-ray computed tomography axial 
images (gray scale) with the overlaid dose distributions (color wash) for proton plans 
calculated with MCTP (section 7.3.1). Second beam for patient B is not visible for this image, 
but can be seen in figure 7.3. 
 
 
 
 
 
Table 7.1: Patient proton plans characteristics from TPS. The information about the dose per 
fraction, number of fractions and beams are reported. It provides information on the angles 
between beams and the close by OARs taken into account for the optimization. 
Planned dose / fraction 
[GyRBE]
Number of 
fractions
Number 
of beams
Angles between 
beams [°]
Critical organ at risks
Temporal lobes (left/right)
Brain stem
Optical system
Brain stem
Chiasma
Optic nerves (left/right)
Intra-auricular nerve (right)
Brain stem
Chiasma
Optic nerve (right)
Optic nerve (left)
Eye (left)
1,8
1,8
1,8
1,8
29
30
30
28Patient D (H02552)
Patient C (H02524)
Patient B (H02433)
Patient A (H02202) 2 180
2 75
32
\
2
1
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Table 7.2: Optimal constraint parameters for PTV and OAR found with MCTP to reproduce 
the TPS proton DVH characteristics presented in table 7.3. Hard constraints are defined for 
D50 and D5 in the PTV, while only for D5 in the OAR. However, as the MCTP works only 
with maximum dose up to now (Appendix C), a second D5 at lower dose with a softer 
constraint is used for OAR, to reduce the irradiated volume of normal tissues. 
 
 
Table 7.3: DVH parameters extracted from the clinical TPS proton plans. The dose volume 
parameters for each ROI, in GyRBE - D5, D10, D20, D33, D50, D66, D75 and D95 - are 
presented for a full plan delivery. The MCTP optimization with fixed RBE protons tries to 
reproduce these values. 
Dose constraint 
[GyRBE]
weight
Dose constraint 
[GyRBE]
weight
PTV 1,8 20 1,93 20
Temporal lobe left 1,15 5 0,4 1
Temporal lobe right 0,98 5 0,3 1
Brain stem 1,21 5 0,5 1
Optical system 1,7 10 / /
PTV 1,8 15 1,93 20
Brain stem 1,77 10 0,8 1
Chiasma 1,72 8 0,8 1
Optic nerve left 0,8 5 / /
Optic nerve right 1,7 5 0,8 1
Intra-auricular nerve (right) 1,36 5 0,6 1
PTV 1,8 12 1,93 20
Brain stem 1,35 5 0,5 1
Chiasma 1,38 30 0,7 1
Optic nerve (right) 1,71 30 0,7 1
PTV 1,8 14 1,93 20
Optic nerve (left) 1,55 20 0,8 1
Eye (left) 1,45 20 1 2
PTV 3,3 14 3,53 20
Rectum 2,9 20 1,4 1
Patient E (H01949)
Patient A (H02202)
Patient B (H02433)
Patient C (H02524)
Patient D (H02552)
D5 D10 D20 D33 D50 D66 D75 D95
PTV 53,1 52,8 52,5 52,2 51,6 50,8 50,2 48,1
Temporal lobe left 33,6 29,0 22,9 18,6 15,1 11,9 9,3 2,3
Temporal lobe right 28,7 22,6 18,9 14,5 12,5 10,7 8,4 1,5
Brain stem 35,1 32,2 27,0 22,6 18,0 14,5 11,6 3,5
Optical system 49,9 47,9 42,1 33,9 25,8 17,4 10,2 2,0
PTV 55,2 54,9 54,6 54,0 53,4 52,8 52,5 49,8
Optic nerve left 23,4 17,7 8,4 1,8 0,6 0,3 0,3 0,3
Chiasma 51,6 51,0 50,4 49,2 44,1 35,4 29,4 12,0
Optic nerve right 51,0 50,4 49,5 45,6 27,9 6,9 2,4 0,3
Brain stem 53,4 52,5 46,8 32,1 14,1 5,1 3,0 0,6
PTV 55,8 55,2 54,9 54,0 53,1 52,5 51,6 49,2
Optic nerve (right) 51,3 50,7 50,1 49,5 47,1 41,1 36,6 22,5
Chiasma 50,7 49,8 48,9 43,5 25,5 9,9 1,8 0,3
Brain stem 41,4 27,9 10,5 2,7 0,6 0,3 0,3 0,3
PTV 51,8 51,2 50,7 50,1 49,6 48,7 47,9 44,2
Eye (left) 41,4 38,6 33,6 28,0 21,0 15,1 12,0 5,3
Optic nerve (left) 43,4 40,3 34,2 23,8 9,5 3,4 1,4 0,3
DVH analysis : H (RBE=1.1) TPS Plan
Patient A (H02202)
Patient B (H02433)
Patient C (H02524)
Patient D (H02552)
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For each plan, the optimization is performed with a method similar to Mairani et al. (2013) 
and already applied in Chapter 6 for physically optimized SOBPs (cf. also Appendix C):  
- Dose matrices for each regions of interest (ROI), i.e., the target and the OARs 
presented in table 7.2, are pre-calculated using the FLUKA MC. These calculations 
include the patient voxelized geometry a detailed model of the HIT beamline with the 
RiFi model for helium ions. If needed, the biological model presented in Mairani et al. 
(2016a) and described in Appendix C is used for biological dose calculation with a 
variable RBE. Thus, for each ion, physical matrices are created for each ROI, along 
with the requested biological dose matrices for each tissue type investigated. 
- Initial optimization is performed with protons, for a fixed RBE, to obtain the optimal 
constraints for each ROI in comparison to the original clinical TPS plan. 
- Optimization for each ion is performed with the above presented biological model. 
The resultant plans are simulated with MC FLUKA using the simulation framework presented 
in Chapter 5 and linked to the biological model. As previously stated for the pre-optimization 
process, the planning and simulations for helium ions were performed with the RiFi to avoid 
target dose inhomogeneity as seen in Chapter 6. The final calculations are performed using 
50x10
6
 primary histories, in 50 independent runs, with online calculation of the αion and βion 
parameters, at 1x1x3 mm
3
 resolution. Dose distribution and DVH analysis are calculated and 
plotted with an in-house software (Bauer et al. 2014).  
 Tissue-types attributions 7.2.2.
For the biological dose calculations using variable RBE, tissue-types need to be designated. 
From the ROI, two categories can be distinguished for this study: the target (PTV) and the 
OAR. For the non-tumorous regions, a tissue type with a αx/βx ratio of 2.0 Gy (Santacroce et 
al. 2013) was chosen. For the PTV, two tissue-types were considered describing two kinds of 
target with distinct αx/βx ratio, characteristic of the biological diversity of brain tumors. The 
first target type is meningioma, corresponding to the patient cases selected and representing 
one of the potential tumor types for helium therapy. As recommended in Vernimmen et al. 
(2010), an αx/βx ratio of 3.7 Gy for tumor tissue was selected. For the second target tissue 
types, the αx/βx ratio of the target was changed to 10.0 Gy, representative of the αx/βx order for 
AVM tissues (Vernimmen et al. 2010). It has to be noted that for the selected biological 
model, only the αx/βx ratio is of importance, not the αx and βx individual values.  
 Change in fractionation scheme 7.2.3.
For the challenging patient C, exhibiting the smallest angle between the two beams and many 
sensitive OARs near the PTV, a different daily fractionation scheme of 3 GyRBE instead of 
1.8 GyRBE was investigated for helium ions and both target tissue-types. The results using 
the two fractionation schemes were then compared to protons, calculated with and without 
variable RBE for a dose per fraction of 1.8GyRBE.  
It should be however noticed that by using a different fractionation scheme, the biological 
endpoints could be different, as explained in the report of Suit et al (2010), reviewing the 
clinically used fractionation scheme and the introduction of the biologically effective dose 
(BED). BED takes into account the total dose (Dtot), the dose per fraction (d), and the cell type 
(αx/βx) and can be defined, compared to a reference dose per fraction of 2Gy, as: 
 
𝐵𝐸𝐷 = 𝐷𝑡𝑜𝑡
(𝛼𝑥 𝛽𝑥)+𝑑⁄
(𝛼𝑥 𝛽𝑥)+2⁄
  .                                           (7.1) 
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Thus, the BED (in GyBED) can be expressed in the presented situations for the PTV as well 
as the OAR, assuming that the OAR is receiving the same dose as the planned one. For the 
meningioma case with αx/βx=3.7, the calculated BED for 1.8GyRBE achieved in for example 
30 fractions is 52GyBED. To achieve the same BED with a 3GyRBE fractionation, about 15 
fractions are necessary. This implies for the OAR (αx/βx=2) a BED of 51GyBED and 
56GyBED, respectively, for the 1.8GyRBE and 3GyRBE daily fractionation scheme. For the 
AVM case with αx/βx=10, the calculated BED for 1.8GyRBE achieved in 30 fractions is 
53GyBED. To achieve the same BED with a 3GyRBE fractionation, about 16 fractions are 
necessary. This implies for the OAR (αx/βx=2) a BED of 52GyBED and 60GyBED, 
respectively, for the 1.8 GyRBE and 3GyRBE fractionation schemes. However, while BED 
calculation are straightforward concerning the tumor, for OAR such approach is more 
complex due to the non-uniform dose and the spatial location with respect to the tumor. To 
achieve the constraint mentioned in table 7.2, a voxel per voxel approach could be used to 
calculate the new BED of OAR such as in Unkelbach et al (2013). However, such an 
approach was not available for this study, although it could be considered in future 
implementation within the MCTP framework at HIT. 
Hence, in a first approach without using a more refined BED model of the OARs, the 
1.8GyRBE fractionation scheme was set as reference for the target dose, in order to compare 
the two fractionation schemes. Subsequently, the number of fractions to achieve the same 
BED was calculated for the 3GyRBE fraction dose. According to the originally considered 
number of fractions, for αx/βx=3.7 and αx/βx=10, the new number of fractions were 
respectively about 15 (14.8) and 17 (16.4) for patient B and C, about 14 (14.3) and 16 (15.8) 
for patient A, and about 14 (13.8) and 15 (15.3) for patient D. The numbers into brackets 
indicate the exact number of fractions to achieve the same BED. While using such numbers is 
not realistic in clinical practice, it will be used in the following to allow a more 
straightforward comparison between the two fractionation schemes, acknowledging the 
limitations that such approach holds. 
Thus, for the optimization, the same weight constraints as previously described were applied 
for the planning of a given daily fraction, however, all dose constraints were scaled by a 
3
1.8
 
factor to account for the difference in prescribed dose. The dose for helium ions in the DVH 
figures and tables is displayed in GyRBE, but is calculated for the full delivery taking into 
account the new fractionation scheme and the new number of fractions. Calculations for 
protons were not performed with the new fractionation scheme of 3GyRBE, but it should be 
noted that at this dose level, the RBE tends toward a value of 1.1, as it will be discussed in 
section 7.4. 
 Investigation of the RiFi potential benefits 7.2.4.
In Chapter 3 and Chapter 6, the possibility to use the RiFi for helium ion treatments of 
shallow tumors was discussed, due to the small Bragg peak width presented at low energies. 
In Chapter 6, the physically optimized spread-out Bragg peaks (SOBP) at 5cm depth 
exhibited dose ripples within the target regions due to the chosen absence of RiFi. However, 
for the patient D, presenting a tumor at shallow depth with a single beam, the evaluation on a 
clinical scenario of a delivery without RiFi was investigated, in addition to the optimization 
presented previously with RiFi. The optimization dose matrices were recalculated without 
RiFi and optimized for the meningioma tissue-type target with fraction dose of 1.8 GyRBE. 
Additional optimizations were performed for irradiation schemes without RiFi considering a 
reduced distance between consecutive Bragg peaks, to compensate for the smaller Bragg peak 
width. For this purpose, new matrices were calculated for energy slices separated by about 
1mm instead of the initially planned 2mm, which are commonly used for protons at such 
depths. 
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 Results 7.3.
This section presents the results of the patient plans optimizations, their final MC calculations 
and related dosimetric comparisons. The tables present the differences between DVH 
parameters (in GyRBE), for the full treatment total dose (planned dose x number of fractions) 
as well as the DVHs of the different ROIs. For patient B, the intra-auricular nerves results are 
not displayed to facilitate the comprehension of DVH and tables. For the new fractionation 
scheme, results are taking into account the effect of dose and fractionation on the full delivery 
course. 
 MCTP optimization results compared to TPS 7.3.1.
The DVH results of proton optimization (with fixed RBE) for the MCTP compared to the 
TPS are shown in table 7.4, representing the dose difference between dose volume parameters 
of the MCTP plans against the TPS plans. For the PTV of the four patients, the D5PTV value 
obtained with MCTP was found higher by a maximum of about 2GyRBE compared to TPS. 
However, in general a similar coverage of the target was observed, with on average less than 
1.5GyRBE difference for all extracted DVH parameters. The maximum deviation found was 
for D95PTV at 3GyRBE for patient A.  
Regarding the OARs, a relatively good agreement in terms of the maximum dose is found, 
with less than 2.1 GyRBE difference in the D5OAR. For the other OAR DVH parameters, the 
difference between MCTP and TPS is below 2GyRBE, except for patient D and the brainstem 
of patient B. For patient D and the brainstem of patient B, MCTP was giving higher dose on 
average to the OAR, up to 3.6 GyRBE for the left eye of patient D. On the other hand, the 
MCTP was able to reduce the dose up to 10GyRBE in regions such as the optical system of 
patient A. For this latter patient, all OARs indicated a reduced dose with MCTP compared to 
the TPS plan. For patient C, D5brainstem of brainstem is reduced by 9.6GyRBE with MCTP, as 
well as the D33chiasma of chiasma by about 9GyRBE. As it will be discussed in section 7.4, 
these results are acceptable and demonstrate the capabilities of MCTP as treatment planning 
engine. The constraints and weights chosen to achieve these DVH results were then used for 
further planning.  
 
 Meningioma target tissue-type 7.3.2.
The dose distributions for patient A, B, C and D are displayed in figure 7.2 to 7.5 
respectively, with the helium ion dose prediction (top) and the one for protons (bottom), both 
obtained with a variable RBE scheme. The figure 7.6 displays the dose difference between the 
helium dose distributions minus the protons dose predictions (top), and protons dose minus 
heliums doses (bottom), to highlight the difference between the plans. The dose display uses a 
color-wash system showing certain dose levels w.r.t. the planned dose of 1.8GyRBE. These 
dose levels are as follows: >10%, >20%, >50%, >80%, >95% and >107% of the prescribed 
dose. The 10%, 20% and 50% dose level regions are larger for protons than for helium ions, 
and are best visualized in the dose difference maps. The dose gradients outside the PTV are 
sharper for helium ions than for protons in all directions, as expected. In figure 7.2 for patient 
A, some hotspots can be observed for helium ions outside of the target volume or near the 
vicinity of the PTV. In addition to the shallow dose gradient found for protons for patient D, 
doses above 107% exist within the PTV for the proton patient D plan, as it can be seen in the 
related DVH in figure 7.7. DVH plots for the different ROIs are displayed in figure 7.7.  
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Table 7.4: DVH parameters difference for the ROI of the four patients, in GyRBE, between 
the MCTP optimized proton plans with fix RBE and the original TPS plans.  
 
 
 
 
Figure 7.2: Dose distributions superimposed on the gray scale CT images are shown for 
patient A, with on the top panels helium ions (4He) and bottom panels protons (1H) for the 
sagittal, coronal, axial slices. 
 
D5 D10 D20 D33 D50 D66 D75 D95
PTV 2,0 1,7 1,2 0,9 0,6 0,0 0,0 -3,2
Temporal lobe left -4,1 -2,3 0,0 0,6 0,9 0,6 0,6 0,0
Temporal lobe right -6,7 -3,8 -4,4 -1,7 -1,5 -1,7 -2,0 -0,3
Brain stem -0,9 -2,0 -1,7 -1,5 -0,6 0,0 -0,3 0,0
Optical system -3,5 -4,9 -7,5 -9,9 -8,1 -5,2 -1,2 0,0
PTV 1,5 0,9 0,3 0,6 0,3 0,3 0,3 -1,8
Optic nerve left -0,9 -1,5 -0,3 0,3 -0,3 0,0 0,0 -0,3
Chiasma 1,5 1,2 0,3 -1,8 -2,1 0,6 2,1 2,1
Optic nerve right 2,1 1,8 0,9 -0,9 -0,6 0,9 0,6 0,0
Brain stem -3,0 -5,1 -9,0 -5,4 1,5 3,6 2,7 0,9
PTV 0,6 0,6 0,0 0,3 0,3 0,6 0,6 -0,9
Optic nerve (right) 1,2 1,5 1,2 0,6 0,9 0,9 0,9 1,8
Chiasma 0,3 0,0 -2,7 -9,0 -3,9 -5,4 -0,3 -0,3
Brain stem -9,6 -7,2 -1,5 0,9 0,3 0,0 0,0 -0,3
PTV 2,0 1,7 1,4 0,6 0,3 0,3 0,3 1,1
Eye (left) 1,4 2,2 3,4 3,6 3,6 3,1 2,8 1,4
Optic nerve (left) -3,1 -2,5 -2,5 -0,8 2,8 3,4 2,8 0,8
Patient A (H02202)
Patient C (H02524)
Patient D (H02552)
DVH analysis : H (MCTPS, RBE=1.1) - H (TPS, RBE=1.1)
Patient B (H02433)
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Figure 7.3: Dose distributions superimposed on the gray scale CT images are shown for 
patient B, with on the top panels helium ions (4He) and bottom panels protons (1H) for the 
sagittal, coronal, axial slices. 
 
 
 
 
 
Figure 7.4: Dose distributions superimposed on the gray scale CT images are shown for 
patient C, with on the top panels helium ions (4He) and bottom panels protons (1H) for the 
sagittal, coronal, axial slices.  
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Figure 7.5: Dose distributions superimposed on the gray scale CT images are shown for 
patient D, with on the top panels helium ions (4He) and bottom panels protons (1H) for the 
sagittal, coronal, axial slices.  
 
 
 
Figure 7.6: Dose difference between the helium ions and proton dose predictions for patient 
A: the top panel displays the overdosages due to helium ions (
4
He-
1
H), the bottom panels 
shows the overdosages due to protons (
1
H-
4
He). The isocontours displays the dose per 
fraction >0.1GyRBE, >0.2GyRBE, >0.3GyRBE, >0.4GyRBE, >0.5GyRBE and >0.6GyRBE. 
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Figure 7.7: DVH for the four patient with meningioma as target tissue-type. The different 
ROIs investigated are displayed. Protons are shown for both fixed (dotted lines) and variable 
RBE (dashed lines). Helium ions are displayed with solid lines. 
 
 
Proton results are shown for both fixed (dotted lines) and variable RBE (dashed lines). 
Helium ions are displayed with solid lines. Tables 7.5 and 7.6 show differences between DVH 
parameters extracted from helium ion and proton plans, with either a fixed or variable RBE, 
respectively. It can be seen from figure 7.7, as well as from tables 7.5 and 7.6, that the PTV 
coverage is similar for all cases except patient D, where helium ions afford better coverage, 
with a sharper PTV DVH. For this patient D, the D5PTV is larger with protons by about 
2GyRBE, due to the hot spots previously mentioned. For most of the dose volume parameters, 
the dose is reduced with helium ions compared to protons with a fixed RBE (table 7.5,) with 
dose sparing up to 7.5GyRBE for D95chiasma of Patient B. Only the D5brainstem of patient C and 
D5Opt.Nerve/ D10Opt.Nerve of patient D present for helium ions higher doses above 2GyRBE, with 
values of about 3 and 3.9/2.5 GyRBE, respectively. When comparing helium ions to protons 
with variable RBE, the dose is reduced with helium ions compared to protons (table 7.6) with 
dose sparing up to 7.8GyRBE for D50Opt.System of Patient A. Only the D5Opt.Nerve of patient D is 
having higher dose with helium ions by about 1.7GyRBE. Proton optimized plans show in the 
OARs a DVH slightly shifted toward higher dose, about 1-2GyRBE, particularly for small 
volumes close to the PTV, for example leading to higher D5/D10 values.  
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Table 7.5: DVH parameters difference for the ROIs of the four patients with meningioma 
tissue-types as target, in GyRBE, between the MCTP optimized helium plans and proton 
plans with fixed RBE. 
 
 
Table 7.6: DVH parameters difference for the ROI of the four patients, with meningioma 
tissue-types as target, in GyRBE, between the MCTP optimized helium plans and proton 
plans with variable RBE. 
 
 
 
 
D5 D10 D20 D33 D50 D66 D75 D95
PTV -0,9 -1,2 -0,9 -0,6 -0,3 0,6 0,9 1,2
Temporal lobe left -2,9 -3,8 -3,8 -4,1 -4,1 -3,5 -3,5 -1,7
Temporal lobe right -1,2 -1,2 -1,5 -1,5 -1,7 -2,9 -2,9 -0,9
Brain stem -1,5 -1,5 -2,3 -2,9 -2,3 -3,5 -3,8 -2,0
Optical system 0,6 1,2 0,3 -2,0 -4,4 -4,6 -4,4 -1,7
PTV -0,3 -0,3 0,3 -0,6 0,0 -0,3 -0,9 -0,6
Optic nerve left -3,3 -3,0 -3,6 -1,5 0,0 0,0 -0,3 0,0
Chiasma -1,2 -1,2 -0,9 -0,9 -2,1 -5,1 -6,3 -7,5
Optic nerve right -1,2 -1,2 -0,9 0,3 -4,2 -4,8 -2,1 -0,3
Brain stem -0,3 0,3 0,3 -3,0 -3,9 -3,3 -2,7 -0,6
PTV -0,6 -0,6 0,0 0,0 0,6 0,0 0,3 -0,6
Optic nerve (right) -0,6 -1,2 -1,5 -1,5 -1,2 -1,5 -3,3 -6,0
Chiasma -2,4 -2,1 -0,6 2,1 0,9 0,9 1,5 0,9
Brain stem 3,0 0,0 -1,2 -1,5 0,0 0,0 0,0 0,0
PTV -1,7 -1,1 -0,8 0,0 0,6 0,8 1,4 0,6
Eye (left) 0,6 -1,1 -3,1 -5,0 -6,4 -6,4 -6,4 -4,5
Optic nerve (left) 3,9 2,5 0,0 -3,6 -4,8 -3,6 -2,8 -0,8
DVH analysis : He (Meningioma) - H (RBE=1.1)
Patient A (H02202)
Patient C (H02524)
Patient D (H02552)
Patient B (H02433)
D5 D10 D20 D33 D50 D66 D75 D95
PTV -0,6 -0,9 -0,6 -0,3 0,0 0,3 0,6 0,6
Temporal lobe left -4,4 -4,6 -4,6 -4,1 -3,8 -3,5 -3,5 -2,0
Temporal lobe right -2,3 -1,5 -1,5 -1,5 -1,5 -2,6 -2,9 -0,9
Brain stem -3,8 -4,3 -5,2 -4,6 -3,5 -4,4 -5,2 -3,2
Optical system -0,6 -1,2 -3,2 -5,8 -7,8 -7,3 -5,8 -1,7
PTV -0,3 -0,6 0,0 -0,3 0,0 0,0 0,0 -0,6
Optic nerve left -6,0 -6,0 -5,7 -2,4 -0,3 0,0 -0,3 0,0
Chiasma -0,9 -0,9 0,0 -0,3 -2,4 -5,1 -6,3 -7,8
Optic nerve right -0,6 -0,6 -0,6 -0,9 -6,0 -5,7 -2,1 -0,3
Brain stem 0,3 0,0 -2,1 -5,1 -6,0 -5,1 -4,2 -1,5
PTV -0,6 -0,6 0,0 -0,3 0,0 0,0 0,3 -0,6
Optic nerve (right) -0,9 -0,9 -1,2 -1,2 -1,5 -3,6 -5,4 -6,9
Chiasma -1,2 -1,2 -0,9 -1,5 -3,3 -0,9 0,9 0,9
Brain stem -0,9 -4,2 -3,9 -2,7 -0,3 0,0 0,0 0,0
PTV -2,5 -2,0 -1,1 -0,6 0,0 0,8 1,4 0,8
Eye (left) -0,3 -1,7 -3,4 -5,0 -6,4 -6,7 -7,0 -5,0
Optic nerve (left) 1,7 0,3 -2,8 -5,9 -6,4 -5,0 -3,9 -1,4
DVH analysis : He (Meningioma) - H (Meningioma)
Patient A (H02202)
Patient C (H02524)
Patient D (H02552)
Patient B (H02433)
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Figure 7.8: DVH for the four patients with AVM as target tissue-type. The different ROIs 
investigated are displayed. Protons are shown for both fixed (dotted lines) and variable RBE 
(dashed lines). Helium ions are displayed with solid lines. 
 
 
 
 
 AVM target tissue-type 7.3.3.
The DVH for AVM cases are shown in figure 7.8. Dose distributions are not displayed, 
however, as it can be seen in the DVH (figure 7.8), more hot spots are present within the 
PTV, as well as within the normal tissues close to the PTV boundary, for both protons and 
helium ions with variable RBE, compared to protons with fixed RBE. The difference between 
the ROI DVH parameters of helium plans against protons with fixed or variable RBE are 
presented in table 7.7 and table 7.8, respectively. For meningioma tissue-types cases, the 
coverage was similar between protons with fixed RBE or protons and helium ions with 
variable RBE. However, for AVM tissue-type cases, the PTV coverage is degraded for helium 
ions and protons with variable RBE. It can also be seen that a small volume of the PTV 
(below D5PTV) is receiving high dose for protons and helium ion plans with variable RBE for 
patients B and C, particularly for helium ions. For patient A, except for the presence of hot 
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spots for a small portion of the PTV, the PTV coverage is similar for helium and proton plans 
with variable RBE compared to the proton plans with fixed RBE. For patient D, no difference 
in the PTV coverage is observed compared to the meningioma cases, regardless of the 
presence of hotspots (volume <5%). For the OARs, protons with a variable RBE present a 
DVH shifted towards higher doses in comparison to fixed RBE schemes, and more 
pronounced than for meningioma cases, with dose values increased by about 3-4 GyRBE (for 
D5/D10). This happens for volumes of the OARs close to the PTV. For large volume of the 
OARs (>D33), helium ions, in general, deliver less dose compared to protons with fixed RBE, 
up to 6.2GyRBE for D66eye of patient D. However, compared to protons with fixed RBE, 
helium ions tend to give higher doses to small volumes of OAR close to the high dose region 
of the PTV. Quantitatively, as seen in table 7.7, it means that helium ions for AVM tissue-
type cases compared to protons with a fixed RBE exhibit higher D5OAR for OARs close to the 
PTV, e.g. up to 7.6 GyRBE for D5Opt.Nerve. In comparison, the maximum overdosage for 
meningioma tissue case was only up to 3.9GyRBE with respect to protons with fix RBE for 
the same patient D D5Opt.Nerve. Helium ions compared to protons with variable RBE present a 
dose reduction over large OAR volumes, e.g., about 7.3GyRBE less on D66OptSystem for patient 
Awith a similar PTV coverage. The only OAR presenting a higher dose for the extracted 
DVH parameters with helium ions compared to protons with variable RBE is for patient D, 
showing a D5Opt.Nerve value increased by about 3.4GyRBE.  
 
 
Table 7.7: DVH parameters difference for the ROIs of the four patients with AVM tissue-
types as target, in GyRBE, between the MCTP optimized helium plans and proton plans with 
fixed RBE. 
 
D5 D10 D20 D33 D50 D66 D75 D95
PTV 0,0 -0,9 -0,6 -0,6 -0,3 0,6 0,6 0,3
Temporal lobe left 0,3 -0,9 -1,5 -2,0 -2,6 -2,0 -2,6 -1,5
Temporal lobe right 0,9 0,0 0,0 -0,3 -0,9 -2,0 -2,3 -0,9
Brain stem 2,3 1,2 -0,3 -1,2 -1,2 -2,6 -3,5 -2,0
Optical system 1,4 1,2 2,3 0,6 -2,9 -4,4 -4,1 -1,7
PTV 0,0 0,0 0,3 -0,6 -0,3 -0,6 -2,1 -2,1
Optic nerve left -1,2 -0,9 -2,7 -1,5 0,0 0,0 -0,3 0,0
Chiasma -1,8 -2,1 -2,1 -1,5 -0,3 -2,4 -4,2 -6,6
Optic nerve right -1,2 -1,8 -2,4 0,6 -0,9 -3,9 -2,1 -0,3
Brain stem -0,9 0,3 3,9 0,0 -2,1 -2,7 -2,1 -0,6
PTV -0,3 0,0 0,3 0,3 0,3 0,0 0,3 -4,2
Optic nerve (right) 0,6 -0,9 -2,1 -3,3 -3,9 -0,6 -0,6 -3,9
Chiasma -5,1 -6,0 -4,5 1,8 3,0 1,5 1,8 0,9
Brain stem 4,8 1,5 -1,2 -1,2 0,0 0,3 0,3 0,0
PTV -0,8 -1,1 -0,8 0,3 0,6 0,3 0,8 -0,3
Eye (left) 2,5 1,1 -1,7 -3,6 -5,6 -6,2 -6,2 -4,2
Optic nerve (left) 7,6 5,9 2,2 -2,0 -3,9 -3,4 -2,5 -0,8
DVH analysis : He (AVM) - H (RBE=1.1)
Patient B (H02433)
Patient A (H02202)
Patient C (H02524)
Patient D (H02552)
7.3 Results   
142 
 
 
Table 7.8: DVH parameters difference for the ROI of the four patients, with AVM tissue-
types as target, in GyRBE, between the MCTP optimized helium plans and proton plans with 
variable RBE. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.9: DVH for Patient C with meningioma (top panel) and AVM (bottom) as target 
tissue-type. The various ROIs investigated are displayed. Protons are shown for both fixed 
(dotted lines) and variable RBE (dashed lines for 1.8GyRBE per fraction). Helium ions are 
displayed with continuous lines (thin for 1.8GyRBE and thick for 3GyRBE dose per fraction). 
D5 D10 D20 D33 D50 D66 D75 D95
PTV -0,6 -0,9 -0,6 -0,6 0,0 0,3 0,3 0,0
Temporal lobe left -3,5 -3,8 -3,8 -3,8 -4,1 -3,2 -3,5 -1,7
Temporal lobe right -2,0 -1,7 -1,2 -1,2 -1,5 -2,3 -2,9 -0,9
Brain stem -2,3 -3,8 -4,6 -4,4 -3,2 -4,4 -5,5 -3,2
Optical system -0,3 -1,5 -2,9 -4,4 -7,0 -7,3 -6,1 -1,7
PTV -0,9 -0,3 0,0 -0,6 -0,3 -0,3 -0,9 -0,9
Optic nerve left -6,0 -5,7 -5,7 -2,4 -0,3 0,0 -0,3 0,0
Chiasma -0,6 -0,9 -0,9 -1,5 -2,1 -4,8 -6,6 -7,8
Optic nerve right -0,3 -0,9 -1,5 -1,2 -6,0 -6,3 -2,7 -0,3
Brain stem -0,3 0,0 -0,9 -4,2 -6,0 -5,1 -4,2 -1,2
PTV -0,9 -0,3 0,0 0,0 0,0 0,0 0,3 -2,1
Optic nerve (right) -0,3 -0,3 -1,2 -2,4 -3,0 -3,0 -3,9 -6,3
Chiasma -1,8 -2,7 -2,4 -2,4 -3,0 -1,2 1,2 0,9
Brain stem -1,2 -4,5 -4,8 -2,7 -0,3 0,3 0,3 0,0
PTV -1,7 -2,2 -1,4 -0,3 0,6 0,8 1,4 0,8
Eye (left) 0,6 -0,3 -2,8 -4,5 -5,9 -6,7 -6,7 -4,8
Optic nerve (left) 3,4 1,4 -2,2 -5,6 -6,4 -5,0 -3,9 -1,7
DVH analysis : He (AVM) - H (AVM)
Patient A (H02202)
Patient C (H02524)
Patient D (H02552)
Patient B (H02433)
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 Change in fractionation scheme 7.3.4.
In figure 7.9, the DVH of the considered ROIs for patient C are displayed for protons with 
fixed (dotted lines) and variable RBE (dashed lines), as well as helium ions for the two 
investigated fractionation schemes of 1.8GyRBE (continuous thin line) and 3GyRBE 
(continuous thick line) for the full delivery with their respective exact numbers of fraction, 
and taking into account the simple BED approach introduced in 7.2.3. The difference in DVH 
parameters between helium ions planned for 3GyRBE and 1.8GyRBE is shown in table 7.9. 
Table 7.10 shows the difference between helium ions planned for 3GyRBE and protons plans 
with fixed RBE for 1.8GyRBE. Table 7.11 reports the difference between helium ions 
planned for 3GyRBE and protons plans with variable RBE planned for 1.8GyRBE. Tables 
7.9-11 present both meningioma and AVM tissue-type cases.  
For the meningioma tissue-type target it can be observed that the PTV coverage is similar 
between the two helium dose fractionation schemes, slightly improved with the 3GyRBE 
plans with reduced high dose and improved conformity (lower D5PTV and higher D95PTV). 
Compared to protons with fixed or variable RBE, the new helium dose fractionation of 
3GyRBE presents a similar PTV coverage, with DVH parameter differences below 1GyRBE. 
For the OAR, between the dose fractionation schemes, dose difference in the parameters are 
below 1.4GyRBE, with a general trend of helium ions planned with 3GyRBE to exhibit 
higher doses for OAR volumes below 33%, such as for chiasma. The difference in dose 
between helium ions at 3GyRBE and protons with fixed RBE shows in general better dose 
sparing with helium ions compared to protons, up to 5.9GyRBE for D95Opt.Nerve. This holds 
true except for the D5Brainstem, where the dose is about 1.9GyRBE lower with protons than 
with helium ions as well as reduced down to 1.7GyRBE for a part of the chiasma with volume 
above 33%. Compared to the protons with variable RBE, helium ions with the new 
fractionation scheme present higher dose sparing potential, similar to what was obtained for 
helium with 1.8GyRBE fractionation. 
For the AVM tissue type target, the PTV coverage for helium ions is improved with the new 
3GyRBE fractionation scheme compared to the calculation for 1.8GyRBE. The D5PTV is 
similar but the high dose in smaller volumes below 5% is lowered with the 3GyRBE 
fractionation, while the D95PTV is improved by about 2.3GyRBE. Compared to protons with 
fixed RBE the PTV coverage is similar, except for the PTV volume above 85%, where the 
dose level is lowered by 1.9GyRBE with helium ions at 3GyRBE. The DVH parameter 
differences for the PTV between helium ions at 3GyRBE and the protons planned with 
1.8GyRBE with variable RBE are below 1GyRBE, with a slight improvement for volumes 
below 5% where less high dose due to hot spots is observed, as seen in figure 7.9. For the 
OAR, between the two helium ions fraction dose sizes, the DVH are similar for brainstem, as 
well as for chiasma for more than 33% of the OAR volume. Below 33% of the chiasma 
volume and for the optical nerve below 70% of its volume, higher doses are delivered with 
helium ions at 3GyRBE compared to 1.8GyRBE, even if less hot spots are presents with the 
3GyRBE fractionation (for less than 5% of the volume). Compared to the fixed RBE proton 
plans, helium ions at 3GyRBE present a better sparing of optical nerve up to 5GyRBE for 
D95Opt.Nerve. For the D5brainstem the dose is lower with protons by about 3.7GyRBE than helium 
ions, as well as up to 1.7GyRBE for a part of the chiasma for volume above 33%. Compared 
to protons with variable RBE, helium ions with the new fractionation scheme present higher 
dose sparing potential, up to 7.4GyRBE for D95Opt.Nerve. 
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Table 7.9: DVH parameters differences for the ROIs of patient C, with meningioma or AVM 
tissue-types as target, in GyRBE, between the MCTP optimized helium plans for 3GyRBE 
and 1.8GyRBE 
 
 
Table 7.10: DVH parameters differences, for the ROI of patient C, with meningioma or AVM 
tissue-types as target, in GyRBE, between the MCTP optimized helium plans, for 3GyRBE 
and protons with fixed RBE. 
 
 
Table 7.11: DVH parameters differences for the ROI of patient C, with meningioma or AVM 
tissue-types as target, in GyRBE, between the MCTP optimized helium plans for 3GyRBE 
and protons with variable RBE for 1.8GyRBE 
 
 
 
 
 
D5 D10 D20 D33 D50 D66 D75 D95
PTV -0,4 -0,1 -0,2 -0,1 -0,2 0,2 0,4 0,9
Optic nerve (right) 0,1 0,1 0,6 0,9 0,7 -1,3 -1,1 0,1
Chiasma 1,4 1,1 0,8 -0,4 -0,2 0,4 -0,1 0,0
Brain stem -1,1 -0,4 -0,4 0,2 -0,2 0,1 0,1 0,0
PTV -0,1 -0,4 -0,7 -0,1 0,3 0,0 0,1 2,3
Optic nerve (right) -1,3 -0,7 0,1 1,3 2,3 0,0 -1,8 -1,1
Chiasma 2,0 2,6 2,6 0,6 -0,8 0,1 -0,2 0,0
Brain stem -1,1 -0,6 0,3 -0,2 0,0 -0,2 -0,2 0,0
DVH analysis : Fraction Dose He(3GyRBE) - He(1.8GyRBE)
Patient C (H02524)                       
- He  Meningioma
Patient C (H02524)                       
- He AVM
D5 D10 D20 D33 D50 D66 D75 D95
PTV -1,0 -0,7 -0,2 -0,1 0,4 0,2 0,7 0,3
Optic nerve (right) -0,5 -1,1 -0,9 -0,6 -0,5 -2,8 -4,4 -5,9
Chiasma -1,0 -1,0 0,2 1,7 0,7 1,3 1,4 0,9
Brain stem 1,9 -0,4 -1,6 -1,3 -0,2 0,1 0,1 0,0
PTV -0,4 -0,4 -0,4 0,2 0,6 0,0 0,4 -1,9
Optic nerve (right) -0,7 -1,6 -2,0 -2,0 -1,6 -0,6 -2,4 -5,0
Chiasma -3,1 -3,4 -1,9 2,4 2,2 1,6 1,6 0,9
Brain stem 3,7 0,9 -0,9 -1,4 0,0 0,1 0,1 0,0
Patient C (H02524)    - 
AVM                     
DVH analysis : He (3GyRBE) - H (RBE=1.1)
Patient C (H02524)                       
- Meningioma 
D5 D10 D20 D33 D50 D66 D75 D95
PTV -1,0 -0,7 -0,2 -0,4 -0,2 0,2 0,7 0,3
Optic nerve (right) -0,8 -0,8 -0,6 -0,3 -0,8 -4,9 -6,5 -6,8
Chiasma 0,2 -0,1 -0,1 -1,9 -3,5 -0,5 0,8 0,9
Brain stem -2,0 -4,6 -4,3 -2,5 -0,5 0,1 0,1 0,0
PTV -1,0 -0,7 -0,7 -0,1 0,3 0,0 0,4 0,2
Optic nerve (right) -1,6 -1,0 -1,1 -1,1 -0,7 -3,0 -5,7 -7,4
Chiasma 0,2 -0,1 0,2 -1,8 -3,8 -1,1 1,0 0,9
Brain stem -2,3 -5,1 -4,5 -2,9 -0,3 0,1 0,1 0,0
DVH analysis : He (3GyRBE) - H (1.8GyRBE)
Patient C (H02524)      
- Meningioma                     
Patient C (H02524)     
- AVM                      
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Figure 7.10: DVH for Patient D, with meningioma as target tissue-type for different delivery 
scenarios: a delivery with RiFi, a delivery without RiFi but the same number of energy slices 
and a delivery without RiFi with a reduced distance of about 1mm between Bragg peaks, 
compared to the two first scenarios at about 2mm separation. 
 
 
 
 
 Helium ions with/without RiFi 7.3.5.
Figure 7.10 depicts the DVH for patient D for the meningioma target. The irradiation 
scenarios with RiFi are plotted with continuous lines, without RiFi and usual distance of 
about 2mm between two Bragg peaks with dashed lines, and without RiFi for a reduced 
distance between peaks of 1mm with dotted lines. The differences between the DVH 
parameters for helium ions without (for standard distance between Bragg peaks on the top, 
while reduced distances of about 1mm on the bottom) and with RiFi are listed in table 7.12.  
As seen in figure 7.10 and table 7.12, the coverage of the PTV remains similar without RiFi. 
Differences in DVH parameters are below 1GyRBE. Both irradiation scenarios without RiFi 
tend to deliver higher dose in the PTV, as seen in the PTV DVH for a volume below 5%. For 
the irradiation with reduced distance between Bragg peaks, the D95PTV is slightly improved 
by about 0.8GyRBE. Regarding the optic nerve, the DVH of helium ions without RiFi (both 
scenarios) is shifted toward lower doses, resulting in a reduction of D5Opt.Nerve by roughly 
2GyRBE. For the left eye, higher dose sparing is achieved with the irradiation without RiFi 
but no change in number of energy slices compared to the irradiation with RiFi. However, for 
a volume below 80% of the eye, higher dose is delivered (about ~1.5GyRBE) for the 
irradiation without RiFi but a distance of 1mm between peaks compared to the irradiation 
with RiFi. On the overall dose distribution, delivery without RiFi reduces the integral dose 
received by the normal tissues. 
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Table 7.12: DVH parameters differences, for the ROIs of patient D, with meningioma tissue-
type as target, in GyRBE, between the MCTP optimized helium plans for 1.8GyRBE without 
and with RiFi. The top part of the table 7.12 shows the difference between the plans withand 
without RiFI usingthe same number of energy slices. The bottom part compares the same RiFi 
plan with onewithout RiFi, optimized with a reduced distance of about 1mm between 
consecutive Bragg peaks. 
 
 
 Discussions 7.4.
The observed good agreement in PTV coverage, while successfully fulfilling the constraint 
criteria on the OARs, for the MCTP and TPS optimized cases of proton irradiation at fixed 
RBE demonstrates the applicability of MCTP to plan optimization in clinical scenarios. 
Additionally, these results for proton irradiation demonstrate the capacity of MCTP to provide 
an even better OAR dose sparing in patient cases, preserving in the PTV a D50 value close 
(within 1GyRBE) to the TPS calculation at a similar or only slightly reduced D95, as seen in 
table 7.4. Regarding patient D, the higher dose observed in the OAR can be attributed to the 
difference in beam modeling at shallow depth between TPS and MCTP. The TPS assumes a 
beam spread smaller than that of the MCTP, as seen in Chapter 5 for the AVM patient case. In 
turn, less dose will be given to the OAR using the TPS model at shallow depth. The MCTP is 
predicting, consistently with experimental data, a larger beam broadening than the TPS 
(Chapter 5), and thus enhances the weight of the beams delivering dose in the middle of PTV 
to provide a good PTV coverage, while trying to fulfill the OAR constraints. Although larger 
D5PTV values can be found in the other patient cases, they are still respecting the limits of 
107% set in the constraints. Compared to analytical TPS systems performing calculation in 
water of variable depth, MC dose predictions generally exhibit higher D5PTV values as well as 
lowered D95PTV values, due to the beam transport in heterogeneous material. Therefore, the 
MCTP constraints determined in this work for protons with fixed RBE provide sound 
treatment plans, comparable in quality to the original TPS plans. Hence, these constraints 
were also used for the optimization with variable RBE for protons and helium ions. The 
implementation of constraints on the whole DVH, and not only on the maximal dose, is 
necessary for MC planning and was achieved in this work by putting a low dose constraint on 
the OAR. In fact, as described in Dale and Olsen (1997), depending the type of OAR, parallel 
or serial, the dose constraints should be applied on the OAR mean dose (linked to the whole 
DVH) or maximum dose, respectively. As stated in section 7.2.1, instead of the maximum 
dose, indices as D5 are less prone to MC statistical fluctuation and should be integrated in the 
foreseen MCTP version. 
As seen in figure 7.2-7.4 displaying patient A- C dose ditributions, for helium ions at the 
boundary of the planning target volume (PTV), hot spots (dose superior to 107% of the 
prescribed dose) can be observed. It can be due to to the high linear energy transfer (LET) 
components of helium ion beams at the lateral and distal edge of the tumor, in combination 
with a lower αx/βx  ratio (αx/βx=2) of the normal tissue. These higher dose contributions could 
be reduced by adding dose constraints on the surrounding tissue of the PTV, present on the 
D5 D10 D20 D33 D50 D66 D75 D95
PTV 0,8 0,8 0,3 0,3 0,0 0,0 0,0 0,0
Eye (left) -0,6 0,0 -0,3 0,3 -0,6 -1,7 -1,7 -0,8
Optic nerve (left) -1,4 -2,8 -4,5 -4,2 -1,7 -1,1 -0,3 0,0
PTV 0,6 0,3 0,0 0,0 0,3 0,0 0,6 0,6
Eye (left) 0,8 1,4 1,4 2,2 1,7 0,3 -0,3 -0,3
Optic nerve (left) -0,3 -1,7 -3,9 -4,8 -1,7 -1,1 -0,3 0,0
Patient D (H02552)                       
He (w/o RiFi, 1mm) - 
He (with Rifi)      
Patient D (H02552)  
He (w/o RiFi) -          
He (with Rifi)                       
DVH analysis : He (without RiFi) - He (with Rifi) for Meningioma at 1.8GyRBE 
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PTV optimization matrices, but not yet implemented in the Monte Carlo Treatment Planning 
(MCTP) tool. 
The plans optimized for meningioma as target tissue-type show similar coverage for the PTV 
in patient cases A, B and C with either protons (fixed or variable RBE) or helium ions. For 
patient D, the PTV coverage is found better with helium ions, with a larger D95PTV value and 
a smaller D5PTV value, indicator of PTV dose homogeneity. This finding could be be ascribed 
to the size of the target and the proximity of the OAR. In fact, due to the larger lateral and 
distal fall-off of proton beams, seen in chapter 3, they cannot cover the target optimally 
without impacting the surrounding OARs. Thus, to provide a better coverage, the optimizer 
will choose to allocate higher doses in the middle of PTV as seen in figure 7.5. Compared to 
protons plans with variable RBE, helium ions provide better sparing of OAR in all cases, 
excluding the left optic nerve of patient D. Since the left optic nerve exists within the PTV, 
one could expect higher doses in the OAR due to the better dose homogeneity within the 
PTV, as previously described. In general, the OAR DVH curves of helium ions are shifted 
toward lower doses due to: (1) the reduced lateral straggling, impacting the DVH for volume 
larger than 30% (figure 7.7) and (2) a more favorable ratio between the RBE at high LET for 
αx/βx at 3.7 (target) and RBE at low LET for αx/βx at 2 (for the surrounding non-tumour 
tissue). This ratio is on the order of 15-20% larger for helium ions, as it can be interpreted 
from figure 7.11, leading to less deposited physical dose, compared to protons. Compared to 
the proton irradiation with fixed RBE, helium ions still present the advantages of OAR dose 
sparing, since protons with fixed and variable RBE show similar trends. The largest 
differences between protons with variable and fixed RBE can be seen for OAR at the end of 
the beam range, where LET, and therefore RBE, is enhanced, ultimately leading to higher 
biological dose deposition. This can be seen particularly in the chiasma of patient C in figure 
7.7.  
Regarding the optimized plan with AVM tissue-type as target compared to the meningioma 
case, PTV coverage is maintained with both ion species with variable RBE modeling, for 
patient A with two opposing fields, as well as for patient D. However, the coverage is 
degraded using protons and helium ions with variable RBE for patients B and C, compared to 
the meningioma tissue-type case. Furthermore, hot spots are present within the PTV and can 
be seen in the DVH for volumes smaller than 5% of the PTV, presenting higher dose values 
than D5PTV. In the case of patient A, with the two opposing fields, the high LET components 
for protons and helium ions are smeared out, similar to the findings of Giovannini et al. 
(2016), leading to a region of reduced RBE region at the extremity of the PTV and in the 
adjacent OAR compared to what is seen in figure 7.8 for patient B and C. For patient D, no 
particular loss in coverage of PTV was found, since no OARs are presents at the end of the 
ion range. The advantages in dose sparing of helium ions compared to protons with variable 
RBE are still present, as seen in figure 7.8 and table 7.8, but are reduced. Compared to 
protons with fixed RBE, the dose sparing advantages of helium ions on OAR are reduced. By 
changing the tissue type parameter αx/βx from 3.7 to 10 for the PTV, a greater number (about 
10-15% for protons and helium ions) of primary particles is required to achieve the same 
biological dose level in the PTV. Thus, on the distal and lateral edges presenting higher LET, 
higher biological doses are to be expected compared to the meningioma cases and to protons 
with fixed RBE. Consequently, OAR may exceed the dose limits from the set constraints, and 
the optimizer will attempt to solve this issue by degrading the coverage and/or increasing the 
dose within the PTV (hot spots) in order to recover the lost coverage. Similar increases in 
dose were observed in Grün et al. (2016) for artificial plans with a PTV/OAR presenting 
similar αx/βx ratios as in this work. In patient C the chiasma exhibits a lower D5chiasma value 
for helium ions and protons with variable RBE compared to protons with fix RBE, but only 
resulting from a loss of PTV coverage. The difference between protons with and without 
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variable RBE, which were already present in the meningioma target cases, are found 
amplified in the AVM target cases. While advantages of helium ions over protons with 
variable RBE are evident from figure 7.8 and table 7.8, even though with reduced biological 
advantages, they are more complex to judge against proton with fixed RBE with the 
considered fractionation scheme for AVM cases.  
The behavior of the ions using different tissue types can be explained while looking at the 
evolution of the RBE as a function of different parameters such as dose, LET and tissue types, 
as investigated in Giovannini et al. (2016) and Mairani et al. (2017), and shown in figure 7.11. 
For helium ions, the physical dose needs to be approximatively 20% higher for αx/βx of 10 to 
achieve the same biological dose as for αx/βx of 2, which is within the same order of 
magnitude of the ratio found (~15%) between the AVM (αx/βx ratio of 10) and the 
meningioma target cases (αx/βx ratio of 3.7). Subsequently, for the normal tissue surrounding 
the target (αx/βx ratio of 2), which receives about 50% of the physical dose and is still located 
in the high LET region, the change in αx/βx can lead to an increase of dose by approximately 
40%. A possible approach to mitigate the influence of the varying αx/βx between PTV and 
normal tissue could be to increase the dose per fraction. In fact, as seen in figure 7.11, for 
tissue types with αx/βx of 2 as both target and normal tissue, the biological dose ratio between 
target receiving 1.8GyRBE and normal tissue receiving about 50% of the physical dose in the 
high LET region is about 2. However, for a target with a αx/βx of 10, this ratio is lowered to 
about 1.3. For a prescription dose of 3GyRBE, the biological dose ratio between target and 
normal tissue is of 1.8 and 1.6, respectively, for a target with an αx/βx ratio of 2 and 10. 
Therefore, using higher dose prescriptions could decrease variability between different tissue 
types for helium ions.  
 
Figure 7.11: RBE model predictions as a function of proton
 dose in black, for αx/βx = 2 Gy 
(upper panels) and 10 Gy (lower panels), calculated at LET levels of 1 keV/µm (left) and 6.5 
keV/µm (right), respectively (adapted from Giovannini et al. 2016). The corresponding dose-
dependent predictions for 
4He ions are shown in red, again for αx/βx = 2 Gy (upper panels) 
and 10 Gy (lower panels), at 4 keV/µm (left) and 15 keV/µm (right) LET, respectively 
(adapted from Mairani et al. 2017). 
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When investigating the complex case of patient C, an increase in the prescribed fraction dose 
to 3GyRBE for the meningioma target-tissue case allowed helium ions to exhibit a similar 
coverage as helium ions for the 1.8GyRBE prescription, with improved dose homogeneity 
(higher D95and lower D5) due to reduced RBE variability as a function of LET and dose. 
This higher homogeneity in dose in the PTV, together with reduced biological benefits 
between PTV and normal tissues at higher dose prescriptions, led to an increase in high dose 
level for OARs, as seen with the enhancement of D20chiasma in figure 7.9 (top panel) and table 
7.11. For the AVM target case, the 3GyRBE allowed better PTV coverage compared to the 
helium plan at 1.8GyRBE fraction dose, as seen in figure 7.9 (bottom panel) and table 7.11, 
removing the high dose contributions for volumes below 5% of the PTV. Regarding the OAR, 
the increase in PTV coverage led to higher dose exposure for the OAR volumes close to the 
PTV. But the maximum OAR dose D5OAR and the dose given to smaller volumes was 
reduced. In comparison to protons with variable RBE at 1.8GyRBE , helium ions with a 
3GyRBE fraction dose prescription presented similar DVH characteristics in the OAR high 
dose region, e.g. for volumes below 30% in the chiasma, while having a similar PTV 
coverage. This is due to the fact that with such fractionation the above mentioned biological 
dose ratio between target and normal tissue for protons is similar to the one of helium ions at 
3GyRBE, with values of 1.8 and 1.5, respectively, for a target with a αx/βx of 2.0 and 10 
(figure 7.11). For larger OAR volumes, helium ions exhibit improved dose sparing due to 
their physical properties, leading to a reduction in integral dose delivered. However, as stated 
in 7.2.3, even though introducing a higher dose per fraction is reducing the variability 
between tissue types, particularly in the case of high αx/βx tumors, it could decrease the cell 
survival of normal tissues compared to a lower fractionation scheme. These assumptions can 
be linked to the fact that tumors with high αx/βx are clinically benefiting from 
hyperfractionation, while tumor with low αx/βx from hypofractionation (Schlaff et al. 2014). 
However, deeper investigations using more complex approaches such as tumor control 
probability / normal tissue complication probability (TCP/NTCP) models would be more 
accurate, particularly regarding the OARs presenting non homogeneous biological dose 
distributions (Suit et al. 2010). An investigation on the optimal fractionation scheme using 
methods such as presented in Unkelbach et al. (2013) for these specific cases could be 
foreseen, combined with known patient outcomes from protons and carbon ion treatments at 
HIT. 
The use of RiFi was suggested in Chapter 6 for the spread-out Bragg peak at shallow depth 
(5cm) in order to reduce dose ripples within the PTV. However, in the case of patient D with 
meningioma as target-tissue type, MC predictions without RiFi did not affect PTV coverage 
and could indicate that a RiFi may not be necessary for helium therapy. Even if higher dosage 
in the target can be seen for low volumes (<5%), hinting at possible ripples, the constraints on 
the maximum dose are still fulfilled and the coverage on the larger volume is kept. For the 
irradiation without RiFi and a reduced distance between Bragg peaks, the coverage was found 
slightly better, as seen in figure 7.10, due to the increased number of pencil beams available to 
cover the proximal and distal part of the target, together with the reduced lateral straggling 
compared to the irradiation with RiFi. For OAR DVH, the curves are shifted to lower dose 
values for irradiation without RiFi, due to the reduced lateral spread compared to the helium 
ion delivery with RiFi. However for the left eye, the delivery without RiFi and 1 mm distance 
between Bragg peaks led to higher dose compared to the delivery with RiFi. This finding can 
be explained by the higher dose within the PTV and the special location of the left eye, next to 
the PTV. Higher dose in the PTV was achievable in the scenario of a delivery without RiFi 
and 1mm distance between Bragg peaks due to the reduced lateral straggling and improved 
distal/proximal coverage. Delivery of helium ions without RiFi could lead to sparing about 
10GyRBE in roughly one third of the optic nerve volume compared to irradiation with 
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protons (with variable RBE), without considering the improved PTV coverage with helium 
ions. 
Although further investigations are needed, the analyzed case suggests that the RiFi may be 
unnecessary for helium ion therapy in the clinic. It can be noted that in the prostate case 
presented in appendix D, the PTV coverage between protons and helium ions without RiFi is 
similar. However, better OAR dose sparing can be achieved with helium ions. In the prostate 
case, with a target depth of about 15-20 cm, the PTV location is deeper compared to the 
shallow target of patient D. At such range the dose ripple effect are less pronounced due to the 
increased range straggling, as demonstrated in Chapter 6. 
 
 Summary 7.5.
From all the analyzed four beam geometry cases, advantages of helium ions over protons are 
evident in the meningioma patients for 1.8GyRBE fractionation, due to both physical (lateral 
and distal straggling) and biological advantages (RBE enhancement in the target with high 
LET at this fraction dose), particularly when using a variable RBE. However, in the AVM 
target tissue-type, helium ions do not clearly demonstrate the benefits for a 1.8GyRBE 
fractionation. As indicated in Grün et al. (2016), the advantages of one ion over the other ones 
can be discussed as a function of the tissue type, beam geometries and fractionation dose. 
However, our study indicates that when comparing helium ions and protons with a variable 
RBE, helium ions for 1.8GyRBE and 3GyRBE could provide better DVH characteristics in 
all meningioma cases, and appear promising with a 3GyRBE fractionation scheme for AVM. 
Furthermore, not using the RiFi could provide improved OAR dose sparing while maintaining 
optimal PTV coverage. 
This chapter demonstrated the capabilities of the MCTP with proper constraints to provide 
sound plans, comparable in quality to those from the clinical TPS for protons with fixed RBE. 
For the meningioma cases with a fraction dose of 1.8 GyRBE, the plans optimized with 
MCTP show promising results for helium ions, with similar coverage to protons and better 
sparing of OAR for all beam configurations investigated, featuring two fields (from opposing 
to small angles) as well as single field. For the AVM cases, when using a higher fractionation 
dose of 3GyRBE, helium ions present improved DVH characteristics compared to helium ion 
with a fraction dose of 1.8GyRBE, and are advantageous in dose sparing compared to protons 
with a variable RBE. Irradiation without RiFi for helium ion beam therapy seems possible 
even at shallow depth, thus furthering the potential for OAR dose sparing. These results 
indicate than helium ions could be an alternative to proton therapy due to their favorable 
physical and biological characteristics. Helium ions could provide promising treatments for 
head low-grade meningioma, and prostate as seen in Appendix D. Further investigations using 
TCP/NCTP models or robust planning, to take into account the planning and delivery 
uncertainty, could also be of interest to support physicians and medical physicists for the 
introduction of helium therapy in the clinical routine. 
 
 
 
 
 
 
 
  
 
 
 
 
 
 Conclusion Chapter 8.
& Outlooks 
 
 
 
Helium ion beams have regained momentum over the last decades for patient treatment, after 
the discontinuation of the clinical trial in 1992 at the Berkeley National Laboratory. This 
renewed interest can be observed in the literature, with an increased number of publications 
related to both computational works, including studies based on Monte Carlo or analytical 
calculation engines, and experimental efforts, which focus on new physical and biological 
characterization of helium ion beams, as performed through this thesis.  
 
The aim of this thesis was to provide and validate the key elements necessary to bring helium 
ions from initial measurements in phantoms to clinical treatment planning comparisons 
against other ions, particularly for the treatment of low-grade meningioma cases. Most of the 
studies presented in literature with helium ions were either (1) not supported by thorough 
dosimetric experiments or (2) not taking into account the complex mixed radiation field of 
helium irradiation or (3) not introducing complex biological modelling. This thesis overcomes 
these shortcomings as explained in the following. 
Chapter 2 introduced the four steps needed in order to achieve the overall goal: 
 
- The first step focused on the comparison of various dosimetric characteristics of the ions 
available at the Heidelberg ion beam therapy center, including protons, helium, carbon 
and oxygen ions. This step was achieved in Chapter 3 and Chapter 6, presenting the 
dosimetric advantages and drawbacks of the different ions, for irradiations performed with 
a state-of-the-art fully active beam delivery system. Particularly, these chapters 
demonstrated the potential of helium ions for further particle therapy improvements due to 
the observed favorable physical characteristics, intermediate between protons and heavier 
ions, with a smaller lateral and longitudinal straggling or a lower fragmentation tail, 
respectively.  
 
- The second step was achieved in Chapter 4 and 6, where MC FLUKA predictions were 
found in good agreement with dosimetric measurements for the characterization of the 
helium ion pencil-beams at HIT as well as more complex clinical-like delivery scenarios. 
For the ion species available at HIT, the validation of a research MC-based treatment 
planning engine (MCTP) against measurements opened up the opportunity to proceed 
toward patient planning. 
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- The third step was related to the modelling of biological properties of helium ions. 
Through the physical validation of the MC predictions, as well as the MC-based 
generation of a physical database for input into an established analytical research TPS 
used for simple planning, biological experiment were carried out at HIT to verify the 
radiobiological model used in this thesis. 
 
- The fourth step embodied the main goal of this thesis: treatment planning for meningioma 
patient cases with helium ions. Combining the improved simulation framework presented 
in Chapter 5 linked to a sound biological model, treatment planning comparisons between 
protons and helium ions presented in Chapter 7 for four meningioma cases demonstrated 
that helium ions could bring therapeutic benefits to patients by reducing dose to organs at 
risks. 
 
Through this thesis, the first elements necessary to bring helium ions a step closer to a future 
therapeutic use at HIT have been completed. Nevertheless, additional studies are foreseen to 
proceed further toward clinical translation.  
 
Deepest investigations on the biological side are a priority. New biological cells survival 
characterizations, in a similar fashion as in Mairani et al (2016) and Mairani et al (2016b), are 
ongoing at HIT with several cell lines to compare and verify different radiobiological models 
such as the LEM, MKM (Chapter 2, section 2.7) or the empirical biological model used in 
this thesis. Such work is needed to provide a sound model for treatment planning, validated 
for a wide range of cell types, hence αx/βx ratio, and representative of the different properties 
of tumor, and normal tissue. Following thorough cells experiments, animal experiments as in 
Saager et al (2016) or Karger et al (2006) will lead to more complex investigations, providing 
in-vivo validation of the different biological models, by analyzing the response of tissue (e.g. 
dose tolerance) to radiation. In complement to biological models predicting RBE, other 
models, e.g., based on TCP/NTCP modeling, could gain from such investigations. All these 
in-vitro and in-vivo studies will greatly benefit from the work of this thesis, namely the 
validation of the MC framework (including the MCTP), and the generated database for input 
to the research TPS, in order to create reliable physical or biologically optimized plans. 
 
Besides the overall promising agreements found between FLUKA MC predictions and 
measurements for simple (e.g. depth dose distributions, lateral dose profiles) or complex (e.g. 
physically as well as biologically optimized SOBPs) cases, there is room for improvements of 
the MC code for modeling helium ions. As shown in Chapter 4 and Appendix B, 
disagreements against physical data sensitive to nuclear interaction were observed. Additional 
experimental physics data (e.g. cross sections, energy spectra, projectiles angular distribution) 
obtained in measurements such as Rovituso et al (2017) for 
4
He ions or Dudouet et al (2014) 
for 
12
C ions would be beneficial to guide the improvement of the MC models. Despite the fact 
that the MC code FLUKA is providing dosimetric results considered reliable enough to 
conduct studies toward the clinical level, improvement of specific nuclear models could lead 
to even stronger prediction capabilities of the MC code. 
 
Additionally to the cases presented in this thesis for meningioma tumours and a preliminary 
study on a prostate cancer case, more clinical studies are foreseen to evaluate the anatomical 
localizations that would benefit the most from helium ion therapy. For that purpose reliable 
treatment planning engines are needed. Several approaches can be foreseen: (1) the 
development of MCTP toward a clinical version, featuring all improvements suggested in 
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Appendix C and allowing user-friendly interface and DVH constraints selections; (2) the 
adoption of an analytical TPS such as the SyngoPT system used clinically at HIT, integrating 
the database generated within the scope of this thesis with depth dose distributions, lateral 
Gaussian distributions (double or triple) and fragmentation spectra as in Mairani et al 2010 
and Parodi et al (2012); (3) the use of fast GPU-MC simulation as developed for protons (Jia 
et al 2015) and carbon ions (Qin et al 2017); 
 
To further enhance the quality of treatment planning, new features such as robust planning 
(Fredriksson 2013), taking into account during the optimization process all possible sources 
of uncertainties in patient positioning, beam delivery as well as radiation biology, could 
provide more reliable plans for clinical treatment and comparisons between ions. Other 
biological models, looking at different endpoints than the RBE model used in this thesis, 
could also be of interest for further treatment planning with ions, including helium ions. 
Additionally, the combination of different ions within the same treatment plan, such as helium 
and oxygen ions, could bring particle therapy a step further, taking advantages of their 
respective physical and biological properties. 
 
The uncertainty in the Bragg peak position within the patient, described in Chapter 2, could 
benefit from in-vivo range monitoring techniques such as PET imaging. Investigations on the 
β+ emitters distribution of helium ions on several targets (PMMA, PE, gelatin as in Bauer et 
al 2013) have been started in the framework of this thesis. However, comparisons to MC 
results indicated that there was room for improvement of the MC code nuclear models, for 
reliable prediction of β+ emitter distributions.  
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Appendix 
A-Supplementary material to Chapter 3 
Additional information regarding topics discussed in Chapter 3 is provided in Appendix A. 
 
Depth dose distributions with RiFi 
Figure A.1 displays the depth dose distributions in water measured with the PeakFinder for 
irradiations with the ripple filter (RiFi). These measurements were used for the experimental 
comparisons presented in Chapter 3 (3.3.1.2.), the validation of Monte Carlo FLUKA dose 
predictions for helium ions (Chapter 4), as well as FLUKA input files refinement for protons, 
carbon and oxygen ions.  
 
Figure A.1: Depth dose distribution measurements for protons, helium, carbon and oxygen 
ions, respectively, from the top to the bottom panels, in water with RiFi. 
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Relation between PW/R80 as function of R80 
Figure A.2 shows the relation between the ion peak-width presented in Chapter 3 (3.3.1.3.) 
over the range (R80), times a factor F close to √𝑀, with M the mass of the particles. At higher 
energies with R80>120 mm, protons and helium ions exhibit a PW/R80 ratio 3.5 and 1.9 times 
larger than oxygen ions, respectively, while carbon ions exhibit a PW/R80 ratio 1.1 times 
larger than oxygen. As a function of particle mass M, the PW/R80 results, relative to oxygen 
ions, suggest a relationship for protons, helium and carbon ions, respectively, of about 0.85 ×
(√𝑀𝑂 √𝑀𝑝)⁄ , 0.93 × (√𝑀𝑂 √𝑀𝐻𝑒)⁄  and 0.97 × (√𝑀𝑂 √𝑀𝐶)⁄ . As described in section 
3.3.1.3., the values are slightly inferior to the dependency on 1/√𝑀 described in Schardt et al. 
(2010). At higher energies, effects such as initial energy spread are less impacting the peak-
width, dominated by range straggling. 
 
 
Figure A.2: Relation between the Peak-width (PW) sizes over the range (R80), multiplied by a 
factor F, as a function of R80 for protons (squares), helium (circles), carbon (triangles) and 
oxygen ions (diamonds). The factor F is close to √𝑀, with M the mass of the particles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A-Supplementary material to Chapter 3 
157 
 
Ions σ0corr evolution in water  
 
As seen in figure A.3 and explained in section 3.3.2., the evolution of σ0corr of the different 
ions before the Bragg-Peak has a dependency of 1/√𝑀 and therefore, the heavier the ion, the 
smaller the beam width. Figure A.3 presents the evolution of σ0corr corrected by a factor F 
close to √𝑀 (+/-10%). As a function of particle mass M, the width relative to carbon ions can 
be described by the following relations for protons, helium and oxygen ions 
respectively: 0.9 × (√𝑀𝑐 √𝑀𝑝)⁄ , √𝑀𝐶 √𝑀𝐻𝑒⁄ , and 1.05 × (√𝑀𝐶 √𝑀𝑂)⁄ . 
 
 
Figure A.3: Relation between the σ0corr describing the central Gaussian core of the medium 
energy investigated (corrected for the Gaussian width size at 0 cm), multiplied by a factor F, 
as a function of R80 for protons (squares), helium (circles), carbon (triangles) and oxygen ions 
(diamonds). The factor F is close to √𝑀, with M the mass of the particles. 
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B - Supplementary material to Chapter 4 
Additional information regarding topics discussed in Chapter 4 is provided in Appendix B. 
 
Momentum spread optimization 
The figure B.1 illustrates the χ2 reduction as a function of dp/p performed for the different 
energies presented in table 4.1. For all investigated energies, the value of dp/p minimizing the 
χ2 is recorded. Subsequently with the obtained value, the relation between dp/p and the initial 
helium ions energy can be interpolated to the 255 energies available at HIT as seen in Figure 
4.2. 
 
Figure B.1: Relative momentum spread (dp/p) optimization for 
4
He (56.4MeV/u as seen in 
table 4.1, corresponding to an energy index of #6 on the HIT accelerator library). Points 
represent the χ2 obtained for the corresponding dp/p values. 
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Triple Gaussian parametrizations for low and medium 
energies 
The triple Gaussian parametrization of low and middle energies as shown in figure 4.8 and 
detailed in the results of section 4.3.2 are shown in figure B.2 and figure B.3. As explained in 
section 4.3.2, the different Gaussian widths corrected are in good agreement between 
simulations and measurements. For low energies, the different weights are not significantly 
different and within the error bars, however, for medium energies, as shown for high energies 
in figure 4.8, underestimation of the weight by FLUKA is seen. Further explanations are 
presented in section 4.4 and some tests weighting the dose contributions in FLUKA were 
performed for lateral profiles (figure B.4). 
 
Figure B.2: Triple Gaussian parametrization for the lowest beam energy. Simulations are 
displayed with circles and measurements with squares. The top panels depict the Gaussian 
widths evolution in water (relative to the Bragg peak position), from the smallest Gaussian to 
the broader one from left to right. The bottom panel shows the corresponding weights. 
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Figure B.3: Triple Gaussian parametrization for the medium beam energy. Simulations are 
displayed with circles and measurements with squares. The top panels depict the Gaussian 
width evolution in water (relative to the Bragg peak position), from the smallest Gaussian to 
the broader one from left to right. The bottom panel shows the corresponding weights. 
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Helium ions simulation modifications  
In order to investigate the reasons behind the disagreements found in Chapter 4 between 
FLUKA predictions and dosimetric measurements for depth dose distributions and for lateral 
profiles, modifications to simulation parameters have been tested. 
As explained in section 4.4, the possibility of a non-Gaussian beam in vacuum has been 
evaluated in order to explain the disagreement on the lateral dose distribution, particularly at 
high energy. For this purpose, lateral dose deposition in water as performed in section 4.2.3 
was achieved for an initial double-Gaussian beam in vacuum. In addition to the primary 
Gaussian width, a secondary Gaussian was added with different widths of 9, 15 or 30 mm, 
applied with different weights of 3, 3 or 2%, respectively. These values are representative of 
the FWHM range for the second and third Gaussian, for a weight found after a trial and error 
process. As it can be seen in figure B.4, while these modifications improve the agreement at 
the phantom entrance with measurements (blue points), at further depths near the Bragg-peak, 
the difference remains consistent with the single Gaussian modeling in vacuum. These results 
indicate that beyond the possibility of a non-Gaussian beam in vacuum, improvements of the 
code can be foreseen to allow matching of the dose halo at large depth.  
 
Figure B.4: Lateral dose distribution of the highest energy helium ion beam investigated, at 
the phantom entrance and near Bragg peak as explained in section 4.2.3. Simulation with just 
a normal single Gaussian beam in vacuum (“Normal”) or associated with an additional 
Gaussian with a larger width (9, 15 or 30mm) and a particular weight (3, 3 or 2% 
respectively). 
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In a second step, the dose contribution of each particle type (
1
H, 
2
H, 
3
H, 
3
He, 
4
He) was 
recorded individually for the medium and high energy presented in Chapter 4 (158.1 MeV/u 
and 220.5MeV/u). Thus, it is possible to weight each dose contribution individually. For 
depth dose (Figure B.5 top panel) and lateral distributions (figure B.5 bottom), the dose 
contribution of protons was multiplied by a factor of 2. This leads to a reduced entrance-to-
peak ratio for the depth dose distributions, as seen with the black curve (“Sim. mod.”), 
affording better agreement between simulation and measurements for both investigating 
energies. The same conclusion is obtained with the lateral profiles where, with the modified 
simulations, better agreements are found at both the entrance and greater depths. These results 
could suggest that the dose contribution of large angles secondary particles such as protons 
could be underestimated by the FLUKA code. Either the underestimation of interactions of 
secondary particles, or their production angles, could be the cause of such effect. In figure 
B.6, at around the middle of the Bragg curves, some particles are underestimated at larger 
angles for both energies, such as deuterium for 120MeV/u or protons for 200MeV/u. Such 
experiments presented in figure B.6 and B.7 could help supporting the improvement of 
FLUKA model. 
 
Figure B.5: Depth dose distributions (top) and lateral dose distributions at phantom entrance 
(bottom left panels) or near Bragg peak (bottom right panels) for the medium and high energy 
investigated. for the normal simulation (“Sim.”), the modified simulation (“Sim. Mod.”), and 
dosimetric measurements (“Meas.”). 
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Comparison between FLUKA prediction and published 
physics experiment on 
4
He attenuation  
In order to understand the difference in dose and lateral dose distributions between 
simulations and dosimetric experiments, comparisons with published physics data acquired at 
HIT were performed. The energy telescope described in Krämer et al (2016) and in Rovituso 
et al (2017) was implemented into FLUKA. The detector configurations (energy telescope 
and composing materials) and the target (plastic flasks with their material composition) were 
reproduced with the same geometry described in details in Rovituso et al (2017). The scheme 
of the setup (top panel), the results for the 200MeV/u 
4
He attenuation and the 
3
He build up 
(middle panel), and build-up of H isotopes (bottom panel) are shown in figure B.6.  
For each set-up configuration, with different thicknesses of water (0 to 25.7cm), 5×10
7
 
particles were simulated in five independent runs. Phase space files were produced, recording 
information about the particles (e.g., type, energy, time of arrival from the center of the target) 
crossing the detector surface. After post-processing, the yield (number of particles per 
incoming 
4
He) is displayed as a function of the target thickness in figure B.6.  
As described in section 4.4, the attenuation and build-up of 
4
He and 
3
He, respectively, are 
consistent with experimental findings. Regarding the H isotopes, it seems that the FLUKA 
code is overestimating protons before 17cm and underestimating them afterwards, while 
overestimating tritons and deuterons. This finding could hint at a lack of large angles 
1
H 
produced in the entrance, or lack of secondary production of 
1
H from 
3
H and 
2
H at larger 
depth or a n underestimation of the H isotopes production at larger angles. However, the 
interpretation of these results is not straightforward, and needs more experimental data to 
bring a more conclusive understanding of the missing underlying physics processes within the 
FLUKA code.  
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Figure B.6: Attenuation of 200MeV/u helium ions experiments: The experimental set-up is 
presented in Rovituso et al (2017). The results comparing measurements against FLUKA 
simulations reproducing the setup are plotted in the top (
4
He attenuation and 
3
He build up) 
and bottom panel (H isotopes). (Experimental data from Krämer et al (2016) and Rovituso et 
al (2017). 
 
B - Supplementary material to Chapter 4 
165 
 
Comparison between FLUKA prediction and published 
physics experiment on 
4
He and fragments angular 
distributions  
For the same reason as the previously described study, comparisons with particle physics 
experiment on the angular distributions of 4He ions and their secondary particles were 
performed with FLUKA Monte Carlo code. The experiment described in Rovituso et al 
(2017) involved the irradiation of a target with a helium beam, with a range superior to the 
target size, and the collection of the escaping particles with a detector, at various angles (0 to 
23°), in a similar fashion as in Haettner et al (2013). The detector is similar to the one used 
for the attenuation experiment previously described, only the geometry setup is changed as 
seen described in Rovituso et al (2017). The different geometry setups are reproduced in 
FLUKA. The two energies investigated are 120MeV/u and 200MeV/u, with water target 
thicknesses of 4.28 and 13.96cm, respectively. The targets are obtained using different 
combination of flasks and are modelled in FLUKA. For each angle/energy, 5×10
7
 particles 
were simulated in five independent runs. 
It can be seen that for 120MeV/u the predicted surviving helium ions are in agreement with 
measurements, but present a smaller width than the measured distribution. All fragments at 
the 0° position are overestimated with FLUKA in comparison to the measurements. This 
could be explained considering that at this angle the dominant (by 2 orders of magnitude) 
proportion of 
4
He compared to other particles could lead to shadowing of the fragments in the 
detection process. A measurement setup such as in Haettner et al (2013), stopping the primary 
beam inside the target, could overcome this potential measurement uncertainty. However, for 
larger angles (>4°), better agreement is found for both energies investigated. It can be mainly 
seen in the fragment distribution that for 120MeV/u, the secondary 
2
H distribution is 
underestimated with FLUKA, as well as 
1
H for the 200MeV/u. These underestimations could 
be an explanation for the disagreements found between dosimetric measurements and 
simulations (depth and lateral dose profiles). These measurements could be helpful in 
supporting FLUKA developments in the near future. 
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Figure B.7: Angular distributions of 
4
He, 
3
He (left panels) and 
3
H, 
2
H, 
1
H (right panels) 
recorded at several angles after impinging on a water target (thickness 4.28 and 13.96 
respectively) at an initial energy of 120 MeV/u (middle panels) or 200MeV/u (bottom panels), 
according to the experimental setup reported on the top panel (from Rovituso et al 2017). 
Results from FLUKA appear in red, results from experiments in Rovituso et al (2017) appear 
in blue.No data are displayed for 
4
He, 
3
He angular distribution at 200MeV/u. 
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C - Supplementary material to Chapter 6 
Additional information regarding topics discusses in Chapters 6 is provided in Appendix C. 
 
Monte Carlo Treatment Planning workflow 
The general workflow of the Monte Carlo Treatment Planning tool (MCTP) used in Chapter 
6, and then in Chapter 7, can be summarized as follows, as presented in figure C.1 (for patient 
cases): 
1- Pre-optimization - Dose matrices creation 
The initial steps aim to generate the dose matrices (physical or “biological”) needed for the 
optimization with the MCTP. It can be divided in 3 sub-steps: 
- Plan creation: 
The plan creation corresponds to the generation of a set of pencil beams according to the 
position in depth of the target and its size.  
In the case of the spread-out Bragg peaks (SOBP) targets presented in Chapter 6, knowing 
their positions, sizes, relation between energy and Bragg peak position from Chapter 3, a plan 
was created for each ion/SOBP depth to cover an area of 7 cm × 7 cm × 7 cm, in order to 
optimize afterwards either the 3 cm × 3 cm × 3 cm or the 6 cm × 6 cm × 6 cm SOBPs. The 
distance between two Bragg peaks in depth was kept the same for all ions, i.e., about ~2mm, 
for a lateral step size of 3mm, consistent with the focus size used (about 1/3 of the beam full-
width at half-maximum at isocenter as recommended in Krämer et al 2000). The use of the 
ripple filter (RiFi) for heavy ions was foreseen, and thus the selected energies were adapted to 
compensate for the range reduction in the RiFi. 
For the patient cases presented in Chapter 7, the initial plan from the clinical treatment 
planning system (TPS) was used. This plan was then extended with four additional energy 
slices (two inferiors and two superiors to the planned ones), and extended laterally in order to 
allow for higher freedom on pencil beam choices by the optimizer. The possibility of delivery 
with RiFi for helium ions was taken into account in the plan generation by introducing an 
offset in the selected energy index (corresponding to ~2 mm as seen in Chapter 3).  
- ROI generation: 
The optimization in the MCTP is not performed on the whole dose matrix but rather a region 
of interest (ROI). The ROI describes either the target (e.g. planning target volume (PTV) or 
the SOBP size and position) or normal tissues (e.g. organ at risk (OAR)). A ROI is defined in 
an in-house interface creating a file which delimitates a “box” around the ROI, including all 
voxels in the geometry. This “box” is characterized by its coordinates defining its position in 
the simulation geometry (position in water for the SOBP case, position in the patient 
geometry in case of clinical treatment plans, as presented in Chapter 7). Then, all voxels 
inside this “box” are characterized as part of the ROI or not.  
- Input files generations and computation: 
The MC FLUKA calculation is using the classical geometry presented in Chapter 5, with the 
detailed model of the beamline included in phase space files. For the SOBP target of Chapter 
6, the geometry is assuming the water phantom as target, and for the patient cases of Chapter 
7 the computed tomography (CT) is converted in FLUKA voxel geometry as described in 
Bauer et al 2014. The generated plan is divided according to the number of its energy slices, 
and an equal number of input files are created, each one linked to a particular energy slice. 
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For each ROI, an energy event scoring is selected for creation of a physical dose matrix. For 
biological scoring, using a selected biological model, an event scoring is created in a similar 
fashion and linked with a FLUKA routine to the model. For the model selected in this thesis 
(Mairani et al 2016b), an online calculation of the α and β terms of the linear quadratic model 
(cf. section 2.3 in Chapter 2) is performed, but other models and unique parameters can be 
linked as well. Event scoring implies that for a certain number N of primary histories, the 
(physical or biological) dose contribution to the ROI voxels will be known for every pencil 
beam. Hence, for each input file, hence for every energy slice, a dose matrix per ROI is 
created (together with the associated α and β matrices if needed), describing the contributions 
of each pencil beam to the ROI voxels. The number of primary histories was chosen at 10
5
 for 
every case investigated. The resultant ROI matrices will be used for optimization in the 
MCTP. 
- Matrix size: 
Depending on the size of the ROIs for the targets considered in the planning process and the 
type of ion used, the matrix size can vary from about 50Mb for small targets with protons to 
300Mb for the prostate case presented in Appendix D with helium ions. This huge memory 
requirement per energy slice represents one of the main limitations of the current approach 
with MCTP, e.g. when typically dealing with about 20 to 35 energy slices per beam. Further 
improvements can be foreseen by downsampling the voxel size, set in this study at 1 mm × 1 
mm × 3 mm, to 2 mm × 2 mm × 3 mm, which is a value close to the voxel size used for dose 
calculation in clinical TPS. Another possibility would be, when working with patient cases, to 
improve the generation of the plan used for matrix creation. In the plan generator used in this 
study, the extreme lateral positions of the pencil beams, within an energy slice (maximum and 
minimum positions), were recorded and extended by 2 lateral step size. Subsequently, all 
pencil beams within these extreme values were allowed for matrices generation simulations 
(i.e., resulting in a large rectangular field for each energy slice). To improve this scenario, a 
new “smart” plan generator was created after the initial work presented in this thesis. Its 
process consists of the “dilation” of the initial plan for each energy slice, extending it by 2 
lateral step sizes, but thus keeping a similar field morphology. For the prostate case, using 
such a method of “smart” plan creation could reduce the number of pencil beam by at least a 
factor 2. Associated to the voxel downsampling, it could bring the larger matrices to a 
reasonable size below 40Mb.  
- Time: 
The time needed to create the matrices is the second limitation of MCTPS. Depending on the 
energy, the number of pencil beams within one energy slice, and the selected number of 
primary histories for every pencil beam, the calculation time could rise to 4-5 days for the 
prostate case with helium ions (about 850 pencil beams for the largest energy slice, with 
10000 primary history, for a deep seated target, with physical dose and biological matrices). 
With a reduction of the primary history and number of pencil beams, computational time 
could be reduced by a factor 4, then by splitting in two the energy slices with a high number 
of pencil beam, the largest matrices could be obtained within half a day with simulations 
running on a 100 nodes cluster. Despite such improvements in calculation performance, 
clinical implementation of MCTP remains a challenge. 
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2- MCTP optimization 
- Optimization and constraints: 
The optimization is performed according to Mairani et al (2013), using a dose-difference 
optimization algorithm, similar to the approach of Lomax (1999). Each voxel within the ROIs 
is given a dose constraint and corresponding weight. For the target, the constraint corresponds 
to the prescription dose, while for OAR the constraint corresponds to the maximum dose 
allowed. In addition to the planned dose constraint, a constraint on the maximum dose 
allowed of 107% of the planned dose was added to avoid hot spots within the target region. 
This constraint was not yet set for 6 cm × 6 cm × 6 cm SOBPs optimization, as could be seen 
in figure 6.6. The weights on the ROI are set to achieve the desired dose in the target while 
sparing the OAR. In the case of SOBP optimization, only the target was selected as the ROI. 
However, for the patient cases, PTV and OARs were selected as ROI. Dose constraints were 
set to respect dose volume histogram (DVH) objectives from the clinical TPS plan, as 
explained in Chapter 7. The calculation can be achieved either considering the physical dose 
only, or both biological doses, using physical and biological generated dose matrices.  
A convergence criterion, which corresponds to the relative change brought to the plan (more 
specifically to the cost function) between two iterations, is set at 0.1%. When the optimizer 
reaches this point, result files are produced. 
The optimizer work can be broke down into three steps per iteration: 
o Computing the steps: optimizing particle numbers per pencil beams 
o Computing the dose: calculating physical & biological dose 
o Computing the cost function to find the new cost values  
- Additional constraints: 
For the patient optimizations, in addition to the constraint on the maximum dose for the OAR, 
additional dose constraints were set to reduce the mean dose delivered to the OAR. The 
MCTP constraint for OAR is dealing only with maximum dose constraint in its current 
version. Consequently, to reduce the mean dose, a second maximum dose constraint needs to 
be added, for a dose level about 50% of the first maximum dose chosen, but with a lower 
weight. It allows reducing the overall dose received by the OAR, and thus reducing the OAR 
mean dose, by increasing the dose gradient around the target region.  
- Results: 
Once the convergence criterion is reached, the optimizer produces the new optimized plan. 
Other files are created such as 2D dose maps or DVH, allowing for quick checks on the 
optimization dose results. These results are only preliminary, based on the dose changes to the 
optimization matrixes with pencil beams weighting. Final calculations on the CT geometry 
are needed to obtain the dose predictions. 
- Time: 
The optimization with the above mentioned convergence setting and the matrices described 
previously is taking from below 1 minute, for simple plans with small targets and only 
physical dose optimization, to about 30 minutes for large plans with biological optimization, 
on a 12 GB RAM computer. This time could be reduced by reducing the matrix size as 
previously described and adding a dose threshold in the optimizer, where below a certain level 
of dose compared to the maximum delivered dose by a pencil, the matrix voxels are discarded 
for optimization.  
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3- Final dose calculation: 
The final dose calculations are done in a similar way as in Chapter 5, using the phase space 
approach coupled with the newly obtained plans. For Chapter 6, the dose scoring was made in 
water phantom to be compared to measurements. In Chapter 7, dose (physical and biological) 
was computed in the patient voxelized geometry and then imported in the in-house framework 
for analysis (Bauer et al 2014). The number of primary histories was set to 5x10
7
 for patient 
cases and to 2x10
8
 for SOBPs final calculation. 
 
 
 
 
 
Figure C.1: Schema of the MCTP workflow for both physical (solid arrows) and biological 
(dashed arrows) optimization. 
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Forward calculation of SOBP from Chapter 3 for carbon 
ions 
To investigate the difference in absolute deviation between measured and planned doses 
found in Chapter 3 and Chapter 6 for carbon ions, the dose calculation of the SOBP presented 
in Chapter 3 was performed with the MC code FLUKA. In Chapter 3, the difference in the 
SOBP region between measurements and planned dose (from analytical TPS) was about -
1.8%, while in Chapter 6 the difference between measurements and planned dose (from 
MCTP) was found about +2.7%. Compared to the planned dose, the MC dose prediction in 
the high dose region, for the same SOBP presented in Chapter 3, shows deviations around -
4.5%, and deviations to the measurements of about 3%. Figure C.2 shows that when 
correcting for the systematic offset of 3%, FLUKA predictions and measurements are well 
matching. This result is consistent with the findings of Chapter 6, pointing out the fact that the 
beam monitor calibration is tuned for the clinical and research analytical TPS. 
 
Figure C.2: Depth dose distribution of the Chapter 3 SOBP: Measurements are displayed with 
squares. The dose prediction from FLUKA multiplied by a factor 1.03 is represented by the 
solid line (green). 
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MCTP biological optimization and verifications 
The MCTP system can be interfaced with experimentally validated biological models, such as 
phenomenological (Wedenberg et al 2013, Mairani et al. 2016a) or biophysical (Elsässer et al 
2010, Inaniwa et al 2010) models. Thus, the MCTP tool can be used to calculate biologically 
optimized treatment plans. The model used in this thesis (Mairani et al 2016b, Mairani et al 
2017a) is based on parametrizations of the RBEα (= αion/αphoton) and Rβ (= βion/βphoton), as a 
function of LET, with α and β being the parameters of the linear quadratic model (Chapter 2). 
The used RBEα parametrization is based on a linear-exponential model for helium ions 
(Mairani et al 2016b) and a linear model for protons (Mairani et al 2017a) as a function of 
rescaled LET. Thus, online-computation of the dose-weighted average α̅ and β̅ parameters 
with FLUKA can be achieved for every voxel j of the equation (2.15) in Chapter 2, with ∆𝑑𝑖,𝑗, 
the dose from the i-th charged particles, associated to the corresponding 𝛼𝑖,𝑗 and 𝛽𝑖,𝑗 obtained 
knowing their relation to LETi,j from the above-mentioned parametrization. Other models can 
also be linked by introducing their own biological database. 
Using the data-driven biological model described in Mairani et al (2016a) and the 
experimentally validated MC engine fine-tuned to physical data in this thesis work, a 3.1 
GyRBE helium ion SOBP was created for the investigations of Mairani et al (2016b) and then 
recalculated with an improved RBE model, as described in Mairani et al (2016b). 
Prior to the cell irradiations performed in Mairani et al (2016b), pinpoint ionization chambers 
measurements in water were performed to verify the quality of the delivery. The agreement 
between measurements and FLUKA predictions was found within 2% for the whole dose 
distribution, and below 1% in the high dose region (figure C.3 bottom). The expected 
biological dose (figure C.3 bottom) calculated from the measured cells survival (figure C.3 
top) is plotted against the predictions of the MC code FLUKA linked with both the previously 
mentioned models (Mairani et al 2016a and Mairani et al 2016b). For both models a good 
agreement within the uncertainties of the biological measurement was found. 
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Figure C.3: Top figure: Cell survival as a function of depth into water. Cell survival 
prediction using the model described in Mairani et al (2016a) used for optimization is 
displayed in dashed lines, while in dotted line for the cell survival using the model from 
Mairani et al (2016b). Experimental cell survival is displayed with squares (adapted from 
Mairani et al (2016b)); Bottom figure: Depth dose distribution of a biologically optimized 
SOBP for helium ions. The physical dose is displayed in solid line. The biological dose 
appeared with dashed line for prediction using the model from Mairani et al (2016a) or with 
dotted lines for the model described in Mairani et al (2016b). Absorbed dose measurements 
are displayed as squares (blue) while the calculated biological dose extracted from 
experimental cell survival data with circles.  
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D- Supplementary material to Chapter 7 
Additional information regarding topics discussed in Chapter 7 is provided in Appendix D. 
 
Additional patient – a prostate patient case study 
As in Chapter 7, this section presents the comparison between treatment plans of protons and 
helium ions for a prostate case. This patient was treated at the Heidelberg Ion Beam Therapy 
Center (HIT) with protons for a dose per fraction of 3.3 GyRBE for a total dose of 66GyRBE 
(with fixed RBE of 1.1), with two opposite beams as seen in table D.1 and figure D.1. Besides 
the PTV, the other regions of interests (ROI) are the rectum, the bladder and the femurs (left 
and right). The αx/βx ratio for the PTV is defined as 1.5 Gy and 3 Gy for the OAR, based on 
the rectum (late complication) from Fowler (2005). The selected αx/βx ratio for OAR is also 
within the range of αx/βx ratio presented in Fowler (2005) for bladder. The optimization dose 
matrices (physical and biological) were created for an irradiation of the patients without ripple 
filter for both ion species. This choice for helium ions is supported by the fact that prostate is 
a deep-seated organ, thus the effect of range straggling allows a peak wide enough to provide 
a good PTV coverage, without additional peak broadening, as performed in Chapter 6 for the 
deepest SOBP (~centered at 20cm). The generation of these matrices was performed 
following the same protocol presented in both Chapter 7 and Appendix C, for the PTV and 
the rectum, with FLUKA simulations using the phase approach of Chapter 5, with 10000 
primary histories per pencil beam, a dose scoring coupled to a biological model (cf Appendix 
C) and for particle transport in the patient voxelized geometry (1x1x3 mm
3
 voxel size). The 
optimization with MCTP was performed in a first step for protons (without variable RBE) 
with the dose constraints presented in table D.2, in order to reach comparable dose volume 
histograms (DVH) values as the ones of the clinical TPS. The DVH parameters values are 
presented in table D.2. 
After defining these constraints, optimization was performed for both protons and helium ions 
using a variable RBE model. Using these final plans, including for protons both options with 
and without variable RBE model, final dose calculations were performed on a 1x1x3 mm
3
 
voxel grid for physical and biological dose matrices. The final calculations were performed 
using 50x10
6
 primary histories, in 50 independent runs. 
 
 
 
 
Table D.1: Patient proton plan characteristics from the clinical TPS for the considered 
prostate case. The information about the dose per fraction, number of fractions and beams are 
reported. It provides information on the angles between beams and the close by OAR used for 
optimization. 
 
 
Dose constraint [GyRBE] weight
Dose constraint 
[GyRBE]
weight
PTV 3,3 14 3,53 20
Rectum 2,9 20 1,4 1
Patient E (H01949)
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The comparison between the DVH parameters of the proton plans with fixed RBE, obtained 
from MCTP and TPS, is shown in table D.4. While a good agreement is found between the 
PTV coverage with difference below 1GyRBE, the MCTP plan does not provide the same 
sparing for the femoral heads, with higher delivered dose about 8-9 GyRBE. On the contrary, 
the rectum optimized with MCTP presents a dose lowered by about 6 to 13GyRBE in the 
D33-D22 DVH behavior. The bladder shows similar parameters for both MCTP and TPS 
plans. The reason behind the discrepancies in the dose to the femoral heads is ascribed to the 
optimization approach followed with the MCTP, in comparison to the TPS. Due to the large 
size of the optimization matrices (up to ~300Mb per energy slice), not enough RAM was 
available to combine several OAR in the optimizer. Thus, the critical OAR rectum was 
selected with priority. By reducing the matrices sizes as suggested in Appendix C, an 
optimization with all OAR could be possible, aiming to reproduce the TPS DVH results.  
The FLUKA dose predictions for protons and helium ions using a variable RBE model are 
displayed in figure D.1 with the corresponding DVH in figure D.2. The difference, in 
GyRBE, of the DVH parameters between helium ions and protons with a fixed RBE are 
shown in table D.5, and in D.6 for helium ions against protons with a variable RBE. 
 
 
 
 
Table D.2: Optimal constraint parameters (per fraction) for PTV and OAR found with MCTP 
to reproduce similar values of the TPS proton DVH characteristics presented in table D.3. 
 
 
 
 
 
Table D.3: DVH parameters extracted from the TPS proton prostate plan. The dose volume 
parameters for each ROI, in GyRBE - D5, D10, D20, D33, D50, D66, D75 and D95 - are 
presented for a full plan delivery of 66GyRBE to the target. The MCTP optimization with 
protons at fixed RBE tries to reproduce these values. 
 
Planned dose / fraction 
[GyRBE]
Number of 
fractions
Number 
of beams
Angles between 
beams [°]
Critical organ at risks
Rectum
Bladder
Femur left
Femur right
Patient E (H01949) 3,3 20 2 180
D5 D10 D20 D33 D50 D66 D75 D95
PTV 67,6 67,2 67,2 66,6 66,0 65,6 65,0 61,0
Femur (L) 24,8 23,8 22,8 22,0 21,2 20,6 20,4 18,6
Femur(R) 28,0 26,2 24,4 23,4 22,4 21,6 21,2 19,4
Rectum 55,2 49,0 32,6 13,6 2,8 0,4 0,4 0,0
Bladder 62,4 42,0 7,6 1,0 0,6 0,6 0,0 0,0
DVH analysis : H (RBE=1.1) TPS Plan
Patient E (H01949)
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Table D.4: Difference of DVH parameters for the ROIs of the prostate patient case, in 
GyRBE, between the MCTP optimized proton plan with fixed RBE and the TPS plan.  
 
 
 
 
 
Figure D.1: Dose distributions superimposed onto the X-ray CT are shown for patient E, with 
helium ions on the top panel and protons in the middle panels for an axial slice, centered on 
the PTV. The bottom panels display the dose difference between the helium ions and proton 
dose predictions. (Displayed in RayStation (RaySearch Laboratories)) 
D5 D10 D20 D33 D50 D66 D75 D95
PTV 0,6 0,4 0,0 0,0 0,0 0,4 0,4 0,0
Femur (L) 9,0 9,6 9,6 9,6 9,6 9,4 9,2 9,4
Femur(R) 7,4 7,8 7,8 6,8 6,2 5,6 5,0 0,6
Rectum -5,8 -11,0 -12,8 -6,2 -1,4 0,0 0,0 0,0
Bladder -0,4 1,2 1,4 0,0 0,0 0,0 0,0 0,0
DVH analysis : H (MCTPS, RBE=1.1) - H (TPS, RBE=1.1)
Patient E (H01949)
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Figure D.2: DVH for the prostate patient case. The different ROIs investigated are displayed. 
Protons are shown for both fixed (dotted lines) and variable RBE (dashed lines). Helium ions 
are displayed with solid lines. 
 
 
 
Table D.5: Difference of DVH parameters for the ROIs of the prostate patient case, in 
GyRBE, between the MCTP optimized helium ion plans and proton plans with fixed RBE. 
 
 
 
Table D.6: Difference of DVH parameters for the ROIs of the prostate patient case, in 
GyRBE, between the MCTP optimized helium ion plans and proton plans with variable RBE 
model. 
 
 
D5 D10 D20 D33 D50 D66 D75 D95
PTV 0,2 0,2 0,0 0,0 0,2 -0,4 -0,4 0,2
Femur (L) -5,2 -5,2 -5,0 -4,8 -5,0 -4,8 -4,8 -5,0
Femur(R) -4,4 -4,0 -3,4 -2,6 -2,6 -2,6 -3,0 -5,4
Rectum -1,2 -5,4 -8,8 -4,8 -0,4 0,2 0,2 0,0
Bladder -1,4 -9,0 -6,2 -0,4 0,0 0,0 0,0 0,0
Patient E (H01949)
DVH analysis : He (Prostate) - H (RBE=1.1)
D5 D10 D20 D33 D50 D66 D75 D95
PTV 0,2 0,2 0,2 0,0 0,2 0,2 -0,4 0,6
Femur (L) -4,2 -4,0 -4,0 -4,2 -4,4 -4,2 -4,0 -4,2
Femur(R) -2,4 -2,2 -2,2 -1,6 -1,4 -1,4 -1,6 -4,2
Rectum -0,8 -5,4 -9,8 -5,4 -1,0 0,2 0,2 0,0
Bladder 0,2 -7,4 -6,6 -1,0 0,0 0,0 0,0 0,0
Patient E (H01949)
DVH analysis : He (Prostate) - H (Prostate)
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It can be observed in figure D.2 that the proton plans (with or without RBE) provide the same 
dose results (within 1GyRBE). This is due to the high dose per fraction (3.3GyRBE), leading 
to a high physical dose. At a level of 3Gy physical dose the variation of RBE at the same LET 
level are reduced, as seen in figure 7.11, with values close to 1.1.  
Helium ions compared to protons either with fixed or variable RBE present lower dose on all 
OARs up to 9GyRBE for the D10bladder of protons with fixed RBE and up to 9.8GyRBE for 
D20rectum. The coverage of the PTV is similar in both comparisons with difference below 
1GyRBE. Due to the higher LET, helium ions benefit from an increased therapeutic benefit in 
the tumor compared to the OARs. Associated to the physical advantages as such large 
penetration depth (in terms of reduced range and lateral straggling), helium ions allow better 
OAR and normal tissues dose sparing.  
In addition, it can be observed that despite a delivery without RiFi, the PTV coverage and 
homogeneity with helium ions is similar to that of protons, indicating that such treatment 
could be performed without RiFi. This result was expected knowing that at such large depth 
(larger than 15cm), due to range straggling effect, the Bragg peak width for helium ions 
without RiFi is about the same than for carbon ions with RiFi, as seen in Chapter 3, figure 3.3. 
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